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Abstract 
 
HER-2 gene amplification or overexpression occurs in approximately 25 % of breast 
cancers, and trastuzumab (Tmab) is a monoclonal antibody currently used to treat 
patients with HER-2-overexpressing breast cancer. Signalling through alternative 
receptor tyrosine kinases, such as insulin-like growth factor I receptor (IGF-IR), has 
been implicated in resistance to Tmab.  The main aim of this study was to investigate 
mechanisms of resistance and in particular the role of IGF-IR in resistance to Tmab.   
 
Response to Tmab was analysed in a panel of HER-2-positive breast cancer cell lines; 
no correlation was found between HER-2, IGF-IR, EGFR expression or 
phosphorylation and response to Tmab. However, both HER-2 and phospho-HER-2 
levels were found to correlate positively with phospho-IGF-IR levels (HER-2, p = 
0.16; p-HER-2, p = 0.002).  
 
Tmab (T)-resistant cells showed reduced response to Tmab compared to parental cells. 
T-resistant BT474 have significantly elevated HER-2, phospho-HER-2, EGFR and 
phospho-EGFR levels compared to parental cells, while T-resistant SKBR3 cells have 
significantly elevated IGF-IR levels compared to parental cells (p = 0.026).  
 
Targeting IGF-IR with anti-IGF-IR siRNA or an IGF-IR tyrosine kinase inhibitor 
(TKI) (NVP-AEW541) inhibited the growth of both parental and T-resistant SKBR3 
and BT474 cells. Combined treatment with Tmab and IGF-IR inhibitors also inhibited 
significantly more proliferation than single agents in T-resistant BT474 cells, and in 
parental and T-resistant SKBR3 cells. 
 
SKBR3 cells were conditioned in lapatinib (a dual HER-2/EGFR TKI), and the 
conditioned SKBR3-L cells showed significantly reduced response to lapatinib, and to 
Tmab, compared to parental SKBR3 cells. Phosphoproteomic analysis revealed 
alterations in the levels of a number of phosphoproteins in lapatinib resistant cells. 
 
HER-2 and IGF-IR expression were measured by immunohistochemistry in tissue 
microarrays (TMAs) of patient breast tumour samples. Membrane IGF-IR staining 
correlated inversely with HER-2 expression (p = 0.026). 
 
In conclusion, these data suggest that increased signalling through alternative RTKs 
may play a role in acquired resistance to Tmab.  The combination of anti-IGF-IR 
therapies with Tmab may be clinically beneficial for patients with HER-2-positive 
breast cancer.  We have identified a number of phosphoproteins with potential 
involvement in trastuzumab and/or lapatinib resistance, and further analysis of these 
targets may lead to novel therapeutic targets in HER-2-resistant breast cancer. 
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1.1 HER-2 IN BREAST CANCER 
 
A recent analysis of breast tumours has identified four distinct sub-types of tumours [1, 
2]. The sub-types are classified as (i) luminal (further sub-divided into A and B) (ii) 
HER-2 positive/ER negative, (iii) normal-like and (iv) basal-like. The basal-like sub-
type lacks expression of estrogen and progesterone receptors and HER-2. A number of 
studies have shown that the HER-2 positive and the basal-like sub-types have a poorer 
prognosis than either luminal or normal-like tumours [1-3].  Many efforts are now 
underway to develop and improve HER-targeted therapies. The following section will 
review the structure and function of HER-2 and the HER family, and describe the 
downstream signalling events which they activate. The role of HER-2 in cancer 
development, and the value of HER-2 as a prognostic and predictive marker in breast 
cancer will also be reviewed. Efforts to target HER-2 with targeted therapeutics will 
also be briefly reviewed.  
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1.1.1 The HER system/signalling pathway 
1.1.1.1 HER family structure 
The HER system consists of at least 12 ligands that interact with four known receptor 
tyrosine kinases (RTKs), resulting in a signalling network that regulates cellular 
processes such as proliferation, differentiation, cell survival, and gene transcription. 
The HER receptors are expressed in many tissues of epithelial, mesenchymal, and 
neuronal origin, where they play fundamental roles in development, proliferation and 
differentiation.  The HER-2/neu/c-ErbB-2 proto-oncogene is located on chromosome 
17q12, and encodes a 185 kilo Dalton (kd) transmembrane glycoprotein belonging to 
the epidermal growth factor receptor (EGFR) family [4-6].  This family includes four 
known members; EGFR (HER-1 or erbB1) (170 kd), HER-2 (neu or erbB2), HER-3 
(erbB3) (180 kd), and HER-4 (erbB4) (180 kd).  All four receptors have in common an 
extra-cellular ligand-binding domain, a single hydrophobic transmembrane domain, 
and a cytoplasmic tyrosine kinase domain. Four subdomains have been identified in 
the extracellular domain; subdomains I (L1) and III (L2) mediate ligand binding, while 
the cysteine-rich subdomains II (S1/CR1) and IV (S2/CR2) play roles in receptor 
dimerization [fig 1.1.1]  [7].  
 
At least 12 ligands are known to interact with the HER family, including EGF, 
transforming growth factor-a (TGF-a), amphiregulin, epiregulin, betacellulin, and 
heparin-binding EGF-like growth factor (HB-EGF), which have higher affinity for 
EGFR,  and neuregulins 1-4, which have higher affinity for HER-3 and HER-4 [8]. 
 
In the resting state, the receptors exist as monomers which, in response to ligand-
binding, form either homo- or heterodimers. The crystal structure of ligand bound 
EGFR shows that ligands bind EGFR in a bivalent manner, forming a 2:2 complex 
with EGFR dimers [9, 10]. The structure of unliganded HER-3 suggests a similar 
dimerization conformation [11]. No specific endogenous ligand has been identified for 
HER-2, but ligand binding to other members of the HER family induces receptor 
heterodimerization and activation of HER-2. The crystal structure of the HER-2 
ectodomain was recently described, and reveals that the HER-2 ectodomain 
conformation is very different to that of the unliganded HER-3, but rather is similar to 
 5 
the EGFR ectodomain in its liganded conformation.  The potential ligand binding site 
in HER-2 also differs significantly from that of EGFR and HER-3, resulting in a 
receptor structure that is constitutively poised in an active conformation [fig 1.1.2] 
[12]. 
_______________________________________________________________________________________________________ 
 
 
 
 
 
 
 
 
 
Figure 1.1.1. Ribbon structures comparing ErbB2(1–509) with sEGFR501 and sErbB3(1–
621) as determined by X-ray crystallography: helices are indicated by curled, red ribbons and 
strands by broad arrows. The blue, green, and yellow strands depict the three prominent 
parallel sheets within the L1 and L2 domains. The strands in the cysteine-rich domains are 
coloured orange, except for those in the CR1 loop which are coloured brown. The side chains 
of disulfide-linked cysteine residues are depicted as yellow sticks [From Garrett et al, 2003]. 
_______________________________________________________________________________________________________ 
 
Dimerization is accompanied by trans-phosphorylation of specific tyrosine residues 
within the cytoplasmic tail, which leads to the activation of numerous signalling 
pathways [fig 1.1.2]. The kinase domain of HER-3 is inactive [13], and its signalling 
functions are therefore mediated through the kinase of its heterodimeric partners. 
HER-2 is the preferred dimerization partner for each of the HER receptors [14, 15], 
and as HER-2 has the strongest kinase activity, dimers containing HER-2 generate a 
stronger intracellular signal than other complexes  [16].  HER-2/HER-3 dimers are 
believed to be the most active and potent signalling heterodimers of the family. In 
addition, HER-2-containing dimers undergo slower dissociation and endocytosis, and 
are more frequently recycled back to the cell surface, prolonging the potent signals 
(reviewed in [7, 17]).   
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_______________________________________________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.2.  HER dimerization: A the extracellular domains are represented by two 
cysteine-rich daomins (S1 and S2), and two cysteine-free, ligand-binding domains (L1 and 
L2). HER-2 exists on the cell surface in an active dimer conformation resulting from the 
interactions between S1 and S2 domains. Bivalent binding of ligands (for example neuregulin, 
NRG) to the L1 and L2 domains of HER-3 rearranges the conformation of the extracellular 
domain, leading to protrusion of the S1 dimerization loop. In the case of HER-2, the 
intramolecular interaction between L1 and L2 results in a preextended conformation of the S1 
dimerization loop. Dimerization between a ligand-bound HER-3 and a HER-2 molecule is 
mediated primarily by the dimerization loop (dotted circle I), with additional possible 
contributions from the loop in the S2 domain (dotted circle II). Additional stabilizing 
interactions between the transmembrane and kinase domains may also play a role;  B 
Overexpression of HER-2 at the cell surface may spontaneously recruit HER-3 into 
heterodimers. The formed dimers may assume the ligand-induced conformation, resulting in 
weak but prolonged activation. Alternatively, spontaneous homodimers formed upon 
overexpression of HERS-2 cannot be excluded. [From Citri et al, 2003]. 
_______________________________________________________________________________________________________ 
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1.1.1.2 HER signalling  
The cytoplasmic tail of the HER receptors contain multiple tyrosine phosphorylation 
sites, varying from 19 in HER-2, to 27 sites in HER-4. These phosphorylated residues 
serve as docking sites for a range of signalling effector molecules containing Src 
homology-2 (SH2) and phosphotyrosine binding (PTB) domains.  Individual receptors 
have distinct patterns of tyrosines, and each tyrosine residue has different affinities for 
different molecules. Furthermore, a given receptor can be differentially 
transphosphorylated in distinct dimers [18]. The specific signalling molecules 
recruited, therefore, and the potency of the signal initiated, depend on the identity of 
the stimulating ligand, the receptor to which it binds, and the second receptor of the 
dimer formed [19, 20]. The best characterized signalling pathways induced by the 
HER family are the phosphatidylinositol-3 kinase-Akt (PI3K-Akt), the Ras-mitogen-
activated protein kinase (Ras-MAPK) and the phospholipase C?-protein kinase C 
(PLC?-PKC) pathways [fig. 1.1.3].  
_______________________________________________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.3. HER-2 signalling pathway: Ligand binding or HER-2 overexpression induces 
hetero- or homo-dimerization of HER-2. HER-2 phosphorylation activates Akt, MAPK and 
PKC signalling pathways, ultimately promoting proliferation and cell survival. Hsp90 
maintains HER-2 stability and regulates its function. Cleavage of HER-2 by ADAM proteases 
produces an extracellular domain (ECD), which is shed, and a truncated membrane-bound p95 
fragment.   
____________________________________________________________________________ 
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__________________________________________________________________________________________________________________________________________ 
Each of the four HER proteins contains at least one docking sites for Shc (SH2-
containing proto-oncogene). Of the cellular proteins that interact with HER-2, Shc is 
the most common, with at least five docking sites. Shc has three known isoforms, and 
mediates signalling from a number of other receptor tyrosine kinases (RTKs), 
including nerve growth factor receptor (TrkA) [21], platelet-derived growth factor 
receptor (PDGFR) [22] and IR [23].  Phosphorylation of Shc causes it to associate with 
adaptor protein Grb2 (Growth factor Receptor Bound 2). Grb2 can also bind directly to 
tyrosine 1139 of HER-2. In the cytosol, Grb2 is bound to the guanine nucleotide 
exchange factor Sos [24], and recruitment of the Grb2-Sos complex to the plasma 
membrane stimulates the activation of GTP-binding protein Ras, by exchanging its 
GDP for GTP. Ras then activates various downstream signalling cascades including 
the mitogen-activated protein kinase (MAPK) pathway. Ras associates with and 
activates the serine/threonine kinase Raf, which in turn phosphorylates MEK1 (also 
known as MAPK kinase). MEK1 then phosphorylates p42/44 MAPK [extracellular 
signal-related kinase 1 (ERK1 and ERK2)]. Once activated, MAPKs phosphorylate 
many cytoplasmic and nuclear substrates that include growth factor receptors, 
transcription factors and other proteins kinases, which mediate cellular processes such 
as proliferation, differentiation, cell survival and gene transcription [fig 1.1.4] [25].  
________________________________________________________________________________________________________ 
__________________________________________________________________________________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.4.  The MAP-kinase pathway activated by Ras. The pathway activated by Ras 
begins with a MAPK-kinase-kinase called Raf, which activates the MAPK-kinase Mek, which 
then activates the MAPK Erk. Erk in turn phosphorylates a variety of downstream proteins.  
[From Molecular Biology of the Cell, 4th Edition, Alberts et al, 2002]. 
_______________________________________________________________________________________________________ 
 9 
Activation of PI3K occurs through binding of its p85 regulatory subunit to a 
phosphotyrosine residue on a receptor, such as those of the HER family.  Activated 
PI3K initiates a major signalling cascade involved in promoting cell growth and 
survival. The p110 subunit of active PI3K phosphorylates phosphatidylinositol (PI), 
producing lipids such as PI(3,4,5)P3 and PI(3,4)P2. These lipids act as docking sites for 
proteins containing a pleckstrin homology (PH) domain.  PH-containing proteins then 
transmit signals from the plasma membrane into the cell. Two such proteins are 
phosphatidylinositol dependant kinase-1 (PDK1) and protein kinase B (PKB/Akt). 
Binding of Akt to the inositol lipids causes its translocation to the plasma membrane, 
where its conformation is altered, enabling its phosphorylation by PDK1 [26, 27].  
Active Akt is released into the cytosol, where it phosphorylates target proteins, 
mediating multiple biological responses, including proliferation, metabolic responses 
and protection from apoptosis [28]. The tumour suppressor protein PTEN (phosphatase 
and tensin homolog deleted on chromosome 10) is known to regulate Akt signalling by 
dephosphorylating PIP2 and PIP3, thereby preventing Akt recruitment [29].  One of the 
downstream substrates of Akt is BAD, a member of the Bcl-2 family of apoptotic 
proteins [30]. BAD neutralizes anti-apoptotic proteins Bcl-2 and Bcl-XL, promoting 
cell death. Akt signalling inhibits BAD thereby protecting cells from apoptosis [31].  
HER-2 and EGFR do not contain binding sites for PI3K, but active HER-3, though 
kinase-deficient, contains six PI3K-binding sites, and HER-2/HER-3 or EGFR/HER-3 
dimers can therefore transmit potent survival signals through the Akt pathway [fig. 
1.1.5] [32].  
 
Activation of PLC? by HER-2 occurs through the recruitment of its SH2 domain to 
HER-2 phosphotyrosine sites, as well as through the binding of its PH-domain to PI3K 
products at the plasma membrane.  Activated PLC? hydrolyses PIP2 into IP3 and 
diacylglycerol leading to activation of calcium/calmodulin-dependant kinases and 
phosphatases, and protein kinase C (PKC) (reviewed in [19]).  
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_______________________________________________________________________________________________________ 
 
Figure 1.1.5. IGF-IR – PI 3-kinase signalling promotes cell survival. Activated IGF-IR 
recruits and activates PI3K. PI3K in turn phosphorylates PIP3, which serves as docking sites 
for PDK1 and Akt/PKB. Activated Akt dissociates from the plasma membrane and 
phosphorylates BAD, which regulates a number of death-inhibitory proteins. Activated BAD 
releases the inhibitory proteins, which block apoptosis, thereby promoting cell survival. [From 
Molecular Biology of the Cell, 4th Edition, Alberts et al, 2002]. 
_______________________________________________________________________________________________________ 
 
Other important signal effectors activated by the HER family include Src tyrosine 
kinase, which is activated upon binding to EGFR, and phosphorylates additional 
tyrosine docking sites, enhancing EGFR activity.  Activated Src plays a role in 
multiple cellular processes, including endocytosis of RTKs such as EGFR, and the re-
arrangement of the cytoskeleton.  Signal transducer and activator of transcription 
proteins 5 (STAT5), is also phosphorylated by HER proteins, and by activating protein 
kinases of the JAK family, is translocated to the nucleus, where it binds to specific 
promoter sequences in target genes. The JAK/STAT pathway regulates the 
transcription of many genes involved in cell proliferation, differentiation and apoptosis 
[19].   
 
One of the important downstream effects of HER family signalling is the promotion of 
cell cycle progression and cellular survival.  Cyclin D1 is a key cell cycle regulator, 
and is modulated by HER-2 through both the MAPK and PI3K pathways [33].  Cyclin 
D1 activates cyclin dependant kinases (CDKs) to promote G1/S phase cell cycle 
progression.  Furthermore, MAPK and Akt signalling mediate additional cell cycle 
regulatory effects downstream of HER-2 through p27kip1 and p21waf1, two key 
regulators of CDK function [7].   
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1.1.1.3 HER-2 function in normal development 
The HER receptors are widely expressed and functionally important in multiple 
tissues, particularly in mammalian development. Mice with mutated HER-2, HER-3 or 
neuregulin-1 proteins displayed a lack of neural crest precursor cells [34], and mouse 
embryos lacking HER-2, HER-3, HER-4, or neuregulins, died during embryogenesis 
due to severe cardiac abnormalities, as well as brain defects [35-39].  Extensive studies 
of Schwann cells have focused on neuregulin signalling in the development of the 
peripheral nervous system, and have identified that the HER-2/HER-3 dimer is 
activated by neuregulin in these cells [40]. 
 
Cross-talk between HER-2 signalling and other pathways has been reported during 
cardiac development. In a mouse model with inactive 5-hydroxytryptamine (5-HT) 
receptors, embryonic or neonatal death was accompanied by a specific reduction in 
HER-2, and cardiac malformations, suggesting that 5-HT receptors use the HER-2 
signalling pathway for cardiac differentiation [41]. Another example of cross-talk was 
seen between neuregulin-1 and insulin-like growth factor-I (IGF-I) pathways. Hertig et 
al, reported that stimulation of cardiomyocytes with the two ligands had synergistic 
effects on DNA synthesis and cell growth, and this interaction was demonstrated to 
converge at the activation of PI3K [42]. The importance of neuregulin in promoting 
angiogenesis via activation of the HER receptors in endothelial cells has been 
demonstrated.  In a rat corneal angiogenesis model, neuregulin administration led to 
the growth of new blood vessels, and the use of anti-vascular endothelial growth factor 
(VEGF) antibodies demonstrated that these anti-angiogenic effects were independent 
of VEGF [43].  
 
Due to lethality in utero, following gene-targeting, it has been difficult to establish a 
role for HER proteins in normal adult tissues. In in vivo studies, targeted disruption of 
HER-2 led to a striking ductal elongation defect, and reduced branching in the pubertal 
adult mammary gland. However, the absence of HER-2 did not affect the ability of the 
animals to lactate, demonstrating the functional importance of HER-2 in the initial 
stages of mammary gland morphogenesis [44].  
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Press et al investigated HER-2 in a variety of normal adult and fetal tissues, and found 
low expression on the cell membranes of epithelial cells in the gastro-intestinal, 
reproductive and urinary tract, skin, breast and placenta [45]. HER-2 expression has 
also been found in normal ovaries and kidney [46, 47]. These studies imply that HER-
2 is expressed in of a variety of epithelial cell types. 
 
1.1.1.4 Regulation of HER-2 
The levels and activity of HER-2 are regulated by a number of mechanisms. Cell 
surface receptor levels are down-regulated by ligand-induced receptor endocytosis, 
whereby receptor dimers are internalized via clathrin-coated regions of the plasma 
membrane which form endocytic vesicles.  Receptors are then either recycled back to 
the cell surface, or targeted to lysosomes for degradation. There is also evidence to 
suggest that internalized receptors might interact with effector molecules in pre-
degradative intracellular compartments, thereby activating signalling pathways distinct 
from those that are activated at the cell surface [48].  
 
Heat shock protein 90 (Hsp90) plays an important regulatory role in HER-2 activity. 
Hsp90 and its complex of chaperone proteins promote the maturation of HER-2 from 
its nascent form into its stable mature form. Hsp90 then interacts with the kinase 
domain of HER-2, where it is responsible for maintaining the mature protein in a state 
competent for dimerization and activation [49].  A recent study also reported a novel 
interaction between surface Hsp90 and the extracellular domain (ECD) of HER-2, and 
suggests that this interaction promotes HER-2-mediated cytoskeletal re-arrangements 
[50]. 
 
Herstatin is an alternatively spliced form of HER-2 consisting of subdomains of the 
extracellular domain of HER-2 and a novel carboxyl-terminus domain encoded by an 
intron. It acts as an autoinhibitor by binding to HER-2, and blocking its activity and 
heterodimerization [51]. A similar type of naturally secreted protein, p85-s, composed 
of the extracellular domain of HER-3, binds neuregulin and inhibits activation of 
HER-2, HER-3 and HER-4 [52].  
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1.1.2 HER-2 expression in breast cancer 
HER-2 overexpression occurs in 15-30 % of breast cancers  [53], and this is usually 
due to amplification of the HER-2 gene by 2-fold to greater than 20-fold more then the 
number of copies in normal cells. Amplification of the HER-2 gene results in increased 
receptors on the cell surface; while a normal breast cell has approximately 20,000 
HER-2 molecules, tumours cells have up to 2 million  [54, 55].  
 
1.1.2.1 HER-2 in transformation and tumorigenesis 
Overexpression of HER-2 has been implicated in the transformation of epithelial cells, 
and in tumorigenesis in human tissues.  Overexpression of HER-2 in NIH/3T3 cells or 
NR6 mouse fibroblast cells induced cell transformation and tumorigenic growth [56-
58]. When simultaneously overexpressed, HER-2 and EGFR act synergistically in the 
transformation of NIH/3T3 cells [59]. Transformation can also be induced by co-
expressing HER-2 or EGFR with HER-3 or HER-4 [60]. Overexpression of HER-2 in 
MCF7 breast cancer cells resulted in elevated signalling through the PI3K pathway, 
and enhanced tumorigenesis when implanted into nude mice [61].  In a 3-D model of 
MCF10A mammary epithelial acini, HER-2 overexpression enhanced proliferation, 
suppressed apoptosis, and promoted the formation of solid multiacinar structures, 
resembling those seen during the early stages of epithelial transformation [62].  Anti-
apoptotic survivin is also upregulated by the coexpression of EGFR and HER-2 in 
MCF7, MMC-1 and HMC-2 breast cancer cells [63]. 
 
As well as playing a role in tumorigenesis, HER-2 has also been implicated in 
invasion, by regulating expression of integrins on the cell surface. In human mammary 
epithelial (HME) cells, HER-2 overexpression downregulated a4-integrin, leading to 
increased invasiveness of the cells. This was mediated by signalling through Rac1-
p38MAPK and PI3k-Akt-PKC-d pathways [64, 65].  
 
Overexpression of HER-2 in tumours results in increased formation of HER-2-
containing heterodimers and HER-2 homodimers [66].  HER-2 homodimerization can 
cause constitutive activation of its kinase domain [67]. Zhan et al [68] compared and 
identified the roles of HER-2 homodimers and HER-2/EGFR heterodimers in normal 
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breast cell transformation and invasion, and observed that while activation of both 
types of dimers induced disruption of the epithelial acini-like structures, only the HER-
2/EGFR heterodimers promoted invasion of cells through the extracellular matrix. The 
ability of the heterodimers to induce invasion required HER-2 kinase activity and was 
mediated through activation of PI3K, MAPK and phospholipase C?1 signalling 
pathways.  The synergistic effects of HER-2 and EGFR may be explained, at least in 
part, by HER-2 increasing affinity for EGFR ligand binding and interfering with the 
rate of EGFR internalization, resulting in prolonged activation of downstream 
signalling [69].  
 
HER-2 overexpression in breast cancer has also been implicated in the promotion of 
angiogenesis, another important prognostic indicator in breast cancer.  In in vitro 
studies, activation of HER-2 upregulated vascular endothelial growth factor (VEGF) 
levels, and treatment with anti-HER-2 antibody 4D5 resulted in a dose-dependant 
reduction of VEGF expression [70]. 
 
1.1.2.2 Detection of HER-2 overexpression in breast cancer 
Most reports find that the HER-2 gene is either amplified or overexpressed at the 
protein level in 15-30 % of primary invasive breast cancers [53]. Reports have varied, 
however, probably due to different techniques used to assess HER-2.   Southern 
blotting was first used to assess HER-2 gene amplification [71], while other studies 
have used slot blot, Western blot, reverse transcriptase-polymerase chain reaction (RT-
PCR), enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), 
and fluorescent in situ hybridization (FISH) methods to measure gene amplification or 
overexpression [72].  IHC has been most commonly used, and this technique measures 
the amount of HER-2 protein expressed on the surface of cells, using a qualitative 
scoring system from 0 to 3+, with 3+ regarded as overexpression.  Inconsistencies in 
results can occur due to variation in sample storage, fixation techniques, intensity of 
antigen retrieval, the type of antibody used, and scoring systems.  Two commercially 
available HER-2 IHC tests, the HercepTestTM (Dako Corporation, Denmark) and the 
Ventana PATHWAYTM (Ventana Medical Systems, Tucson, AZ), have been approved 
by the US Food and Drug Administration (FDA) for use in determining the eligibility 
of patients to receive trastuzumab (HerceptinTM), and studies have shown that when 
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standardized IHC techniques are used, there is excellent correlation between gene copy 
number and protein expression levels [72]. FISH detects amplification of the HER-2 
gene and tumours are thus interpreted as negative or positive based on the number of 
HER-2 gene copies.  This method is also commonly used, and is arguably a more 
sensitive and accurate method of measuring HER-2 status [73]. FISH also has the 
advantages of having a more objective scoring system; however, this test is also more 
expensive and time-consuming to run.  Two FISH assay kits have been approved by 
the FDA; the Ventana INFORMTM (Ventana Medical Systems), and the Abbott-Vysis 
PathVysionTM (Abbott Laboratories, Abbott Park, IL).  An approach now taken by 
many clinicians is to use IHC as a primary screening tool, and to use FISH to confirm 
HER-2 status in cases with IHC scores of 2+. 
 
A novel method of hybridization, chromogenic in situ hybridization (CISH), uses a 
chromogen-labelled probe and offers the advantage of the ability to use a light 
microscope. Studies comparing CISH and FISH analysis of breast cancer samples 
report a strong correlation between the two techniques [74, 75]. A recent study used 
silver enhanced in situ hybridization (SISH), and reported this technique to be as 
accurate and reliable as FISH [76].  Another recent study combined IHC and CISH, 
calling the new technique ‘protein and gene double staining’ (PGDS), and the authors 
suggest that this technique will aid in improving IHC scoring, and increase the 
sensitivity and specificity of HER-2 testing [77].  
 
1.1.2.3 HER-2 as a prognostic factor 
HER-2 gene amplification or overexpression is reported in 15-30% of invasive human 
breast cancers [53]. In 1987, Slamon et al [71] reported that in 86 patients with lymph 
node-positive breast cancer, HER-2 amplification correlated significantly with both 
time to relapse and overall survival. Univariate analysis demonstrated that HER-2 
amplification was equivalent to the number of lymph node metastases as a prognostic 
marker, but stronger than that of hormone receptors or tumour size. In multivariate 
analysis, the prognostic impact of HER-2 gene amplification was also significant and 
independent of number of metastatic axillary nodes [71]. 
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Subsequent studies confirmed the adverse prognostic impact of HER-2 in lymph node-
positive breast cancer patients. In a review of 16 different reports, Revillion et al [78] 
showed, using univariate analysis with disease-free interval as an endpoint, that 
overexpression of HER-2 correlated with poor outcome in 11 studies but failed to 
correlate in 2 reports.  In the remaining 3 studies, HER-2 lacked prognostic impact in 
the overall population but predicted outcome in specific subgroups. In 11 studies 
where multivariate analysis was performed, 5 confirmed the prognostic value of HER-
2 but 6 others did not.  Similar conflicting results were obtained with overall survival 
as the endpoint [78].   
 
In a more recent review of 81 studies, involving > 27,000 patients, 73 (90%) studies 
found that either HER-2 gene amplification or protein overexpression predicted patient 
outcome using either univariate or multivariate analysis [72]. In 52 of the 73 studies 
(71%) that used multivariate analysis, the adverse prognostic impact of HER-2 was 
found to be independent of the other variables investigated. Only 8 (10%) of the 
studies showed no significant association between HER-2 and patient outcome.  When 
the breast cancer patients were separated by nodal status, most authors found that 
HER-2 overexpression correlated with poor outcome in node-positive patients but 
found conflicting results in node-negative patients [79]. The prognostic value of HER-
2 in lymph node-positive breast cancer patients may be partly attributed to its ability to 
predict response/resistance to specific therapies. 
 
Currently, measurement of HER-2 for determining prognosis in breast cancer is 
recommended by a number of expert panels including the St Gallen Consensus Group  
[80, 81], the  National Academy of Clinical Biochemistry (NACB) (USA) [82], and 
the European Group of Tumour Markers (EGTM) [83].   
 
As well as tissue levels, levels of serum HER-2 extracellular domain (ECD), have also 
been shown to correlate with high histological grade, lymph node involvement, 
hormone receptor negativity, disease recurrence, metastasis, and shortened survival 
[84, 85]. Most studies used ELISAs to quantify the soluble ECD of HER-2, which is 
cleaved from the cell surface by a matrix metalloproteinase-like protein [84].   
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Proteolytic shedding of the HER-2 ECD also generates an N-terminal truncated 
fragment p95HER-2 [86, 87].  Studies in patients have found that the presence of 
p95HER-2 in primary breast tumours correlates with the extent of lymph node 
metastasis, while the full length receptor was unrelated to nodal disease.  p95HER-2 
was also detected more frequently in lymph node metastasis than primary tumours, and 
high levels of p95HER-2 significantly correlated with reduced five-year survival in 
primary breast cancer patients. This truncated form of HER-2, therefore, is an 
independent predictor of patient outcome and may define a group of patients with 
HER-2-positive cancer with significantly worse outcome [86, 88].  
 
The level of HER-2 protein does not necessarily reflect the level of activity of the 
receptor.  Studies have been performed therefore, to examine the levels of 
phosphorylated HER-2 (pHER-2) in breast tumour samples, and to assess the 
prognostic value of pHER-2 in patients. In a study of invasive breast cancers, pHER-2 
was detected in 12% of 307 HER-2-positive samples [89].  pHER-2 levels correlated 
with a higher percentage of HER-2 positive cells, higher number of positive lymph 
nodes, and elevated cellular proliferation. Both HER-2 and pHER-2 were associated 
with poor prognosis in node-positive patients.  In a similar, though smaller, study of 
DCIS patients, pHER-2 was detected at a higher frequency (58%) compared to HER-2-
positive invasive cancers [90]. A recent study of 70 primary breast cancers also found 
that pHER-2 correlated inversely with hormone receptor status, and was associated 
with poor clinical outcome [91].  These results suggest the potential use of 
phosphorylated HER-2 as a prognostic marker.  
 
1.1.2.4 Association of HER-2 with other prognostic parameters 
HER-2 overexpression has been positively correlated with other prognostic parameters 
such as tumour size, lymph-node infiltration, high tumour grade, DNA aneuploidy, 
p53 mutation,  and  high proliferation index [92, 93]. HER-2 amplification or 
overexpression correlates inversely with the presence of estrogen receptor (ER) and 
progesterone receptor (PR) [94].  Approximately 50% of HER-2-postive breast cancers 
are ER-negative, and in the other 50%, ER levels are significantly lower compared to 
those in ER-positive/HER-2-negative breast cancers [95]. ER stimulation decreases 
HER-2 protein levels, while antiestrogens, such as tamoxifen, increase HER-2 
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expression. Cross-talk between the ER and HER-2 signalling pathways has been 
demonstrated; estradiol activates the PI3K/Akt pathway in breast cancer cells, and this 
has been shown to be mediated by HER-2, while heregulin also activates Akt and 
upregulates ER activity [96, 97].  In a study of the prognostic value of combining 
HER-2 and ER status, patients with HER-2-positive tumours that also express ER had 
longer overall survival than those without ER [98]. 
 
1.1.2.5 HER-2 as a predictive marker in breast cancer 
Clinical evidence demonstrates an association between HER-2 overexpression and 
response to a number of anti-cancer therapeutics. Amplification or overexpression of 
HER-2 has been implicated as a potential predictor of reduced response to the 
chemotherapy regimen of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), 
though results of different studies have been controversial [94]. A recent study 
examined post-adjuvant chemotherapy in 1625 primary breast cancer patients. Six 
hundred patients were given CMF, 600 were given CEF (epirubicin, an anthracycline, 
replacing methrotrexate), while 425 were given an anthracycline plus taxane regimen. 
In the CMF-treated patients, disease-free survival was significantly lower in HER-2-
positive than in HER-2-negative patients. In the node-positive subgroup, this 
difference was enhanced. Compared to CMF, the anthracycline-containing regimens 
were significantly more effective in node-positive HER-2-overexpressing patients than 
in node-negative HER-2-positive patients [99]. These results confirm that HER-2-
positive patients are more resistant to CMF, but sensitive to anthracycline-based or 
anthracycline plus taxane regimens.  Previous studies have also reported the benefit of 
adding the anthracycline doxorubicin to chemotherapy regimens in HER-2-positive 
patients, and have demonstrated that HER-2-overexpressing patients benefit from 
higher doses compared to lower dose of CAF (cyclophosphamide, doxorubicin and 5-
fluorouracil) [100].   
 
HER-2 overexpression has also been reported to play a role in resistance to hormonal 
therapy. In a number of studies, HER-2-positive tumours were specifically resistant to 
tamoxifen treatment [98], while in others, HER-2 overexpression did not show any 
predictive effect [94]. In one study, HER-2-positive tumours were not only resistant to 
tamoxifen, but the adjuvant use of tamoxifen had an adverse effect on overall survival 
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compared with untreated patients [101]. In this study, HER-2 overexpression was 
found to be a better predictor of hormone therapy response than the hormone receptor 
itself.  Another report also suggested that the soluble HER-2 ECD is more predictive 
of response to hormone therapy than the hormone receptor itself [92].  A more recent 
study showed that ER-positive/HER-2-positive tumours respond more favorably to 
aromatase inhibitors,, such as letrozole, in the neoadjuvant setting [72].   
 
Based on studies in cell lines and animal models, it is assumed that HER-2 gene 
amplification or overexpression of HER-2 protein is necessary for trastuzumab to 
mediate its anti-cancer actions. Although not proven, clinical evidence supports the 
value of HER-2 in predicting response to HER-2-targeted therapy.  The predictive 
value of HER-2 in response to trastuzumab was originally shown in patients with 
advanced breast cancer. In one of the first phase II trials, 46 women with HER-2 
positive (2+ or 3+ by IHC) metastatic chemo-refractory breast cancers were treated 
with trastuzumab.  Response was observed in 12% of the women, providing proof-of-
principle that trastuzumab was effective in at least some HER-2 positive tumours 
[102].  In a phase III trial, using IHC to select patients, trastuzumab improved survival 
and reduced the risk of recurrence when given as a first line treatment in combination 
with chemotherapy in patients with metastatic breast cancer [103]. Addition of 
trastuzumab to chemotherapy regimens in the adjuvant setting has also improved 
survival, and a recent study reported a positive correlation between level of HER-2 
amplification by FISH and increased complete response to trastuzumab-based 
neoadjuvant treatment [104]. Elevated levels of serum HER-2 ECD have also been 
associated with a higher response rate to trastuzumab-based therapies [72], while 
expression of the p95 fragment in breast tumours correlated with reduced response to 
trastuzumab [105]. Measurement of HER-2 is recommended by multiple expert panels 
for selecting patients with breast cancer for treatment with trastuzumab [80, 82, 83, 
106].   
 
Recent data also demonstrate a predictive role for HER-2 in response to lapatinib, a 
dual HER-2/EGFR inhibitor. In phase II/III trials, only patients with HER-2-
overexpressing tumours responded to lapatinib, and preliminary data also suggest that 
EGFR overexpression and an intact ECD of HER-2 may also be related to response  
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[107]. Co-expression of phosphorylated HER-2 and HER-3 also correlated with 
favourable response to lapatinib in inflammatory breast cancer  [108]. 
 
1.1.2.6 HER-2 targeted therapies 
The discovery of HER-2 overexpression and its role in aggressive cancers led to efforts 
to develop agents targeting HER-2 for anti-cancer therapy. HER-2 targeted therapies 
that are currently in clinical use or in development can be divided into two main types, 
namely monoclonal antibodies and tyrosine kinase inhibitors (Table 1.1.1). Several 
groups developed murine monoclonal antibodies against the ectodomain of HER-2, 
many of which demonstrated inhibition of growth in preclinical models. One particular 
antibody, 4D5 was developed by Genentech (San Francisco, CA), and due to its anti-
tumour effects in vitro and in vivo, this antibody was humanized for clinical use. This 
antibody, trastuzumab (HerceptinTM, Genentech), was the first monoclonal antibody 
approved for breast cancer treatment.  Trastuzumab demonstrated higher binding 
affinity for HER-2 than the murine 4D5, and potent anti-tumour effects in human 
tumour xenografts [109].  Trastuzumab binds to the ectodomain of HER-2, preventing 
its interaction with the transmembrane domain [Fig. 1.1.6]. Trastuzumab does not 
prevent heterodimerization of HER-2, as the specific binding site for trastuzumab is 
not involved in dimerization [110]. Trastuzumab will be discussed further in section 
1.3.1.  
 
A second anti-HER-2 antibody, pertuzumab (Omnitarg), was developed by Genentech 
and is currently in phase II clinical trials in breast cancer patients [111]. Pertuzumab 
has properties distinct from those of trastuzumab; its binding site on HER-2 enables it 
to block dimerization with other HER receptors, and in contrast to trastuzumab, 
pertuzumab is able to inhibit tumours with low levels of HER-2 by preventing ligand-
induced activation of HER-2 heterodimers [110] [Fig. 1.1.6]. Furthermore, the 
combination of pertuzumab and trastuzumab synergistically inhibited the survival of 
BT474 breast cancer cells in vitro, partly due to increased apoptosis [112].  
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Figure 1.1.6. Inhibition of HER-2 signalling: Trastuzumab binds the extracellular domain of 
HER-2 dimers and reduces HER-2 signalling; Pertuzumab also binds the extracellular domain 
and prevents HER-2 homo- and hetero-dimerization; Lapatinib inhibits the tyrosine kinase 
domain of HER-2 and EGFR; and Tanespimycin inhibits Hsp90 activity, disrupting HER-2 
stability and function. 
_____________________________________________________________________ 
 
Another approach to targeting HER-2 is to directly target the tyrosine kinase activity. 
Small molecule tyrosine kinase inhibitors (TKIs) have been developed, and one class 
of TKIs are the quinazolines, which mimic ATP, reversibly binding to the ATP 
binding site, thereby inhibiting their kinase activity.  Lapatinib (GW572016, Tykerb) is 
a quinazoline TKI, and is a dual inhibitor of both EGFR and HER-2. Lapatinib inhibits 
breast cancer cell proliferation in vitro, and downregulates HER-2, Raf, Akt, and Erk 
phosphorylation. The combination of lapatinib and trastuzumab had synergistic anti-
proliferative effects in HER-2-overexpressing breast cancer cell lines [113]. Lapatinib 
has also demonstrated activity in HER-2-positive patients [114], and was recently 
approved by the FDA for use in combination with capecitabine in patients with 
advanced metastatic breast cancer, and is also in phase III clinical trials in breast and 
other carcinomas (discussed further in section 1.3.2). Many other HER-2, and HER 
family, TKIs are being developed pre-clinically, including both reversible and 
irreversible TKIs  (Table 1.1.1).   
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Other strategies under investigation for targeting HER-2 include ribozymes, antisense, 
small interfering RNA, and HER-2 antibodies conjugated to cellular toxins, or to 
chemotherapy-containing immunoliposomes [115]. Vaccines eliciting a response to 
HER-2 antigen are currently in clinical trials [116]. A number of other agents 
indirectly affect HER-2 protein expression and may prove beneficial in HER-2-
overexpressing cancers, such as HSP90 inhibitors, COX-2 inhibitors, deacetylase 
inhibitors, or gene therapy with transcriptional factors (reviewed in [115]).  
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_____________________________________________________________________ 
 
Table 1.1.1.  HER-2 antagonists currently in clinical use or in pre-clinical/clinical 
development. 
 
Inhibitor Category Targets Status 
Trastuzumab 
(Herceptin) 
Monoclonal 
antibody 
HER-2 Approved for HER-2 
positive metastatic breast 
cancer and for node positive 
early stage breast cancer. 
Pertuzumab 
(Omnitarg) 
Monoclonal 
antibody 
HER-2 Phase III trials 
Lapatinib 
(Tykerb) 
TKI - Reversible EGFR & HER-2 Approved for trastuzumab-
refractory HER-2 positive 
metastatic breast cancer 
CP-724,714 TKI - Reversible HER-2 Phase I/II trials 
TAK165 TKI - Irreversible HER-2 Phase I trials 
AEE-788 TKI - Reversible EGFR, HER-2 & 
VEGFR 
Phase I/II trials 
BMS-599626 TKI - Reversible EGFR & HER-2 Phase I trials 
Arry-334543 TKI - Reversible EGFR & HER-2 Phase I trials 
BIBW2992 TKI - Irreversible EGFR & HER-2 Phase II trials 
HKI-272 TKI - Irreversible EGFR & HER-2 Phase II trials 
MP-412 TKI - Irreversible EGFR & HER-2 Preclinical evaluation 
CI-1033 TKI - Irreversible Pan-HER Phase II trials 
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1.2 HER-2 Targeted Therapies 
1.2.1 Trastuzumab 
 
1.2.1.1 Mechanisms of action of trastuzumab 
As mentioned above trastuzumab binds to the extracellular domain of HER-2 and 
inhibits tumour cell growth. The mechanisms of action of trastuzumab are not yet fully 
understood. Several models have been proposed, some of which are discussed below. 
   
(i) Downregulation of HER-2 
It is still unclear as to whether trastuzumab causes down-modulation of HER-2. Ligand 
binding to EGFR family members causes ligand-receptor complexes that are 
internalized within endosomes.  Once there, the ligand-receptor complex dissociates 
and the receptor can either be transported to lysosomes for degradation, or recycled 
back to the cell surface. When HER-2 is overexpressed, signalling is mediated 
preferentially by heterodimers containing HER-2 [15]. Dimers containing HER-2 
preferentially result in receptor recycling, thereby efficiently sending prolonged 
proliferative signals to the nucleus [117].  It has been hypothesized that anti-HER-2 
antibodies promote the degradation pathway for HER-2-containing endosomes [117].  
This hypothesis, however, was challenged by Austin et al [118], who demonstrated 
that trastuzumab does not downregulate HER-2, but recycles passively with the 
receptor after endocytosis. Other groups have also demonstrated that membrane 
receptor levels do not change in response to trastuzumab  [119, 120].   
 
(ii) Reduced HER-2 signalling 
A proposed mechanism of action is the reduction of signalling through Akt and MAPK 
pathways, thereby promoting apoptosis and inhibiting proliferation [119, 121] (Figure 
1B).  Nagata et al [122] demonstrated that trastuzumab specifically disrupts HER-2-
Src interactions, leading to inactivation of Src.  This in turn causes reduced PTEN 
phosphorylation, increasing PTEN phosphatase activity. This leads to rapid Akt 
dephosphorylation and inhibits cell proliferation.  
 
(iii) Inhibition of HER-2 extracellular domain (ECD) shedding 
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When overexpressed, HER-2 undergoes proteolytic cleavage by matrix 
metalloproteinase-like enzymes, which results in the shedding of its ECD, and the 
production of a truncated membrane-bound fragment, p95 [123]. In vitro studies have 
demonstrated that this p95HER-2 fragment has kinase activity, can form heterodimers 
with HER-3, and can be tyrosine phosphorylated by neuregulin-1 [86, 87].  The ECD 
can be detected in cell culture medium, and in the serum of breast cancer patients.  
ECD cleavage was shown to be a ligand-independent method of HER-2 activation in 
vivo [124]. Trastuzumab inhibited ECD shedding in SKBR3 and BT474 breast cancer 
cell lines, by blocking matrix-metalloproteinase-mediated cleavage of the ECD  [125].  
Clinical studies also report a decline in serum ECD levels during trastuzumab 
treatment [126], and suggest that serum levels prior to treatment may be predictor of 
response  [127, 128]. 
 
(iv) G1 arrest 
One of the mechanisms of action of trastuzumab is the induction of cell cycle arrest at 
the G1 phase, and this is associated with reduced expression of proteins involved in 
sequestering the cyclin-dependent kinase (cdk) inhibitor p27kip1, including cyclin D1. 
This results in the release of p27kip1, allowing it to bind and inhibit cyclin E/cdk2 
complexes [129-131].  A number of signalling pathways, including the Akt cascade, 
have been associated with trastuzumab-mediated induction of p27kip1 activity [132].  
 
(v) Induction of apoptosis 
Single agent trastuzumab reduces tumour size in patients with HER-2-overexpressing 
metastatic breast cancer [133].  Whether this cytotoxic effect is a direct effect on the 
cancer cells or whether it is mediated by indirect mechanisms (by the immune system 
or anti-angiogenic activity) has yet to be defined.  Trastuzumab-induced apoptosis has 
not been observed using in vitro models, but the situation in vivo is less clear. Mohsin 
et al [134] report that reduction of tumour size after three weeks of trastuzumab 
treatment in 35 breast cancer patients is accompanied by an average 35% increase in 
apoptosis.  In another small pilot study (n=11), Gennari et al [120] found no decrease 
in tumour size following treatment with trastuzumab, but reported a strong increase in 
infiltrating lymphoid cells.  The authors suggest that the response seen by Mohsin et al 
[134] may be due to an inflammation response caused by the core biopsy method used, 
rather than an early apoptotic response to trastuzumab [135].  Though further 
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investigation is required to characterize the cytotoxic effect of trastuzumab alone in 
cancer cells, trastuzumab has been shown to sensitize breast cancer cells to apoptosis-
inducing agents. Trastuzumab sensitized cells to paclitaxel and etoposide by reducing 
the inhibitory phosphorylation of p34(Cdc2), down-regulating p21(Cip1), and reducing 
expression of anti-apoptotic Bcl-2 family member MCl-1 [136, 137].  Trastuzumab 
also enhanced tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-
induced apoptosis, by inhibiting Akt signalling in ovarian and breast cancer cells 
[138].  
 
(vi) Inhibition of angiogenesis 
Overexpression of HER-2 in breast cancer cells correlates with elevated vascular 
endothelial growth factor (VEGF) expression and increased angiogenesis [139-141].  
Trastuzumab induced normalization and regression of vasculature in a mouse model by 
reducing the expression of VEGF, and increasing expression of the anti-angiogenic 
factor thrombospondin-1 [142].  Klos et al [143] showed that the combination of 
trastuzumab and paclitaxel inhibited angiogenesis to a greater degree than either drug 
alone in breast cancer xenografts.  This result may reflect a more efficient drug 
delivery to trastuzumab-normalized tumour vasculature. The HER-2/trastuzumab-
regulation of VEGF activity was mediated by Akt and mTOR signalling [144].  
 
(vii) Inhibition of DNA repair 
Trastuzumab interferes with the ability of cells to repair DNA damage after platinum 
therapy or ionizing radiation [145-147]. Pietras et al [145] demonstrated that 
trastuzumab reduced unscheduled DNA synthesis (a measure of DNA repair) by 35-
40% after cisplatin treatment of breast and ovarian cell lines, and termed this 
phenomenon ‘receptor enhanced chemosensitivity’.  Trastuzumab also decreased DNA 
repair by 25-44% after irradiation of MCF7-HER-2-transfected cells [148], and the 
combined treatment caused complete remission of  MCF7-HER-2 xenograft tumours 
in mice.  p21 is likely to be involved in trastuzumab-inhibition of DNA repair, as 
trastuzumab blocks cisplatin-induction of p21 [148] and blocks phosphorylation of p21 
after radiation [147].  Trastuzumab also promoted DNA strand breaks in BT474 and 
SKBR3 breast cancer cells [149], and increased gene transcription of proteins involved 
in DNA repair  [150].  These data suggest that trastuzumab either promotes DNA 
 27 
damage independently, or inhibits its repair in association with therapeutic agents, 
resulting in apoptosis.  
 
(viii) Antibody-dependant cell-mediated cytotoxicity (ADCC) 
Animal studies and clinical trials have demonstrated that trastuzumab possesses 
cytotoxic as well as cytostatic properties, and these properties may be due to the 
induction of an immune response.  ADCC is mainly due to the activation of natural 
killer (NK) cells, which express the Fc? receptor (Fc?R), and can be bound by the Fc 
domain of trastuzumab IgG1.  Clynes et al [151] used  Fc?R-knock-out mice models 
with BT474 xenografts, and showed that while trastuzumab reduced tumour volume by 
90% in Fc?R+/+ mice, its cytotoxic activity was significantly impaired in Fc?R-/- mice, 
where it reduced tumour volume by only 29%.  Mutations in the Fc? binding domain 
of trastuzumab also decreased its binding, and anti-tumour activity demonstrating the 
importance of the Fc- Fc?R interaction in mediating the ADCC effects of trastuzumab.   
 
1.2.1.2 Trastuzumab clinical trials 
Trastuzumab achieved overall responses of between 11 and 15%, as a single agent, in 
HER-2-positive metastatic breast cancer patients who had progressed after 
chemotherapy [102, 133, 152]. As a first-line treatment, trastuzumab produced 
response rates of 26-34% in HER-2-positive metastatic breast cancer patients [133]. 
The pivotal phase III trial of trastuzumab in combination with chemotherapy, in HER-
2 positive metastatic breast cancer, demonstrated improved overall response rate (50% 
versus 32%), longer duration of response (time to progression: 7.4 versus 4.6 months), 
longer survival (overall survival: 25.1 versus 20.3 months) and a 20% reduction in risk 
of death, compared to chemotherapy alone [103]. Trastuzumab has been tested in 
combination with a variety of chemotherapy agents, including taxanes, platinum salts, 
vinorelbine and gemcitabine, with response rates ranging from 24% to 84% [153].  
 
In early clinical studies with trastuzumab, cardiomyopathy was observed in a small 
percentage of patients. This cardiotoxicity was most notable in patients who 
concurrently received anthracyclines [103]. On the basis of these findings, concurrent 
use of anthracyclines and trastuzumab is not recommended. The 
trastuzumab/anthracycline-enhanced cardiotoxicity is believed to be mediated by 
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inhibition of neuregulin-1 growth and survival signals in cardiomyocytes. Neuregulin-
1 signalling via HER-2 and HER-4 protects cardiomyocytes from anthracycline-
induced cell death, therefore inhibition of HER-2 by trastuzumab may enhance the 
cytotoxic effects of anthracyclines in cardiomyocytes, increasing the likelihood of 
cardiac dysfunction [37, 154].  
 
The most significant advancement in the treatment of HER-2-positive breast cancer 
came from five randomized trials demonstrating the benefit of trastuzumab treatment 
for early stage HER-2 positive breast cancer. Addition of trastuzumab to adjuvant 
therapy resulted in 39-52% reduction in disease recurrence [155]. A recent meta-
analysis of the five adjuvant trials, comparing adjuvant trastuzumab plus chemotherapy 
versus chemotherapy alone, showed a significant reduction in mortality (p < 0.00001), 
recurrence (p < 0.00001) and rates of metastasis (p < 0.00001) for the trastuzumab-
containing regimens [156]. 
 
In the neo-adjuvant setting, addition of trastuzumab to chemotherapy has achieved 
pathological complete response (pCR) rates of 12-65% and clinical complete response 
rates of 30-86% [153]. A randomised trial to comparing trastuzumab plus 
chemotherapy to chemotherapy alone in the neo-adjuvant setting was performed in 42 
patients but was stopped early by the Data Monitoring Committee because of the 
superior results observed for the trastuzumab plus chemotherapy group (pCR 66.7% 
versus 25%) [157].  
 
1.2.1.3 Mechanisms of trastuzumab resistance 
Despite the proven clinical benefits of trastuzumab therapy, either as a single agent or 
in combination, not all patients that overexpress HER-2 respond to trastuzumab. In 
fact, less than 35% of patients with HER-2 overexpressing metastatic breast cancer 
respond to trastuzumab as a single agent [133] and the majority of those who achieve 
an initial response, acquire resistance within one to two years [119, 158] . Several 
mechanisms have been proposed in an attempt to explain both intrinsic and acquired 
resistance to trastuzumab. HER-2 is the preferred dimerization partner of the HER 
family and has been described as a non-autonomous amplifier of the HER signalling 
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network [17]. Alterations at any stage of this complex network may confer resistance 
to trastuzumab. 
 
(i) Altered receptor-antibody binding 
Trastuzumab binds to the extracellular domain (ECD) of the HER-2 receptor; 
disruption of this binding is therefore a potential mechanism of resistance.  Nagy et al 
[159] studied the properties of trastuzumab-resistant cell line, JIMT-1, derived from a 
HER-2 overexpressing patient with primary resistance to trastuzumab.  They found 
that though HER-2 expression, internalisation and down-regulation were similar to 
those of trastuzumab-sensitive cell lines, there was reduced number of antibody-
binding sites, indicating that HER-2 was partially masked in these cells. Expression of 
MUC4, a membrane-associated mucin that contributes to the masking of membrane 
proteins, was higher in JIMT-1 cells compared to sensitive cell lines, and high levels of 
MUC4 correlated with decreased trastuzumab binding capacity. Thus, elevated MUC4 
may promote resistance to trastuzumab by masking the antibody-binding epitopes of 
HER-2.  Knock-down of MUC4 by RNA interference increased the binding of 
trastuzumab.  JIMT-1 cells also had reduced phosphorylation of HER-2, suggesting 
that masking by MUC4 also prevents its interaction with other receptors and 
subsequent activation.  
 
(ii) Cleavage of HER-2 ECD 
The extent of enzymatic cleavage of HER-2 may also be a contributing factor in 
trastuzumab resistance. Scaltriti et al [105] showed in a small-scale study (n = 46), that 
breast cancer patients expressing p95 were less likely to respond to trastuzumab than 
those expressing the full length receptor, and that cells expressing p95 were not 
sensitive to trastuzumab but were responsive to the tyrosine kinase inhibitor lapatinib, 
which targets the ATP binding pocket of the intracellular domain of HER-2.  There is 
also evidence that the metalloprotease ADAM 10 may play a role in the cleavage of 
the HER-2 ECD. Inhibition of ADAM 10 reduced shedding of HER-2 ECD and 
increased cell line sensitivity to trastuzumab [160]. Although elucidation of the role of 
p95 in trastuzumab resistance and breast cancer is still at an early stage, inhibiting the 
cleavage of HER-2 may be an attractive target for treating trastuzumab refractory 
tumours. 
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(iii) Alternative HER signalling 
HER-2 is the preferred dimerization partner for each of the HER receptors. 
Trastuzumab does not inhibit ligand-induced heterodimerization [161, 162]. Therefore, 
increased activity of other ligands and receptors of the HER network could maintain 
HER signalling despite the presence of trastuzumab.  Ritter et al [163] reported 
increased levels of EGFR ligands such as TGF-a and heparin binding EGF in 
trastuzumab resistant BT474 cells. Increased levels of EGFR, phospho-EGFR and 
EGFR/HER-2 heterodimers were also detected in the resistant cells.  Co-expression of 
EGFR determined EGFR/HER-2 homo- and heterodimerisation in BT474 and SKBR3 
cells, and was related to reduced response to trastuzumab. The modulation of response 
was dependant on the presence of growth factors such as EGF [164]. Other studies 
have also shown that increased expression of specific HER ligands, such as TGF-a, 
made cells less responsive to trastuzumab, and in fact TGF-a was induced by 
trastuzumab treatment of metastatic breast tumours [165, 166]. Furthermore, inhibition 
of EGFR restores sensitivity to the trastuzumab resistant cells [163, 165]. These data 
suggest that trastuzumab-resistance may be associated with an EGFR-related escape 
mechanism to HER-2 inhibition.   
 
(iv) Aberrant Akt and PTEN signalling 
Alterations in the intracellular signalling of the HER network have also been 
implicated in the development of trastuzumab resistance. Increased PI3K/Akt activity 
has been reported in trastuzumab resistant cells [167, 168].  There are a number of 
independent studies which suggest that loss of the protein phosphatase PTEN may be 
responsible for this deregulated signalling in resistant cells [122, 168, 169]. PTEN 
functions as a tumour suppressor gene that negatively regulates the AKT signalling 
pathway via direct inhibition of PI3K signalling. Downregulation of PTEN by 
antisense in breast cancer cells conferred resistance to trastuzumab in vitro and in vivo 
[122].  Inhibition of proteosomal degradation of PTEN also restored sensitivity to 
trastuzumab resistant cells [168].  In 47 patients with HER-2-overexpressing breast 
cancer, reduced PTEN levels correlated significantly with decreased response to 
trastuzumab-based therapy [122], and this was confirmed in another study of 17 
clinical samples [168].  However, not all studies have linked PTEN loss with 
trastuzumab resistance. Neve et al [170] showed in a panel of nine HER-2 positive cell 
lines that there was no association between PTEN protein levels and trastuzumab 
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response. This discrepancy in the literature can perhaps be explained by a recent study 
by Berns et al [171]. Using an unbiased RNAi genetic screening approach, they 
identified knock-down of PTEN as the only gene from 8,000 screened to confer 
trastuzumab resistance on BT474 cells. Yet measurement of PTEN protein expression 
in a small group of patients (n = 51) revealed only a weak association between PTEN 
loss and poor trastuzumab response. Another mechanism by which increased activation 
of AKT signalling can occur is by activating mutations in the gene encoding the p110a 
subunit of PI3K. The authors measured the existence of these mutations in the same 
cohort of patients and again only found a weak association with poor responses to 
trastuzumab [171]. Data from this study and others suggests that PTEN loss and 
activating PI3K mutations are mutually exclusive in cancer [171, 172]. When patients 
were grouped as either PTEN lost or PI3K mutant there was a strong significant 
association with poor trastuzumab response [171]. These data suggests that increased 
activation of Akt signalling, either by loss of PTEN or by activating mutations in 
PI3K, plays a role in trastuzumab resistance. 
 
(v)  Modulation of p27kip1  
Activation of the Akt pathway has been shown to increase tumour cell proliferation via 
direct phosphorylation of the cell cycle inhibitor p27kip1. Phosphorylation of p27kip1 by 
Akt prevents its translocation to the nucleus [173, 174].  Trastuzumab-mediated 
growth arrest is dependant on p27kip1, and its inhibitory interaction with cdk2 [131].  
Nahta et al [175] demonstrated that p27kip1 levels were reduced in trastuzumab-
resistant SKBR3 cells, while expression of cdk2 was increased. Exogenous addition of 
p27kip1 into these cells restored sensitivity to trastuzumab.  Cellular localization of 
p27kip1 may also be important for trastuzumab response, as trastuzumab-resistant 
BT474 cells demonstrated loss of nuclear p27kip1 expression [176]. 
 
(vi) Increased IGF-IR signalling 
Evidence of cross-talk between IGF-IR and HER-2 signalling pathways has led to 
investigations of the role of IGF-IR in response or resistance to trastuzumab.  Lu et al 
[177] reported that IGF-IR signalling interfered with the action of trastuzumab in 
breast cancer cell lines. Trastuzumab inhibited growth of HER-2 transfected 
MCF7/HER2-18 cell lines, which express high levels of IGF-IR, only when IGF-IR 
signalling was minimized by reduction of serum concentration, or treatment with IGF-
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IR antibody aIR3 or with recombinant human (rh) IGFBP3.  On the other hand, the 
growth of SKBR3 cells, which have low IGF-IR levels, was inhibited by 42% by 
trastuzumab. However, transfection of IGF-IR into these cells conferred almost 
complete resistance to trastuzumab. Again, rhIGFBP3 restored sensitivity to 
trastuzumab.  Combining trastuzumab with reduction of IGF-IR signalling by a heat-
induced dominant negative IGF-IR, 486/STOP, resulted in synergistic effects on 
growth inhibition in MCF7/HER2-18 cells [178].  
 
Transfection of IGF-IR into SKBR3 cells also reduced p27kip1 levels [177], and IGF-I 
stimulation antagonised trastuzumab-induced p27kip1 upregulation [179].  This was 
accompanied by increased expression of Skp2, a ubiquitin ligase for p27kip1, and by 
increased association of Skp2 and p27kip1.  Nahta et al [175] established trastuzumab-
resistant SKBR3 cells by long-term exposure to trastuzumab. These cells were more 
resistant to trastuzumab, and had reduced p27kip1 levels. In both models, proteosome 
inhibitors induced p27kip1 expression [175, 179], suggesting that IGF-I-mediated 
resistance to trastuzumab involved targeting of p27kip1 to the proteosome degradation 
machinery. Akt signalling was also shown to be involved in IGF-I mediated reduction 
of p27kip1, while MAPK inhibition had no effect [179].  
 
Recently, Jerome et al [180] confirmed that rhIGFBP3 enhanced the effect of 
trastuzumab in MCF7/HER2-18 and SKBR3/IGF-IR cell lines. They also studied IGF-
IR signalling in trastuzumab-resistant BT474 cells (BT474/HerR), which had acquired 
resistance through long-term exposure to trastuzumab. BT474/HerR cells had 3-fold 
higher expression of IGF-IR compared to parental cells, and were more resistant to 
trastuzumab; trastuzumab inhibited 22% of growth, compared to 40% in parental cells. 
The combined treatment of rhIGFBP3 and trastuzumab also had significant growth-
inhibitory effects in BT474/HerR cells compared to either treatment alone, and this 
was associated with decreased phosphorylation of IGF-IR and its downstream 
signalling molecules Akt and MAPK [180].  This combined treatment also had 
significant anti-tumour effects on MCF7/HER2-18 xenografts.   
 
Nahta et al [181] demonstrated that HER-2 and IGF-IR heterodimerize in trastuzumab-
resistant SKBR3/HerR cells, and not in parental SKBR3 cells, suggesting that this 
heterodimerization contributes to trastuzumab resistance.  IGF-I also stimulated 
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phosphorylation of HER-2 only the resistant cells, while a specific IGF-IR TKI, I-
Ome-Ag538, decreased phosphorylated HER-2, again only in the resistant cells. 
Earlier studies, however, have shown that HER-2/IGF-IR heterodimers can be induced 
by IGF-I or heregulin in MCF7 cells [182], and that knocking out IGF-IR expression 
in breast cancer cells and xenografts also reduced HER-2 phosphorylation [182, 183].  
Heterodimerisation and activation of HER-2 by IGF-IR, therefore, is not exclusively a 
characteristic of trastuzumab-resistant cells.    
 
These data highlight the influence of IGF-IR signalling on response to trastuzumab in 
pre-clinical models. Kostler et al [184] analysed IGF-IR levels by IHC in 72 patients 
receiving trastuzumab for HER-2-overexpressing metastatic breast cancer. No 
correlation was observed between IGF-IR and any clinical or biological characteristics, 
including response or survival, and IGF-IR expression levels were not predictive of 
response to trastuzumab. The authors acknowledge, however, that the frequency of 
IGF-IR in this study was low, probably due to the fact that many of the tumours 
studied were grade 3 and hormone-negative, in which IGF-IR is usually down-
regulated. This analysis, therefore, included only 39 IGF-IR-positive tumours.  
Smith et al analyzed tissue samples from 77 patients who received trastuzumab and 
chemotherapy for HER-2-overexpressing metastatic breast cancer [185].  This study 
used tissue microarrays to measure expression and activation of a number of receptors, 
ligands, and downstream signaling molecules.  While HER-2, EGFR and neuregulin-1 
levels significantly correlated with patient outcome, IGF-IR expression alone did not. 
Similarly, phosphorylation of S6 ribosomal protein (pS6), which integrates signals 
through mTOR and p70 S6 kinase (p70S6K), did not have independent predictive 
value.  However, the combination of low IGF-IR expression and high pS6 levels 
predicted a favorable patient response, and the combination of low IGF-IR, high 
neuregulin-1, and high pS6 levels were most strongly correlated with response to the 
trastuzumab-containing regimen. Though the numbers of patients in each subgroup of 
this study were quite small, these data suggest that elevated IGF-IR expression may 
contribute to resistance to trastuzumab in breast cancer patients. 
 
Further studies with a larger cohort of HER-2 and IGF-IR expressing patients may 
more accurately determine the role of IGF-IR in predicting response to trastuzumab. 
Phosphorylated IGF-IR levels, or phosphorylation levels of its downstream signalling 
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mediators, such as IRS-1 or -2, Akt or MAPK, may give a more accurate indication of 
IGF-IR activity.   
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1.2.2 Lapatinib 
 
HER-2 and EGFR are co-expressed in approximately 30% of  breast cancers [186], 
and increased EGFR signalling may compensate for loss of HER-2 activity in 
trastuzumab-resistant tumours. Lapatinib (TykerbTM, GlaxoSmithKline) is a small 
molecule tyrosine kinase inhibitor of both HER-2 and EGFR, which binds reversibly 
to the ATP-binding site of both receptors and blocks receptor phosphorylation and 
activation [187].  Correlation of lapatinib response with levels of EGFR and HER-2 in 
61 cell lines, from different cancer types, showed that very high levels of EGFR and/or 
HER-2 expression increased sensitivity to lapatinib sensitivity. However, Konecny et 
al showed that in a panel of 22 breast cancer cell lines, sensitivity to lapatinib 
correlates with HER-2 expression and not with EGFR expression [113].  
 
Lapatinib inhibited the proliferation of HER-2-overexpressing breast cancer cell lines 
and xenografts [113], and also had synergistic inhibitory effects when combined with 
trastuzumab in four breast cancer cell lines, and significantly inhibited the proliferation 
of cell lines with acquired resistance to trastuzumab [113]. Lapatinib induces apoptosis 
in tumour cells in vivo [188] and the combination of lapatinib and trastuzumab 
enhanced apoptosis-induction in HER-2 overexpressing breast cancer cells in vitro 
[189]. Lapatinib in combination with tamoxifen also effectively inhibited the growth of 
HER-2-overexpressing tamoxifen-resistant tumour cells in a xenograft model [190].  
 
Lapatinib inhibition of EGFR and HER-2 phosphorylation results in inhibition of 
phospho-Akt and phospho-Erk 1/2, both in vitro and in tumour xenografts [191]. 
Konecny et al showed that lapatinib response correlates with its ability to inhibit HER-
2, Raf, Akt and Erk phosphorylation [113]. Lapatinib can also inhibit phosphorylation 
of the truncated p95 form of HER-2, which lacks the extracellular domain [87].   
 
Lapatinib has also shown clinical efficacy in breast cancer patients [187]. In one phase 
II study, single agent lapatinib was evaluated in patients with relapsed or refractory 
inflammatory breast cancer. The patients were divided into two cohorts; cohort A 
included patients with HER-2-positive disease, while cohort B included patients with 
EGFR-positive/HER-2-negative disease.  In 36 patients in total, a 62% response rate 
 36 
was reported in cohort A, compared to 8% in cohort B.  75% of cohort A patients had 
previously treated with trastuzumab, and were either refractory or resistant to 
treatment, suggesting the success of targeting the HER-2 kinase domain in HER-2 
resistant breast cancer.  Interestingly, the frequency of expression of IGF-IR was 84% 
in cohort A, suggesting that elevated IGF-IR signalling may also be contributing to 
trastuzumab resistance in these patients [186].  In another similar phase II trial, 
tumours co-expressing pHER-2 and pHER-3 were more likely to respond to lapatinib, 
and Prior trastuzumab therapy or loss of PTEN did not preclude response to lapatinib 
[108].  A decrease in serum levels of HER-2 ECD has also been correlated with 
clinical response to lapatinib [192].  
 
It has also been suggested that TKIs may have the advantage over antibody therapy of 
the ability to cross the blood brain barrier, and may therefore reduce the risk of CNS 
metastasis. In a study of 39 HER-2-positive advanced breast cancer patients with CNS 
metastatic disease, lapatinib showed clinical benefit in 5% of patients [186]; 
investigation with larger studies are warranted to explore this clinical benefit.  
Lapatinib has also shown clinical efficacy alone or in combination with trastuzumab 
against breast cancer in phase II and III trials [187], and a trial combining lapatinib and 
trastuzumab versus lapatinib alone given at progression only to HER-2-overexpressing 
breast cancer patients developing resistance to trastuzumab is currently underway.   
 
Evidence from preclinical and clinical testing of lapatinib suggests that lapatinib and 
trastuzumab have non-overlapping mechanisms of resistance. In three cell line models 
of trastuzumab resistance, lapatinib retained significant activity [113]. Biomarkers 
studies in tumour samples from patients treated with lapatinib suggest that neither loss 
of PTEN nor expression of IGF-IR preclude response to lapatinib [188, 193, 194].  
 
A recent study by Sergina et al [195], showed that reactivation of HER-3 mediated 
resistance to EGFR and HER-2 inhibition. While EGFR (gefitinib) and HER-2 
(tyrophostin) selective TKIs efficiently inhibit auto-phosphorylation of EGFR, HER-2 
and downstream MAPK and JNK signalling in HER-2 positive breast cancer cells, 
HER-3 signalling resumes after 12-24 hours of treatment. Reactivation of HER-3 leads 
to reactivation of Akt signalling and is believed to be mediated by Akt-driven negative 
feedback signalling. Concentrations of the TKIs which completely inactivate HER-2 
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effectively suppress HER-3 signalling, but these concentrations are not likely to be 
safely achievable in vivo. Although lapatinib was not tested in this study, the HER-3 
mediated escape from EGFR and HER-2 inhibition may apply to all HER TKIs. 
 
An in vitro model of acquired resistance to lapatinib was developed by chronic 
exposure of lapatinib-sensitive BT474 cells to lapatinib [196]. In this model, acquired 
resistance is attributed to a switch in cell survival dependence from HER-2 alone to co-
dependence upon ER and HER-2. The increase in ER signalling was mediated, as least 
in part, by derepression of the transcription factor FOXO3a caused inactivation of Akt 
by lapatinib. Xia et al also showed that short-term exposure to lapatinib increased 
FOXO3a activity and ER signalling in breast cancer patients after 14 days of lapatinib 
treatment [196]. Mechanisms of acquired resistance to lapatinib in HER-2 positive, ER 
negative breast cancer have not yet been reported. 
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1.3 IGF-IR IN BREAST CANCER 
 
The insulin-like growth factor system is a complex regulatory network of two peptides 
(IGF-I and IGF-II), two cell surface receptors (IGF-IR and IGF-IIR), six IGF binding 
proteins (IGFBPs), as well as IGF receptor-interacting proteins, such as those of the 
insulin-receptor-substrate (IRS) family, and IGFBP-regulating molecules such as 
proteases. The IGF system plays key roles in cellular growth, proliferation, 
differentiation, migration and apoptosis, and by regulating these cellular processes, the 
IGF system asserts its physiological influences on tissue formation and remodelling, 
bone growth, brain development, energy metabolism, and body growth and longevity 
[197-199].  Aberrant signalling through IGF-IR or its downstream pathways is known 
to contribute to human malignancy [200]. Numerous studies have reported associations 
between IGF-I, IGF-II and IGFBP levels and risk of developing a number of cancers  
[201], and overexpression of IGF-IR in cell and animal models demonstrates its role in 
transformation, tumour growth, and metastasis  [202].  In this section, the structure and 
function of the IGF system components, the signalling events that they can activate 
and the contribution of IGF-IR signalling to the malignant phenotype will be reviewed. 
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1.3.1 The IGF-I/IGF-IR system/signalling pathway 
1.3.1.1 IGF-I and IGF-II structure and function 
IGF-I and IGF-II are single chain polypeptides of 70 and 67 amino acids respectively, 
and contain four domains, A, B, C, and D.  The A and B domains of both are 50% 
homologous to those of insulin (Rinderknecht and Humbel, 1978), though the C-
termini (containing the D domain) share no homology with the proinsulin C-peptide, 
and are not cleaved from the molecule as occurs in proinsulin processing.   
 
The majority of circulating IGF-I is produced by the liver, and its production is 
strongly regulated by growth hormone (GH). However, most tissues can produce IGFs, 
and when circulating IGF-I concentration was reduced by 80% in a mouse model 
[203], the growth rate was not significantly reduced, suggesting the importance of 
autocrine or paracrine production of IGF-I in growth regulation.  In some tissues, IGF-
I gene expression is under the control of other hormones; for example, estradiol 
regulates IGF-I expression in the endometrium [204].  
 
IGF-II expression is much higher in foetal development than in postnatal or adult life 
[205]. Disruption of the IGF-I or IGF-II gene in prenatal mice leads to a 60% decrease 
in birth weight, though in postnatal mice, IGF-II is no longer expressed.  In humans, 
however, IGF-II is expressed throughout life, but cannot compensate for loss of IGF-I 
activity in patients with an IGF-I deficiency, which leads to severe developmental 
retardation [206, 207].  IGF-II is also expressed in the liver and other tissues, but is not 
tightly regulated by GH [208].  IGF-I and IGF-II bind with different affinities to IGF-
IR, IGF-IIR and IR, and despite the significant structural similarity between the 
ligands, they produce very different outcomes depending on which receptor they bind. 
 
1.3.1.2 IGF-IR structure and function 
IGF-IR is related to, and structurally similar to IR, and both are transmembrane 
tyrosine kinase receptors (TKRs). They differ from other TKRs in that they have a 
covalent dimeric structure of two a and two ß chains. Both are synthesized as single 
chain precursors that are glycosylated on the extracellular regions, dimerized and 
proteolytically processed to yield the mature receptors (reviewed in [209]).  The a-
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subunits of IGF-IR are ~135 kiloDalton (kDa) each and are extracellular, and contain 
the ligand-binding domains  [210, 211] [fig. 1.3.1].  The ß-subunits, which are 95 kDa 
each, span the membrane, and their cytoplasmic portions contain the tyrosine kinase 
domains [212]. The kinase domains are flanked by two regulatory regions, a 
juxtamembrane region used as a docking site for IRS and Shc as well as for receptor 
internalization, and a C-terminal tail containing two phosphotyrosine binding sites 
(reviewed in [213]). The kinase domains of IGF-IR and IR are 84% homologous  
[209].  
_______________________________________________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.1. Structure of the IGF-IR dimer showing the distribution of domains across the 
a-and ß-chains and the approximate location of the a-ß disulfides and the a-a dimer disulfide 
bonds [From Adams et al, 2000. © 2000 Birkhäer Verlag, Basel]. 
_______________________________________________________________________________________________________ 
 
The 3D structure of the first three domains (L1-Cys-rich-L2) of IGF-IR has been 
solved [Fig 1.3.2].  These domains surround a cavity large enough to accommodate a 
ligand molecule [214]. The cysteine-rich domain was identified as the major IGF-I 
binding site, and both the L1 and cys-rich domains are critical for IGF-I binding, 
whereas only the L1 domain is needed for IGF-II binding (reviewed in [207]). The 
structures of the active and inactive kinase domains of IR and the active kinase of IGF-
IR have also been described [215-217].  They reveal a novel mechanism of auto-
inhibition, whereby a vital tyrosine of an “activation loop” competes with protein 
substrates before phosphorylation, blocking the active site of the receptor until 
 41 
transphosphorylation, at which point the loop becomes stabilised in an open position 
(reviewed in [25]).  
_____________________________________________________________________ 
 
 
Figure 1.3.2.   3D structure of the L1-Cys-rich-L2 domain of A IGF-IR and B IR as 
determined by X-ray crystallography. The amino acids determined by site-directed 
mutagenesis to be important for ligand binding are shown in yellow as van der Waals spheres 
[213]. The 3D structures of IGF-I [218] and insulin [219] molecules are shown to scale.  
_______________________________________________________________________________________________________ 
 
Ligand binding to the a-subunits of the extracellular region of IGF-IR or IR causes a 
conformational change resulting in ATP binding and tyrosine phosphorylation of the 
activation loop of the intracellular ß-subunits, increasing the kinase activity of the 
receptor [216, 220, 221].  IGF-I, IGF-II and insulin bind to IGF-IR, IGF-IIR and IR 
with different affinities [fig. 1.3.3]. Stimulated IGF-IR can activate signalling 
pathways involved in cell proliferation, differentiation, migration and protection from 
apoptosis [197-199].  Insulin receptor-A (IR-A) and insulin receptor-B (IR-B) have 
similar affinities for insulin, though IR-B activation produces the well characterised 
metabolic responses to insulin, while IR-A has higher affinity for IGF-I and IGF-II 
than IR-B [222], and its activation leads to similar cellular responses to IGF-IR 
activation. In cells that express both IGF-IR and IR, hybrid receptors form consisting 
of one half of IGF-IR and one half of either IR-A or IR-B. These heterodimers bind 
IGF-I with high affinity, and insulin with low affinity [223]. Their cellular or 
physiological roles are unknown.  
 
IGF-IR is expressed at its highest levels during foetal and early postnatal development, 
but is expressed at lower levels in most adult tissues [224]. IGF-IR and IR have 
different, but partially overlapping physiological functions [225]. IGF-IR-deficient 
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mice, have severe foetal growth retardation, and die within minutes of birth, mainly 
due to under-developed respiratory muscles [226]. These mice also develop metabolic 
abnormalities. Genetic studies that knock out expression of one or both of IR and IGF-
IR indicate that IGF-IR is primarily a growth promoter, mediating IGF-I and IGF-II 
action on prenatal growth and IGF-I action on postnatal growth, while IR mediates 
IGF-II-induced prenatal growth, but is mainly a mediator of the metabolic effects of 
insulin. Each receptor, however, has overlapping functions with the other (reviewed in 
[199, 225]).  
 
_______________________________________________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.3. Affinity of interactions of various insulin family ligands with their receptors. 
Insulin and IGF peptides have different affinities for IR, IGF-IR and IGF-IIR. Thickness of the 
arrow represents the affinity of a ligand for a receptor. IGF-I has a higher affinity for IGF-IR 
than for IR. Binding of the ligands to IR or IGF-IR initiates signalling pathways such as IRS-1 
pathway. Binding of IGF-II to IGF-IIR leads to the degradation of this ligand. [© 2000-2005 
Landes Bioscience]. 
_______________________________________________________________________________________________________ 
 
1.3.1.3 IGF-IIR structure and function 
Unlike IGF-IR and IR, IGF-IIR (also known as cation-6-phosphate receptor) is a large 
single-chain peptide, with no intrinsic tyrosine kinase activity [227].  The receptor is a 
300 kDa protein containing an extracellular, a transmembrane, and an intracellular 
domain (reviewed in [228]).   
 
IGF-IIR binds IGF-II with high affinity, but binds IGF-I with low affinity and does not 
bind insulin (reviewed in [207] [fig. 1.3.2].  The majority of IGF-IIRs are located on 
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intracellular membranes, and their primary function is to transport IGF-II to liposomes 
for degradation, which occurs upon IGF-II ligand binding, preventing receptor 
activating interactions.  IGF-IIR also binds many other ligands, including proteins 
containing mannose-6-phosphate, and through these interactions exerts IGF-
independent effects on cell proliferation (reviewed in [229]).  
 
1.3.1.4 IGF binding proteins  
The IGFBPs are a family of six known proteins, IGFBP1 to IGFBP6, ranging in 
molecular weights from 22.8 – 31.3 kDa [230].  Each IGFBP has three distinct 
domains of approximately equal size; the N- and C-termini are highly conserved, while 
the middle or linker domain is the least conserved region [231-233]. Both the N and C 
domains are cysteine-rich and contain various disulphide bonds, and both contain IGF 
binding sites (reviewed in [232]. Both domains are required for wildtype IGF binding 
[234, 235].   
 
IGFBP precursor proteins have secretory signal peptides, and the mature proteins are 
all found extracellularly.  IGFBPs have higher affinity for IGFs (~0.1 nM) than does 
IGF-IR (~1nM); thus, by sequestering the IGFs, IGFBPs regulate their availability to 
receptors, thereby inhibiting, or enhancing, IGF actions. About 75% of circulating IGF 
is bound with IGFBP3 to form a 150 kDa complex with acid-labile-subunit (ALS) 
[236, 237].  The complex prolongs the half-life of IGFs and maintain them in 
circulation, as the complexes cannot cross the vascular endothelium.  Other IGFBPs 
bind the remaining 20 – 25% of circulating IGFs, forming smaller complexes of 40 – 
50 kDa, which can penetrate the vascular endothelium, making the IGFs available to 
local tissues [232, 237].  
 
IGFBP activity is regulated by a number of proteolytic enzymes; both IGFBP-specific 
and non-specific proteases have been identified to cleave IGFBPs. Matrix 
metalloproteinases (MMPs) are a family of proteolytic enzymes involved in tissue 
remodelling by degradation of extracellular matrix (ECM) and are known to proteolyse 
IGFBPs. Prostate specific antigen (PSA) is a serine protease that specifically acts on 
IGFBP3.  The proteolysis of IGFBPs generates protein fragments with reduced, or no 
affinity for IGFs, increasing free IGF levels [238].   
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1.3.1.5 IGF-IR activation and signal transduction 
Ligand binding to IGF-IR causes a conformational change, resulting in ATP binding, 
and autophosphorylation of its intracellular kinase domain  [216, 220, 221].  IGF-IR 
has fifteen tyrosine residues in total in its cytoplasmic domain; three at positions 1131, 
1135 and 1136 are contained within the activation loop and are vital for ligand-
stimulated activation. The subsequent phosphorylation of five other tyrosines  [239, 
240] provides docking sites for a wide range of intracellular proteins (summarised in 
table 1.3.1), which then initiate multiple signalling cascades.  
 
______________________________________________________________________________________________________ 
Table 1.3.1. Cellular proteins interacting with the cytoplasmic domain of IGF-IR (from 
Adams et al, 2000).  
 
Protein Function 
  IRS-1 adaptor 
  IRS-2 adaptor 
  IRS-3 adaptor 
  Shc adaptor 
  Grb10 adaptor 
  CrkII adaptor 
  SH2-B adaptor 
  p85 regulatory subunit of PI3K 
  p55? regulatory subunit of PI3K 
  GAP GTPase-activating protein 
  Syp/SHP-2 tyrosine phosphatase 
  CSK cytoplasmic tyrosine phosphatase 
  Jak-1 cytoplasmic tyrosine phosphatase 
  SOCS-1 suppressor of cytokine receptor signalling 
  SOCS-2 suppressor of cytokine receptor signalling 
  14.3.3ß adaptor ‘scaffolding’ proteins 
  14.3.3? adaptor ‘scaffolding’ proteins 
  14.3.3e adaptor ‘scaffolding’ proteins 
_______________________________________________________________________________________________________ 
 
The two best characterised pathways associated with IGF-IR activation are the MAPK 
signalling cascade, initiated by the phosphorylation of Shc, and the Akt pathway, 
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initiated by phosphorylation of IRSs.  Shc contains a phosphotyrosine binding (PTB) 
domain as well as numerous tyrosine residues which can be phosphorylated by IGF-IR 
[24]. There are four known IRS proteins (IRS-1 – 4), and each contains a 
phosphotyrosine binding (PTB) domain, an N-terminal PH domain, and a C-terminal 
rich in tyrosine residues, but no SH2 domain.  IRS-1 and IRS-2 are the best 
characterised. The PTB domain of IRS-1, IRS-2 and Shc bind to the same 
phosphotyrosine (p-Tyr 950) within the juxtamembrane region of IGF-IR, and for Shc 
and IRS-1 binding, a tyrosine-phosphorylated NPEY motif within the juxtamembrane 
domain is required [24].  The C-terminal domain of the IRSs contain multiple tyrosine 
phosphorylation sites, varying from 13 in IRS-3 to over 20 in IRS-1 [209], and these 
residues are within motifs known to favour interaction with SH2 domains [241].  
Phosphorylated IRSs interact with various SH2-containing proteins such as adaptor 
proteins Grb2, Shc and Nck, the tyrosine phosphatase Shp2, the cytoplasmic tyrosine 
kinase Fyn and the p85 regulatory subunit of phosphoinositol 3-kinase (PI3K) [242, 
243]. IRS-1 responds more rapidly than Shc to IGF-I stimulation; maximal 
phosphorylation of IRS-1 is seen within 1 – 2 minutes of simulation, while for Shc this 
occurs between 5 – 10 minutes [244, 245].  Receptor internalisation also seems to be 
required before maximal phosphorylation of Shc is achieved  [244].  IRS-1 may also 
activate the MAPK pathway, as Grb2 can also associate with IRS-1 via its SH2 
domain. IRS-2 can also bind Grb2, though this association is not linked to activation of 
the MAPK cascade  [209].  In the absence of IRS-1, MAPK signalling provides an 
alternative pathway to IGF-IR-mediated protection from apoptosis, and a second 
alternative is through 14.3.3 protein [246].  
 
IGF-IR signalling, through multiple pathways, mediates cell cycle progression, cell 
proliferation, differentiation and apoptosis, and in doing so, plays key roles in tissue 
formation, specific organ development, energy metabolism, and overall body growth 
and longevity.  
 
Aberrant signalling through IGF-IR or its downstream pathways contributes to 
malignant transformation. The critical role of the ß-subunit of IGF-IR in the 
stimulation of cancer cell growth was elucidated using site-directed mutagenesis [220, 
239, 247-250]. Cells transfected with a truncated ß-subunit, lacking the kinase domain, 
were completely unresponsive to IGF-I stimulation and were unable to sustain 
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anchorage-independent growth or form tumours in nude mice.  The specific signalling 
roles of some of the tyrosine residues of the kinase domain have been identified: 
tyrosines 1131, 1135 and 1136, which are needed for signal activation, are required for 
induction of transformation, and mitogenesis.  Mutation of tyrosine 1136 resulted in 
decreased colony formation in soft agar, and mutations of any two or all three, of the 
tyrosines blocked transformation and metastasis.  Tyrosines 1250 and 1251 have been 
identified to have roles in the maintenance of a tumorigenic/metastatic phenotype, and 
may also have other functions [251]. 
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1.3.2 The IGF-IR system in breast cancer 
1.3.2.1 IGF-I ligand and IGFBP3; population studies 
IGF-I levels are highest at puberty and decline afterwards, and IGF-I and IGFBP3 
concentrations vary hugely between individuals. Normal adults of age 40 - 60 years 
have IGF-I serum levels of approximately 100– 300 ng/ml, and IGFBP3 levels of 
approximately 2000–6000 ng/ml [252-255]. Since 1998, several epidemiological 
studies have reported that higher circulating levels of IGF-I are associated with 
increased risk of developing breast cancer [253, 256-258].  The ratio of IGF-I to 
IGFBP3 has also been associated with an increased risk of cancer [259, 260].  Most of 
these studies divided the population into categories (tertiles, quartiles or quintiles) 
based on IGF-I or IGFBP3 concentrations, and compared the uppermost and 
lowermost categories.  The results from studies of breast and other cancers have been 
inconsistent, probably due to varying methods of sample collection and analysis 
(enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) or 
immunoradiometric assay (IRMA)).  In 2004, Renehan et al [260] published a 
systematic review and analysis of published data on prostate, colorectal, breast and 
lung cancer. They concluded that though the associations were weaker than previously 
suggested, higher circulating levels of IGF-I was associated with increased risk of 
prostate, colorectal and premenopausal breast cancer, but not lung cancer.  Higher 
IGFBP3 levels were related to decreased risk of lung cancer only [260]. Evidence from 
patients with acromegaly – a condition caused by excess production of growth 
hormone and resulting in IGF-I levels above the normal range – support the role of 
IGF-I in cancer development as patients with this condition are at an increased risk of 
cancer, particularly colorectal cancer [261]. 
 
Data from population studies of IGF-I and IGFBP3 levels and risk of breast cancer are 
inconsistent. Early studies demonstrated that IGF-I serum levels are significantly 
higher in breast cancer patients than normal controls [262-264]; that IGFBP3 levels are 
higher in breast cancer patients than controls [263, 265]; that the ratio of IGF-I to 
IGFBP3 is significantly elevated in premenopausal breast cancer [266]; and that high 
IGF-I and/or low IGFBP3 is associated with increased risk of premenopausal breast 
cancer [256, 264, 267]. Later studies, however, reported no association between IGF-I 
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levels and pre- or postmenopausal breast cancer [268, 269], while another reported 
positive associations between both IGF-I and IGFBP3 and risk of breast cancer [270].  
There is overall consensus regarding lack of an association between either IGF-I or 
IGFBP3 and postmenopausal breast cancer, with the exception of a small study of 
African-American women with 30 postmenopausal breast cancer patients and 30 
controls that found a significant association between high IGF-I levels and increased 
breast cancer risk [271].  
 
Renehan et al [201] carried out a meta-analysis of 12 prospective cohort studies, 
calculating cumulative risk ratios (see table 1.3.2). They conclude that higher IGF-I 
levels are associated, though not as strongly as previously thought, with increased risk 
of pre-menopausal breast cancer (risk ratio = 1.69), or in women under 50 (risk ratio = 
2.13). IGFBP3, however, is not associated (risk ratio = 1.11) with risk of pre-
menopausal breast cancer. Rollison et al [272] recently demonstrated that high pre-
menopausal levels of IGF-I (at ages 25-35) in 152 women were associated with risk of 
post-menopausal breast cancer. Further investigation is needed to determine the 
significance of these findings. 
 
These data identify IGF-I as a risk factor for premenopausal breast cancer, and suggest 
that IGFBP3, either by its independent actions, or by its association with IGF-I ligand, 
may also influence the development of breast cancer in premenopausal women.  
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______________________________________________________________________________________________________________________________________________________________________________ 
 
Table 1.3.2.  Sumamry of studies of IGF-I and IGFBP3 levels and risk of premenopausal breast cancer (NA, not available). 
 
 
Study Year Summary of findings Group
no. cases / 
controls
OR for  
IGF-I
OR for 
IGFBP3
Rinaldi et al 2006 Associations with IGF-I and IGFBP3 in women > 50 only. < age 50 NA 1.03 0.92
Schernhammer et al 2006 No associations in pre- or post-menopausal women. pre-meno 239/478 0.98 1.10
Rinaldi et al 2005 Modest associations with IGF-I and IGFBP3 in pre-menopausal women. pre-meno 138/259 1.41 1.77
Schernhammer et al 2005 Modest association with only IGF-I in pre-menopausal women. pre-meno 218/281 1.60 1.20
Allen et al 2005 Modest association with only IGF-I in pre-menopausal women. pre-meno 70/209 1.71 0.49
Muti et al 2002 Associations with IGF-I and IGFBP3 in pre-menopausal women. pre-meno 69/267 3.12 2.31
Krajeik et al 2002 Associations with IGF-I and IGFBP3 in pre-menopausal women. pre-meno 66/66 2.01 5.28
Kaaks et al 2002 No associations in pre- or post-menopausal women. < age 50 116/330 0.63 1.37
Toniolo et al 2000 Association with only IGF-I in pre-menopausal women. pre-meno 172/486 1.60 1.18
Hankinson et al 1998 Association with IGF-I in pre-menopausal women. pre-meno 76/105 2.88 -
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1.3.2.2 Overexpression of IGF-IR in breast cancer 
Studies in breast cancer in the 1990s, using ligand-binding methods (histo-
autoradiographic analysis (HAA), radio-receptor assay (RRA or RIA) reported that 
IGF-IR is expressed in 39 – 93% of breast cancer samples  [273-275], that IGF-IR 
expression is higher in breast cancer than normal tissues [274, 276], and that it 
correlates with favourable prognosis in breast cancer patients [274].  Later studies of 
larger numbers of cases, however, have quantified IGF-IR expression by 
immunohistochemistry (IHC). IGF-IR staining of breast cancer tissues is scored on a 
scale of 0 – 3+.  Nielson et al [277] reported high expression  (scores of 2+ - 3+) in 
87% of 707 breast cancers by tissue micro-array (TMA). Interpretation of scoring may 
vary between studies, and two other groups reported overexpression (scores of 2+ - 3+) 
in 44% of 210 breast cancers by IHC [278], and 47% of 150 breast cancers by TMA 
[279]. Tissue studies report no correlation with survival [277, 278, 280].  Other tissue 
sample studies compared tumour samples to benign, adjacent or normal samples. 
Happerfield et al [273] reported either no difference between breast carcinoma and 
normal tissue, and a more recent, though smaller, study with paired breast cancer and 
adjacent non-malignant tissue also found no difference in expression (n=31 pairs) 
[281]. Recent studies report higher mRNA levels in normal or tumour-adjacent breast 
than breast cancer [280, 282, 283], and higher levels in benign breast disease (n=206) 
than primary breast cancer (n=508) [280]. Schnarr et al [284] found that IGF-IR is 
expressed at high levels in control samples and in well- and moderately-differentiated 
carcinomas, but at low levels in poorly differentiated breast cancers.  Downregulation 
of IGF-IR correlated with tumour progression. Expression of IGF-IR was also found to 
be more frequent in primary breast tumours (56%) than lymph node metastasis (44%) 
[285]. These data suggest that progression of breast cancer is accompanied by a 
reduction of IGF-IR signalling.  
 
LeRoith and Roberts [286] suggest that decreased expression of IGF-IR may protect 
cells from a recently described, non-apoptotic form of programmed cell death that is 
triggered by the unliganded IGF-IR [287].  
 
Although IGF-IR may not be overexpressed in breast cancer to the extent that was 
originally suggested, there is evidence to support the role of the IGF-IR signalling 
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pathway in breast cancer.  IGF-IR is present in most breast cancer tissue samples [273, 
277, 279, 280, 288] and cell lines studied to date [289, 290].  
 
Resnik et al [200] have demonstrated that IGF-I receptor activation is also enhanced in 
malignant breast tissue.  IGF-IR/insulin receptor hybrids, which can also mediate IGF-
I signalling, are also overexpressed in breast cancer [291].   
 
Increased IRS-1 levels have also been associated with tumour development, hormone 
independence, and anti-estrogen resistance in breast cancer [292].  IRS-1 levels also 
correlated with recurrence in 195 early stage tumours [293]. Schnarr et al [284] found 
higher IRS-1 expression in normal tissue and well- and moderately-differentiated 
breast cancers than in poorly differentiated breast cancers, and report that 
downregulation of IRS-1 correlates with disease progression (n=69). Koda et al [294], 
however, found similarly high levels of IRS-1 in both primary and metastatic tumours, 
though in well-differentiated tumours, there was a significant correlation between IRS-
1 levels in the primary and the metastatic tumours. These data seem somewhat 
contradictory, but perhaps the proliferative and anti-apoptotic effects of IRS-1 are 
required for transformation  tumourigenesis, and proliferation of primary or secondary 
tumours, but its downregulation may be required for dedifferentiation and metastasis 
[295]. Its downregulation may facilitate IRS-2-mediated IGF-IR signalling. The 
distinct responses of IRS-1 and IRS-2 to IGF-IR activation have recently been 
demonstrated [296]; proliferation and anti-apoptotic responses are mediated by IRS-1  
[294], while motility and metastasis correlate with increased IRS-2 activity [297].  
 
It is also interesting that loss of heterozygosity of the IGF-IIR locus and mutations of 
the IGF-IIR binding domain of the remaining IGF-IIR allele are prevalent in breast 
cancer; perhaps the loss of ability of IGF-IIR (which has no kinase domain) to bind 
IGF-II allows increased interaction of IGF-II with IGF-IR, thereby increasing kinase 
activity and enhancing IGF-IR signalling [298]. 
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1.3.3 IGF-IR signalling in breast cancer 
1.3.3.1 Anti-apoptotic IGF-IR signalling  
IGF-I/IGF-IR signalling has potent anti-apoptotic effects on cancer cells.  This has 
been demonstrated with the use of antisense RNA technology, and a dominant 
negative mutant form of IGF-IR, both of which inhibited proliferation of cancer cells 
in monolayer and soft agar [299-301]. IGF-IR antisense also prevented the growth of 
C6 glioblastoma and FO-1 human melanoma cells in nude mice [299, 300], and 
expression of 468/STOP, a dominant negative IGF-IR, in C6, 3T3 and R- cells, 
induced expansive apoptosis in vivo [301]. Interestingly, cells expressing this mutant 
form were also shown to have a bystander effect, whereby they can inhibit the growth 
of wild-type tumours when mutant cells are co-injected with wild-type cells [302].  
 
Overexpression of IGF-IR in MCF-10A breast cells enhanced proliferation and 
decreased apoptosis [303].  IGF-I signalling also protects breast cancer cells from 
apoptosis induced by numerous types of chemotherapies including antimetabolites (5-
fluoruracil, methotrexate), antiestrogen (Tamoxifen),  and topoisomerase 1 inhibitors 
(camptothecin) in HBL100 cells [304], and microtubule-stabilising agents (paclitaxel) 
and anthracyclines (doxorubicin) in MCF7 cells [305]. IGF-IR was demonstrated to 
exert some of its anti-apoptotic effects through transactivation of EGFR, which 
activates MAPK signalling and anti-apoptotic protein BAD in mammary epithelia cells 
[306]. Overexpression of IGF-IR in SKBR3 cells promoted resistance to the EGFR 
tyrosine kinase inhibitor gefitinib (Iressa), while downregulation of IGF-IR enhanced 
response and apoptosis-induction [307]. Overexpression of IGF-IR in MCF-10A cells 
upregulated phosphorylation of Ser473 of Akt and Ser2448 of mTOR [303].  Studies have 
shown that IGF-I rescue of MCF7 cells from chemotherapy-stimulated cell death 
involves at least two mechanisms; inhibition of apoptosis through PI3K/Akt, and 
induction of proliferation through both PI3K/Akt and MAPK signalling cascades [298, 
305]. 
 
Several recent reports have demonstrated that IGFBP3 induces apoptosis in cancer 
cells, for example, in MCF7 breast cancer [308] cells, and can enhance ceramide-
induced apoptosis in Hs578T breast cancer cells [309]. These effects may be due to 
sequestering of IGFs, thereby blocking their anti-apoptotic signalling through IGF-IR 
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[308]. However, IGFBP3 can also induce apoptosis in an IGF/IGF-R-independent 
manner, as was demonstrated in an IGF-IR-negative fibroblast cell line [310].  
Transfection of IGFBP3 into T47D and MCF7 breast cancer cell lines also induced 
apoptosis, increased the ratio of pro-apoptotic to anti-apoptotic members of the Bcl-2 
family, and sensitized cells to ionising radiation-induced apoptosis [311].  
Furthermore, paclitaxel-induced apoptosis in Hs578T cells was accompanied by an 
increase in IGFBP3 levels, suggesting that IGFBP3 may be an important modulator of 
paclitaxel-induced apoptosis [312]. Kim et al [313] demonstrated that IGFBP3-
induced apoptosis in MCF7 breast cancer cells is IGF-IR-independent, and is mediated 
via a caspase-7 and -8 pathway, with minimal release of cytochrome c from the 
mitochondria or caspase-9 activity. This suggested that IGFBP3-induced apoptosis is 
executed via the death receptor pathway rather than the intrinsic apoptotic pathway.  
 
1.3.3.2 IGF-IR and PTEN signalling interactions 
The protein encoded by the phosphatase and tensin homolog (PTEN) gene is a 
phosphatase that can regulate both protein and lipid phosphorylation. It can 
dephosphorylate PIP2 and PIP3, and in doing so, prevents PI3K-mediated activation of 
Akt [29]. PTEN protein thus suppresses tumour formation by restraining the PI3K/Akt 
pathway [314].  PTEN mutations and loss of heterozygosity (LOH) of the PTEN locus 
have been reported in a number of cancer cells lines and advanced cancers, including 
breast cancer  [315]. Loss of PTEN has been reported in approximately 40% of 
advanced breast cancers, and is often associated with ER negativity [315-319].  In 
addition to suppressing downstream signalling of IGF-IR, PTEN activity 
downregulates IGF-IR protein expression and function in a number of human cancers, 
including gastric adenocarcinoma, multiple myeloma, pancreatic, lung, and prostate 
cancer [320-324].  PTEN can also downregulate IGF-I, IGF-II activity and upregulate 
IGFBP3 expression in gastric, lung and prostate cancer [325].  Loss of PTEN therefore 
enhances IGF-I/IGF-IR signalling by different mechanisms; increasing PI3K activity, 
increasing IGF-IR, and IGF ligand levels, and reducing IGFBP3 levels.  The role of 
PTEN in regulating IGF-IR signalling in breast cancer has yet to be thoroughly 
examined. Weng et al [326, 327] demonstrated that overexpression of PTEN in MCF7 
cells inhibited the phosphorylation of Akt in response to stimulation by many different 
growth factors, and selectively decreased ERK phosphorylation stimulated by insulin 
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and IGF-I, but not EGF. Inhibition of IGF-I-stimulated ERK was accompanied by 
decreased IRS-1 phosphorylation and reduction in its association with Grb2/Sos [326].  
Insulin, IGF-I and EGF also upregulate the activity of Ets-2, a transcription factor 
whose function is controlled by phosphorylation, in MC7F cells. Akt inhibition had no 
effect on Ets-2 activity, while MEK inhibition decreased its phosphorylation. 
Overexpression of PTEN also decreased the phosphorylation of Ets-2 in response to 
insulin and IGF-I, but not EGF, stimulation [327].  These results demonstrate the role 
of PTEN in regulating insulin and IGF-I-mediated MAPK signalling, and that its 
effects influence their downstream targets such as the Ets-2 transcription factor. 
Moorehead et al [328] reported that IGF-II upregulates PTEN in the mammary gland, 
leading to decreased Akt signalling, epithelial proliferation, and mammary 
morphogenesis. Perhaps, therefore, in the absence of IGF-I, IGF-II-stimulated IGF-IR 
(or IR) signalling promotes apoptotic and anti-proliferative pathways, but in breast 
cancer, increased IGF-I levels and signalling may counteract these effects, protecting 
from apoptosis and enhancing proliferation of malignant cells. 
 
1.3.3.3 IGF-IR and ER signalling 
Estrogen signals through estrogen receptors (ERa and ERß), which are nuclear 
receptors, and members of a superfamily of ligand-inducible transcription factors [329, 
330].  Estrogen signalling has been associated with increased breast cancer risk [331], 
and  many studies of overexpression of IGF-IR in breast cancer tissues report a 
correlation between IGF-IR levels and positive ER status [273, 274, 279, 285].  Koda 
et al [288] also found that ERa expression correlated positively with anti-apoptotic 
Bcl-2 and negatively with pro-apoptotic BAX proteins in breast cancer samples.  In 
recent years, there has been increasing evidence of cross-talk between the IGF/IGF-IR 
and the ER signalling pathways.  Estrogens were shown to increase IGF-I binding, and 
IGF-IR mRNA levels in MCF7 cells by seven-fold, suggesting that a potential 
mechanism by which estrogens stimulate breast cancer proliferation involves 
sensitisation to the mitogenic effects of IGFs by enhancing IGF-IR levels [332].  IGF-
IR gene transcription was recently shown to be under the control of ERa, and mediated 
via interactions between ERa and Sp1 [333].  Estrogen also induced protein expression 
of IGF-IR, IRS-1 and IRS-2, and enhanced phosphorylation of IRS-1 after IGF-I 
stimulation of MCF7 cells [334]. In MCF7 xenografts, estrogen increased IRS-1 
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levels, and withdrawal of estrogen decreased growth and dramatically reduced IRS-1 
expression [334]. Oesterreich et al [335] established MCF7-derived cells selected for 
loss of ERa by long-term withdrawal of estrogen.  Selected cells had reduced IGF-IR 
and IRS-1 mRNA and protein, decreased IGF-IR signalling, and were unresponsive to 
either IGF-I or estrogen stimulus.  Re-expression of ERa restored the IGF-sensitive 
phenotype, demonstrating that ERa is a critical requirement for IGF signalling in these 
cells. In ERa-negative breast tumours, levels of IGF-IR and IRS-1 are often low, and 
IGF-I is non-mitogenic [336], and in MDA-MB-435A and MDA-MB-468 ER-negative 
breast cancer cell lines, which are unresponsive to IGF-I, expression and activation of 
IRS-1 were not sufficient to induce response to IGF-I [337], suggesting that a critical 
factor in the signalling loop was missing.  Bartucci et al [338] compared IGF-IR 
signalling in ER-positive MCF7 and ER-negative MDA-MB-231 cells. While IGF-I 
activated IGF-IR in both cell lines, it did not stimulate growth or improve survival in 
MDA-MB-231 cells, whereas in MCF7 cells, IGF-I had mitogenic and anti-apoptotic 
effects. 
 
There have also been many studies demonstrating that IGF, as well as other growth 
factors, upregulates ER transcriptional activity.  Initial studies showed that in the 
absence of estradiol, IGF-I could stimulate phosphorylation of ER and induce 
expression of an estrogen-responsive reporter gene construct [339].  This effect was 
mediated via IGF-IR, and could be blocked by an anti-estrogen [339, 340].  IGF-I also 
increased transcriptional activity of ER in MCF7, ZR75 and T47D cell lines, and this 
was blocked by tamoxifen. Furthermore, IGFBP1 not only inhibited IGF-I-activation 
of ER, but also decreased estradiol-activation of ER [341]. 
 
The pathways involved in the cross-talk between the IGF-I and ER pathways have 
been examined.  Phosphorylation of ER was carried out by MAPK in cells treated with 
IGF-I or EGF [342], while estrogen induction of IGF-IR and IRS-1 expression and 
phosphorylation led to enhanced MAPK activity in MCF7 cells [334]. IGF-I-simulated 
ERa activity was also blocked by PI3K and PKA inhibitors in MCF7 cells [343], 
demonstrating the involvement of the Akt pathway in cross-talk. ERa expression in 
MDA-MB-231 cells enhanced the stability of IRS-1 and -2 and improved cell survival 
through upregulation of the IRS-1/Akt/Glycogen synthase kinase 3 (GSK-3) pathway 
[344].  Recently Zhang et al [345] demonstrated, using small inhibitory RNA 
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molecules targeting ERa, that IGF-I dependent phosphorylation of Akt and MAPK, 
induction of G1-S phase progression, and enhanced expression of cyclin D1 and cyclin 
E are all dependent on the presence of ERa.   
 
Cross-talk between the IGF and ER pathways thus involves receptors and ligands of 
both systems, survival signalling through Akt and MAPK signalling cascades, as well 
as regulation of transcription and activity of both receptors.   
 
1.3.3.4 IGF-IR and EGFR/HER-2 cross-talk 
Because of their common signalling pathways, possible cross-talk between EGFR or 
HER-2 and IGF-IR signalling has been investigated. Stimulated EGFR can 
transactivate IGF-IR, and IGF-IR in turn can cause transactivation of EGFR [306, 346, 
347].  Blockade of EGFR signalling with the EGFR tyrosine kinase inhibitor (TKI) 
gefitinib (Iressa, ZD1839) decreased IGF-II-induced MAPK signalling, but not IGF-II-
induced Akt signalling in HCC cells, suggesting that IGF-II/IGF-IR activation triggers 
proliferative signals through an EGFR-dependent pathway, while its survival signals 
are mediated independently of EGFR [348].  Ahmad et al [349] report that gefitinib 
also reduced IGF-I stimulated Erk activity, but not Akt, in normal mammary epithelial 
cells. Gefitinib had no effect on IGF-IR signalling in MCF7 and CAL-51 breast cancer 
cell lines, suggesting that the requirement for active EGFR in IGF-IR signalling may 
be lost during the malignant progression.  In the same study, EGFR co-
immuoprecipitated with IGF-IR, suggesting a physical interaction, or 
heterodimerisation, between the two receptors. This was substantiated by Morgillo et 
al [350], who reported that erlotinib (Tarceva, also an EGFR TKI) induced the 
heterodimerisation of IGF-IR and enhanced IGF-IR signalling, and upregulated 
mTOR-mediated protein synthesis of EGFR and survivin in NSCLC cells. IGF-IR 
conferred resistance to erlotinib in these cells, and IGF-IR has also been implicated in 
resistance to gefitinib in breast cancer cells [307, 351].  Jones et al [351] established 
gefitinib-resistant MCF7 cells (which were also tamoxifen resistant), and these cells 
had elevated IGF-IR, Akt and PKC activity, and increased migratory capacity 
compared to parental cells, and were more sensitive to inhibition by the IGF-IR TKI 
AG1024.  Gefitinib and AG1024 had additive-to-synergistic effects on the 
proliferation of MDA-MB-231, MDA-MB-468, SKBR3 and MCF7 cells lines [307], 
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and AG1024 also enhanced the anti-apoptotic effects of gefitinib in these cells.  
Increased overexpression of IGF-IR in SKBR3 cells enhanced resistance to gefitinib 
[307].  
 
Cross-talk between HER-2 and IGF-IR signalling pathways has also been reported.  In 
1996, Ram et al established a series of cell lines from a patient with intraductal and 
invasive ductal breast carcinoma [352]. They compared two metastatic tumour cell 
lines to a non-neoplastic cell line. Both metastatic cell lines had amplified and 
overexpressed HER-2, one having higher protein levels than the other.  With three cell 
lines of different HER-2 protein levels, they found that increasing HER-2 levels 
corresponded with higher HER-2 tyrosine kinase activity, and with loss of requirement 
for IGF and EGF for growth in culture media. These experiments showed that 
constitutively active HER-2 in breast cancer directly stimulates multiple signalling 
pathways, and that HER-2-activated proliferative pathways can substitute for those of 
other growth factor receptors, including IGF-IR.  
 
The study of heregulin and HER-2 signalling in a hormone-dependent mammary 
tumour model showed that heregulin enhanced the proliferation of mammary tumour 
primary culture cells.  Knocking out HER-2 expression with an antisense molecule 
abolished heregulin-induced proliferation, confirming that heregulin mediates its 
proliferative effects through HER-2. However, an antisense molecule targeting IGF-IR 
also completely inhibited heregulin-induced proliferation, demonstrating that a 
functional IGF-IR is required for heregulin/HER-2 mitogenic activity in this model 
[353]. 
 
Balana et al [182] also used antisense technology and showed that blocking IGF-IR 
expression decreased the phosphorylation of HER-2, while suppression of HER-2 
expression had no effect on IGF-IR phosphorylation. This suggests a hierarchical 
interaction, whereby IGF-IR directs HER-2 phosphorylation. Co-localisation studies 
also showed that the two receptors physically interact, and these heterodimers could be 
induced by heregulin or IGF-I stimulation in MCF7 breast cancer cells [182]. IGF-IR 
antisense molecules also inhibited breast tumour growth in vivo, and reduced HER-2 
phosphorylation as well as IRS-1, Akt and MAPK activity [183].  
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Lu et al [354] investigated the molecules involved in HER-2 and IGF-IR related 
signalling, and found that HER-2 overexpression inhibited IGF-I-induced MAPK 
signalling in HER-2 transfected MCF7/HER2-18 cells [354].   Inhibition of MAPK 
signalling was accompanied by decreased IGF-I-induced Shc phosphorylation, 
decreased association of Grb2 with Shc, and decreased Raf phosphorylation.  In this 
study, overexpression of HER-2 increased the basal levels of Shc phosphorylation and 
association with Grb; perhaps this resulted in less free Shc and Grb2 available upon 
IGF-I activation in these cells.  Notably, HER-2 overexpression had no effect on IGF-
I-induced phosphorylation of IGF-IR, IRS-1 or Akt.   
 
Together, these data suggest that HER-2 can send proliferative signals via the MAPK 
pathway, in an IGF-IR-independent manner.  HER-2 overexpression has no effect on 
IGF-IR/IRS-1/Akt signalling. It has also been shown that HER-2-overexpressing cells 
have an increased requirement for the Akt pathway in anchorage-independent growth 
[355],  and in HER-2 overexpressing cells in culture, Akt signalling is predominantly 
activated by serum elements [356]. In HER-2-overexpressing cells, the unliganded 
HER-2 can be transactivated by IGF-IR.  HER-2/Akt-mediated survival signalling in 
cells may therefore be directed by IGF-IR. 
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1.4 Strategies to target IGF-IR 
1.4.1.1 Antisense oligonucleotides and small interfering RNA 
Numerous approaches to blocking IGF-IR in cancer cells are being explored. IGF-IR 
expression can be inhibited at the translational level by the use of antisense 
oligonucleotides which are designed to complement messenger RNA (mRNA), 
causing sequence-specific inhibition of protein synthesis. ASOs are delivered into cells 
via transfection of antisense expressing plasmids, or via infection with antisense 
encoding adenoviruses. Antisense strategies have been successful at down-regulating 
IGF-IR protein expression in a number of cancer types in both in vitro and in vivo 
models [183, 299, 300, 357-365].  IGF-IR is down-regulated, and ASO treatment 
blocks tumour growth, and inhibits metastasis [183, 362, 365].  Down-regulation of 
IGF-IR also sensitized cells towards radiation and chemotherapeutic agents [362, 364]. 
These data suggested that antisense strategies could be useful clinically, and perhaps in 
combination therapy. Andrews et al [366] performed a pilot study on patients with 
malignant astrocytomas to assess the safety and feasibility of the IGF-IR antisense 
approach in a clinical setting.  Clinical and radiographic improvement were observed 
in 8 out of 12 patients, and three of these were patients with distal recurrence who 
showed unexpected tumour regression at either the primary or the distant site [366].  
 
Antisense strategies have limitations; they usually result in only moderately decreased 
IGF-IR levels, and do not produce cells which are completely deficient of the protein 
[367].  Some IGF-IR ASOs also cause non-specific toxicity in survival assays [358], 
and some have caused small but detectable suppression of IR expression [368].  An 
alternative to ASOs are small interfering RNAs (siRNAs), which are short sequences 
of 21-23 base pair duplex RNA sequences. Specific gene silencing has been 
demonstrated with siRNAs [369]. Bohula et al [368]  found that the secondary 
structure of the IGF-IR transcript has a major effect on the efficacy of binding of ASOs 
and siRNAs, and identified regions within IGF-IR mRNA that would be accessible to 
ASOs and siRNAs.  They then synthesised ASO and siRNA molecules homologous to 
accessible regions. Such siRNAs decreased IGF-IR expression, and inhibited survival 
in human and murine tumour cells [368, 370]. IGF-IR siRNAs also downregulated 
IGF-IR expression in lung, liver and breast cancer cells [371-374], promoted apoptosis 
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and increased sensitivity to chemotherapy in liver cancer cells [372], and decreased 
lung cancer metastasis in mice [373]. siRNA molecules seem to be more stable than 
ASOs, probably due to their double-stranded structure, and many chemically 
synthesised and plasmid-based siRNAs are being used in vitro [375]. RNA 
interference as a method of suppression of protein expression is a useful research tool 
as well as a potential therapeutic strategy. 
 
1.4.1.2 Anti-IGF-IR antibodies 
Several antibodies against IGF-IR have been developed.  Table 1.4.1 lists anti-IGF-IR 
antibodies currently in clinical development. The mouse monoclonal antibody aIR-3 
targets the a- domain of IGF-IR, and inhibited the proliferation of a number of cancer 
cells in vitro, including MCF7 cells [376, 377]. However, in some cases it was 
ineffective in blocking IGF-I-sensitive tumours in animal models [378], while in others 
it may have agonistic effects on IGF-IR signalling [220], and has not been developed 
further for clinical use.   
 
Several other monoclonal mouse antibodies have been used experimentally.  MAb 391 
and mAb 4G11 reduced IGF-IR expression in a number of cancer cells, including 
MCF7 breast cancer cells, and downregulation of receptor was accompanied by 
reduced Akt and MAPK signalling [379, 380].  EM164 inhibited IGF-I-, IGF-II-, and 
serum-stimulated proliferation and survival of diverse human cancer cell lines in vitro, 
including breast, lung, colon, cervical, ovarian, pancreatic, melanoma, prostate, 
neuroblastoma, rhabdomyosarcoma, and osteosarcoma cancer cell lines [381].  
 
To overcome immune response problems with mouse antibodies, a single-chain 
humanised anti-IGF-IR scFv-Fc antibody was developed which contains the Fc 
domain of human IgG1 fused to the Fv region of mouse monoclonal 1H7 [382]. This 
antibody downregulated IGF-IR expression in MCF7 cells, rendering the cells 
refractory to IGF-I stimulation, and also suppressed MCF7 xenograft tumour growth 
[383].   
 
Burtrum et al [381] developed a fully human anti-IGF-IR antibody, A12, which 
blocked ligand binding to IGF-IR in MCF7 cells. This antibody also induced 
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internalization and degradation of the receptors, decreasing IGF-IR cell surface 
concentration, and inhibited downstream signalling through Akt and MAPK pathways.  
A12 significantly inhibited the growth of breast, renal and pancreatic tumour 
xenografts, with an increase in apoptotic tumour cells [381].  Importantly, A12 showed 
no cross-reactivity with IR.  A12 has been combined with other anti-cancer agents 
experimentally, and it enhanced growth inhibition by Taxotere (docetaxel) in prostate 
cancer xenografts [384], and by chemotherapeutic agents melphalan and Velcade 
(bortezomib, a proteosome inhibitor) in multiple myeloma (MM) xenografts [384]. 
A12 also suppressed VEGF secretion in MM cells, and MM xenografts treated with 
A12 had reduced vasculature [384].  A12 is now being tested in a phase I clinical trial 
in patients with advanced solid tumours [377].   
 
Wang et al  [385] reported that fully human anti-IGF-IR antibody 19D12 inhibits 
ligand binding and autophosphorylation of IGF-IR homodimers and IGF-IR/IR 
heterodimers, but not IR homodimers. 19D12 also inhibits IRS-1 phosphorylation, and 
signalling through Akt and MAPK.  The antibody also downregulates IGF-IR levels 
and inhibited the growth of an ovarian tumour xenograft [385].  
 
CP-751,871 is a fully human anti-IGF-IR antibody that also downregulates IGF-IR 
expression and showed significant anti-tumour activity as a single agent or in 
combination with Adriamycin, 5-fluorouracil or tamoxifen in multiple tumour models 
[386], and is now being tested in a phase I clinical trial in multiple myeloma patients 
[377]. 
 
Goetsch et al [387] generated a humanized anti-IGF-IR antibody h7C10,  which 
blocked phosphorylation of IGF-IR and IRS-1, and inhibited MCF7 and A549 
xenograft tumour growth. h7C10 also significantly enhanced the effects of 
chemotherapeutic agent vinorelbine, and the anti-EGFR antibody, C225. This antibody 
is also being tested in a phase I trial in patients with advanced solid tumours [377].  
 
Targeting IGF-IR activity with antibodies therefore has much potential in cancer 
therapy, as single agents, or more likely in combination with other agents. Lu et al 
[388] developed a bispecific antibody, or di-diabody that targets both IGF-IR and 
EGFR, using the variable regions from two antibodies, 11F8 to EGFR and A12 to IG-
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IR.  The di-diabody inhibited activation of both receptors, and decreased tumour cell 
proliferation. It also inhibited the growth of pancreatic and colorectal cancer 
xenografts [388].  This report highlights the benefits of targeting multiple receptors, 
and further research may validate the use of bispecific antibodies.  
 
1.4.1.3 Dominant negative proteins 
The use of dominant negative variants of IGF-IR has been investigated as a strategy to 
interfere with IGF-IR signalling. Some IGF-IR variants have been constructed with 
point mutations in the ß-subunits, which cause the formation of kinase-deficient 
heterodimers of mutant and wild-type receptors.   Point mutations or substitutions of 
specific residues (e.g. lysine K1003, essential for ATP binding, or tyrosines Y1131, 
1135 or 1136 of the kinase domain, or Y1250/1251 of the C-terminal domain) 
decreased proliferation of a number of cell lines [220, 248, 389, 390], some causing 
increased apoptosis [391, 392], or increasing sensitivity to chemotherapeutic agents 
[393]. In some studies, these mutations reduced tumour development in animals [248, 
392], while in others they did not exhibit dominant negative effects [389].  
 
Other soluble dominant negative mutants contain only a-subunits, without a 
transmembrane domain, and compete with wild-type receptors for ligand binding.  
Examples of these are 482/STOP and 486/STOP variants, which inhibited the growth 
of a number of cell lines, decreased Akt signalling, and induced massive apoptosis in 
vivo [301, 302, 394-396].   486/STOP also inhibited the adhesion and invasion of 
MDA-MB-435 cancer cells, and decreased their metastasis in vivo [397].  482/STOP 
and 486/STOP were also shown to have a bystander effect, inhibiting the growth of 
wild-type tumour cells when cells expressing the mutant protein are co-injected with 
wild-type cells [302, 394]. The mechanisms of action of these STOP mutants are not 
fully understood. Other dominant negative IGF-IRs, 950/STOP and 952/STOP, have 
a-domains and the juxtamembrane part of the ß-domains, but are lacking the kinase 
domains, and are thus anchored in the membrane. They were shown to inhibit IGF-IR 
signalling, tumour growth and metastasis in vivo [395, 396, 398, 399]. These mutant 
receptors probably block IGF-IR activity by dimerization with wild-type receptors.  
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Deletion of the C-terminus domain of IGF-IR has been shown to enhance survival, and 
led researchers to investigate if overexpression of the C-domain would promote 
apoptosis. Mini-receptors containing the last 108 amino acids of IGF-IR spliced to a 
membrane-targeted myristolated C-terminal (MyCF) caused death of human cancer 
cell types, sensitized cells to UV irradiation, and inhibited tumorigenesis in nude mice 
[400, 401].  
 
1.4.1.4 Down-regulation of IGF-IR ligands 
IGFBPs bind and transport IGF ligands, thereby regulating their availability to bind 
IGF receptors.  The therapeutic potential of a number of IGFBPs is therefore being 
evaluated. IGFBP1 inhibits IGF–I and reduces IGF-induced proliferation and 
migration. IGFBP1 also abrogated estradiol-stimulated growth in MCF7 cells, and 
inhibited breast cancer migration independent of IGF-I presence in vitro [402, 403]. 
 
Increased expression of natural IGFBP3 or treatment with recombinant human 
IGFBP3 (rhIGFBP3) has also been shown to inhibit cancer cell growth and induce 
cancer cell death in a number of experimental systems (reviewed in [404]).  IGFBP3 
reduced cell survival and enhanced apoptosis in response to radiation in MCF7 and 
T47D breast cancer cells in vitro [311, 405]. IGFBP3 also sensitized Hs578T breast 
cancer cells to ceramide-induced apoptosis  [406], and potentiated the effects of Taxol 
(paclitaxel) in this cell model [312] and in gastric carcinoma cell lines [407].  Lu et al 
[177] showed that IGF-IR signalling interfered with the growth-inhibitory effects of 
trastuzumab in MCF7/HER2-18 and SKBR3/IGF-IR transfected cells, and IGFBP3 
treatment reduced IGF-IR signalling and restored sensitivity to trastuzumab. Jerome et 
al [180] confirmed these results in the same cell models, and also demonstrated that 
IGFBP3 had anti-tumour activity, and potentiated the effects of trastuzumab, in 
advanced-stage MCF-HER2-18 xenografts. Their study also showed that IGF-IR 
signalling through Akt and MAPK prevented the suppression of these pathways by 
trastuzumab, and that IGFBP3 restored their downregulation by trastuzumab in vitro 
and in vivo.  
 
Transfection and expression of IGFBP3 in NSCLC [408, 409] and prostate cancer 
[410] cells also inhibited proliferation and induced apoptosis in xenograft models. 
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IGFBP3 overexpression also inhibited IGF-IR phosphorylation in NSCLC cells, and 
treatment with IGF-I or transfection of activated Akt or MAPK kinase-1 partially 
blocked IGFBP3-induced apoptosis in NSCLC cells [409]. This study suggests that the 
growth-inhibitory effects of IGFBP3 were, at least in part, due to inhibition of IGF-
dependant pathways. IGFBP3 is also known to have IGF-independent functions in 
cells, and may induce tumour death independently of IGF binding (reviewed in [404]). 
IGFBP3 may also mediate the anti-proliferative effects of TNF-a, TGF-ß, retinoic 
acid, vitamin D analogs and p53.  
 
Feng et al [411] recently reported their development of human monoclonal antibodies 
targeting IGF-II. They bound with high affinity to IGF-II, without cross-reacting with 
IGF-I or insulin, and inhibited IGF-II/IGF-IR signalling. The most potent, IGG1 m610 
reduced the phosphorylation of IGF-IR, Akt and MAPK, and inhibited growth of 
DU145 prostate cell and MCF7 breast cancer cells. Further investigation of these and 
other ligand-targeting antibodies may determine their potential as therapeutic agents.  
 
1.4.1.5 Tyrosine kinase inhibition 
Another approach to inhibiting IGF-IR signalling is to target the tyrosine kinase 
domain with low molecular weight, or small molecule inhibitors.  IGF-IR tyrosine 
kinase inhibitors (TKIs) currently in pre-clinical or clinical development are listed in 
Table 1.4.1. These TKIs inhibit activity by binding to the ATP binding site or substrate 
binding site in the kinase domain of the activated receptor.  Earlier TKIs, such as 
tyrphostin AG538 or I-OMeAG inhibited IGF-IR signal transduction, but cross-
reactivity with IR was also reported [412-414].   
 
Improved IGF-IR inhibitory activity and cellular selectivity over IR have been reported 
for a new series of pyrrolopyrimidines derivatives, which act as ATP agonists. Two 
examples are NVP-AEW541 and NVP-ADW742 [415, 416].   NVP-AEW541 is 27-
fold more potent towards IGF-IR compared to IR, and inhibited IGF-IR 
phosphorylation in vitro and in vivo  [416].  This inhibitor also induced G1 cell cycle 
arrest in Ewing’s sarcoma [417], hepatocellular carcinoma [418], and neuroblastoma 
[419] cell lines.  The cytotoxic effects on hepatocellular carcinoma and neuroblastoma 
cell lines were due to induction of apoptosis, and in hepatocellular cell lines NVP-
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AEW541 upregulated Bax and downregulated Bcl-2. NVP-AEW541 also enhanced the 
inhibitory effects of chemotherapeutic agents such as vincristine, actinomycin D, 
ifosfamide, doxorubicin and docetaxel, and the anti-EGFR antibody ab-3101 [417, 
418]. Combined treatment of NVP-AEW541 and vincristine also significantly 
inhibited tumour growth of Ewing’s sarcoma  and neuroblastoma xenografts [417, 
419].  In vitro NVP-EW541 downregulated VEGF mRNA, while in vivo NVP-
AEW541 led to decreased tumour vascularization [419]. NVP-ADW742 also inhibited 
growth in small cell lung cancer cell lines, and enhanced the effects of imatinib 
(ST1571), a selective inhibitor of KIT, PDGFR and ABL tyrosine kinase activity [420, 
421]. NVP-ADW742 also sensitized lung cancer cells to etoposide- and carboplatin-
induced apoptosis, and treatment with NVP-ADW742 eliminated IGF-I-mediated 
expression of VEGF [421].  
 
Another class of compounds, cyclolignans, inhibit IGF-IR autophosphorylation, 
though via a non-ATP antagonising mechanism.  Picropodophyllin (PPP) has been 
studied in malignant melanoma cells. PPP selectively inhibited basal IGF-IR tyrosine 
phosphorylation, decreased phosphorylation of Akt and ERK1/2, induced apoptosis, 
and inhibited growth of melanoma cells [422-424]. This activity was accompanied by 
decreased VEGF secretion, decreased CDK1 activity, accumulation of cells in G2/M-
phase, and decreased expression of mcl-1 and survivin, suggesting multiple 
mechanisms of action of this compound.  Vasilcanu et al [425] showed that PPP 
specifically blocked tyrosine Y1136 of the activation loop of the kinase, while sparing 
the other two tyrosines (Y1131 and 1135).  PPP also decreased tumour burden and 
inhibited angiogenesis in nude mice [422].    
 
Recently, two dual-specificity tyrosine kinase inhibitors that target both IGF-IR and 
IR, BMS-536924 and BMS-554417 were developed, and were shown to inhibit tumour 
growth in vitro [426, 427].  BMS-554417 inhibited IGF-IR and IR signalling through 
the Akt and MAPK pathways, and also caused G0/G1-phase growth arrest and 
decreased nuclear cyclin D1 accumulation in MCF7 cells. This compound also reduced 
xenograft tumour growth [426].  BMS-554417 therefore represents a novel class of 
potent dual-kinase inhibitors. 
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INSM-18 is a small molecule tyrosine kinase inhibitor that has demonstrated selective 
inhibition of IGF-IR and HER-2. It has demonstrated anti-tumour activity in 
preclinical studies of breast, lung, pancreatic and prostate tumours, and is the first 
IGF-IR TKI to enter clinical trials.  Two single dose Phase I clinical studies have been 
completed and report that INSM-18 was safe and well tolerated. INSM-18 is currently 
in a Phase I/II trial in patients with refractory prostate cancer (unpublished data, 
www.imsmed.com).  
_______________________________________________________________________________________________________ 
Table 1.4.1 List of  anti-IGF-IR antibodies and IGF-IR tyrosine kinase inhibitors currently 
beeen studied for clinical use. 
 
Antibodies Development stage
A12 Phase I in advanced solid tumours
19D12 Pre-clinical
CP-751,871 Phase I in multiple myeloma
h7C10 Phase I in advanced solid tumours
Tyrosine kinase inhibitors
NVP-AEW541 Pre-clinical
NVP-ADW742 Pre-clinical
BMS-536924 Pre-clinical
BMS-554417 Pre-clinical
INSM-18 Phase I/II in refractory prostate cancer  
 
_______________________________________________________________________________________________________ 
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1.5 Study Aims 
The aims of this study were as follows: 
 
· To investigate the relationship between HER-2 and IGF-IR protein in a large 
panel of breast cancer cell lines; 
 
· To determine if HER-2, EGFR and IGF-IR protein expression or phosphorylation 
correlate with response or resistance to trastuzumab in HER-2-positive breast 
cancer cells; 
 
· To examine alterations in HER-2, EGFR and IGF-IR signalling in breast cancer 
cells with acquired trastuzumab-resistance; 
 
· To investigate if inhibiting IGF-IR ligand binding, receptor expression or tyrosine 
kinase activity restores sensitivity to trastuzumab in trastuzumab-resistant cells: 
 
· To determine if trastuzumab-resistant HER-2 positive breast cancer cells display 
cross-resistance to lapatinib; 
 
· To investigate the development of resistance to HER-2 antagonists, and to 
examine global alterations in protein phosphorylation in resistant cells compared 
to parental cells, and 
 
· To analyse the relationship between HER-2 and IGF-IR expression in breast 
cancer patient samples. 
 68 
 
 
Chapter 2    
 
MATERIALS AND METHODS 
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2.1 Cell lines, cell culture and reagents 
Twenty-seven human breast cancer cell lines were used in this study, including a panel 
of 21 established cell lines, four HER-2 transfected and empty vector control 
transfected cell line pairs, and two trastuzumab-conditioned HER-2 overexpressing 
breast cancer cell lines selected for long-term growth in trastuzumab-containing 
medium.  The cell lines BT474, CAMA-1, HCC1419, HCC1937, HCC1954, MCF-7, 
MDA-MB-175, MDA-MB- 231, MDA-MB-361, MDA-MB-435, MDA-MB-468, 
MDA-MB-453, SKBR3, T47D, UACC-812, and ZR-75-1 were obtained from the 
American Type Culture Collection (ATCC).  CAL51, EFM-19 and KPL-1 were 
obtained from the German Tissue Repository DSMZ.  SUM190 and SUM225 were 
obtained from the University of Michigan, USA.  CAMA-1 cells were grown in 
Minimum Essential Medium (MEM) supplemented with 10% foetal calf serum (FCS);  
MDA-MB-175 and UACC-812  cells were grown in Leibovitz’s L-15 medium with 
15% FCS; CAL51 and KPL1 cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) with 10% FCS; SUM190 and SUM225 cells were cultured in 
Ham’s F-12 supplemented with 5% heat-inactivated foetal calf serum (FCS), 5 mg/mL 
insulin, and 1 mg/mL hydrocortisone; all other cell lines were maintained in RPMI 
1640 medium supplemented with 10% FCS, including HCC-2218 and ZR-75-30 cells, 
which were also supplemented with 1 mM sodium pyruvate. T47D, MCF-7, MDA-
MB-231 and ZR-75-1 cells were stably transfected with a full-length cDNA of the 
HER-2 gene as previously described [56].  Trastuzumab-conditioned cell lines 
BT474/Tr and SKBR3/Tr were generated by continuously culturing cells for a 
minimum of 10 months in RPMI supplemented with 1.4 µM trastuzumab (Genentech). 
All cells were routinely tested for the presence of Mycoplasma. 
  
2.2 Preparation of cell lysates 
Cells were grown in 100 mm petri dishes and whole cell lysates were prepared as 
follows: cells were washed twice with cold PBS and 100-500 µl RIPA buffer (5 mM 
Tris-HCl pH 7.4, 1% NP-40, 0.1% SDS, 150 mM NaCl, 1% Triton x-100) containing 
1x Protease Inhibitor cocktail (Calbiochem), 2 mM PMSF (Sigma), and 1 mM Sodium 
Orthovanadate (Sigma), was added and cells were incubated on ice for 10 minutes. 
Lysates were collected and centrifuged at 14,000 revolutions per minute (rpm) for 10 
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minutes at 4oC. The pellets were discarded and the supernatants collected and stored at 
-80oC. Protein quantification was performed using the BCA quantitation kit (Pierce 
Biotechnology).   
 
2.3 Immunoprecipitation (IP) 
500 mg of protein lysate was diluted in 900 µl RIPA buffer and incubated with 3 mg 
antibody (monoclonal anti-a-HER-2 (Calbiochem) or polyclonal anti-IGF-IRß (Santa 
Cruz Biotechnology)) at 4 oC, shaking, for 30 minutes.  50 ml of packed Protein-G 
agarose beads (Santa Cruz Biotechnology) were added and the samples incubated 
overnight, shaking, at 4 oC.  The samples were centrifuged at 14,000 rpm for 25 
seconds, the supernatants removed and the pellets washed with IP wash buffer (mild 
lysis buffer (Cell Signaling Technology) with protease inhibitors).  The wash was 
repeated twice and the samples were centrifuged for 35 seconds. The supernatants 
were removed and the pellets resuspended in 50 ml denaturing buffer and denatured at 
95 oC for five minutes.  Denatured samples were then centrifuged at 14,000 rpm for 3 
minutes and the supernatants collected and stored at -20oC. 
 
2.4 Western Blot analysis 
5-50 µg protein or 20-25 µl immunoprecipitated sample were electrophoretically 
resolved on denaturing polyacrylamide gels (Lonza Workingham Ltd), transferred to 
nitrocellulose membranes (Amersham), which were blocked with either bovine serum 
albumin (BSA) (Sigma) or skimmed-milk powder (Bio-Rad) in PBS-tween (0.1%), 
and incubated overnight at 4oC with primary antibodies: monoclonal anti-a-HER-2 
(Calbiochem); polyclonal anti-EGFR (Lab Instruments); polyclonal anti-
phosphorylated HER-2/EGFR (Cell Signaling Technology); polyclonal anti-IGF-IRß 
(Santa Cruz Biotechnology); monoclonal anti-survivin (Novus Biologicals), 
monoclonal anti-a-tubulin (Sigma); polyclonal anti-Akt, anti-MAPK, anti-
phosphorylated Akt and MAPK antibodies (Cell Signalling Technology); or 
monoclonal anti-phosphotyrosine antibody (Upstate).  Proteins were visualised using 
horseradish peroxidase-conjugated anti-mouse (Sigma) or anti-rabbit antibodies 
(Sigma) and Luminol reagent (Santa Cruz Biotechnology).  Protein bands were semi-
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quantified by densitometry, and protein levels were calculated relative to a-tubulin 
levels. 
 
2.5 Enzyme-linked immunosorbant assays (ELISAs) 
Total HER-2 protein levels were measured in protein lysates using commercially 
available quantitative ELISA (Calbiochem), according to the manufacturer’s 
instructions. 0.5 µg of each protein lysate was used and HER-2 protein levels were 
calculated as nanogram (ng) HER-2 per milligram (mg) of total protein. Total IGF-IR 
and EGFR, and phosphorylated HER-2, IGF-IR and EGFR protein content were 
measured using ELISAs (R&D Systems), according to the manufacturer’s instructions. 
50 – 100 µg of protein lysate was used for IGF-IR, and 30 µg used for EGFR 
measurement, and protein levels were calculated as ng/mg of total protein. 7 µg, 140 
µg and 30 µg were used for phosphorylated HER-2, phosphorylated IGF-IR, and 
phosphorylated EGFR measurements, respectively, and absorbance was measured at 
570 nm.  For the phospho-ELISAs, values were expressed relative to the sample with 
the highest level of the phosphorylated protein. 
 
2.6 Proliferation assays 
1 - 1.5x104 and 2.5 - 3.75x103 cells were plated in wells of 24-well and 96-well plates 
respectively.  After 24 hours, cells were treated with the appropriate media 
supplemented with 2,  5, or 10 % FCS, with or without 10 or 100 nM trastuzumab, 1 
µg/ml anti-IGF-IR antibody aIR3 (Calbiochem), 1 µg/ml IGF-binding-protein 3 
(IGFBP3) (Sigma), 0-3 µM IGF-IR TKI NVP-AEW541 (Novartis) or 0-3 µM TKI 
BMS-536924 (Bristol-Myers Squibb).  Proliferation was measured after three and/or 
five days. Cell counting was used to measure proliferation in the 24-well plate assays; 
wells were rinsed with PBS, incubated in trypsin-EDTA (Gibco)  (trypsinized), and 
cells were either resuspended in isoton and counted using a Beckman Coulter Counter 
(Beckman Coulter), or resuspended in RPMI containing Guava Viacount reagent and 
counted using a Guava EasyCyte (Guava Technologies). Cell counting, acid 
phosphatase assays or the crystal violet assay was used to measure proliferation of 
cells in 96-well plates. For the acid phosphatase assay, media was removed and each 
well rinsed with PBS; 100 µl of acid phosphatase substrate (10 mM p-nitrophenol 
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phosphate (Sigma) in 0.1 M sodium acetate (Sigma), 0.1% triton X-100 (BDH), pH 
5.5) was then added to each well followed by incubation at 37oC for 45 minutes, at 
which time 50 µl of NaOH (Sigma) was added to each well and the absorbance was 
read at 405 nm with 620 nm as a reference. For the crystal violet assay, media was 
removed from the wells, each well rinsed with PBS, and incubated in 50 ml 0.1% 
crystal violet (Sigma) in methanol for 15 minutes, rinsed three times in H20, dried 
overnight, and incubated in 100 ml Sorenson’s buffer ( 0.1 Msodium citrate and citric 
acid in ethanol and H2O, pH 4.2) for 20 minutes, after which absorbance was read at 
540 nm.  Proliferation or inhibition of proliferation was calculated relative to untreated 
controls.  Each assay was carried out in triplicate. 
 
2.7 Small interfering RNA (siRNA) transfection 
A validated siRNA molecule targeting exon 2, and two pre-designed siRNA molecules 
targeting exons 2 and 4 of the IGF-IR gene were obtained from Ambion [Table 2.1]. A 
siRNA molecule targeting kinesin, and a scrambled sequence siRNA molecule 
(Ambion) were  used as transfection controls.  Each siRNA molecule was transfected 
at a final concentration of 30 nM.  6.5 - 8x103 and 3 – 3.5x105 cells were resuspended 
in 10% RPMI for 96-well and 6-well plates respectively. Each siRNA and NeoFXTM 
transfection agent was diluted in GibcoTM Opti-MEM reduced serum medium 
(Invitrogen), and incubated at room temperature (RT) for 10 minutes. Diluted NeoFX 
was then added to each diluted siRNA and incubated for a further 10 minutes at RT.  
The transfection mix was then added to the wells followed by the addition of the cell 
suspension.  After 24 hours, the transfection media was replaced with 10 % RPMI with 
or without 15 µg/ml trastuzumab.  6-well plates were used to prepare lysates after 72 
hours. Cells in 96-well plates were harvested after four days trastuzumab treatment and 
counted using the Guava EasyCyte. 
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________________________________________________________________________________________________________ 
Table 2.1. Sequences of three anti-IGF-IR siRNA molecules, with the Ambion siRNA 
ID number, and the number  (1-3) assigned to each in this study. 
ID  No. Sense Antisense 
103301 1 GGUCUGUGAGGAAGAAAAGtt CUUUUCUUCCUCACAGACCtt 
74 2 GGAUUGAGAAAAAUGCUGAtt UCAGCAUUUUUCUCAAUCCtg 
144648 3 GCUCACGGUCAUUACCGAGtt CUCGGUAAUGACCGUGAGCtt 
______________________________________________________________________________________________ 
 
2.8   Terminal DNA transferase-mediated dUTP nick end labelling (TUNEL) assay 
3 – 5x104 cells were plated in wells of 24-well plates, in media containing 5 % FCS.  
After 24 hours, cells were treated with trastuzumab (10 nM), NVP-AEW541 (1 µM), 
or both, in 2 % FCS. Dimethyl sulfoxide (DMSO) control wells were included in each 
assay, and lapatinib (2.5 µM) was used as a positive control for apoptosis induction. 
After 48 (MCF7), or 72 hours (SKBR3 and SKBR3/Tr), media was collected into 
microcentrifuge tubes and the wells were washed with PBS, which was also collected.  
Cells were trypsinized and added to the media collected for each sample. The tubes 
were centrifuged at 300 x g for 5 minutes and the media was aspirated. The cell pellets 
were re-suspended in PBS, and the cell suspension of two wells were transferred to 
one well of a round bottomed 96 well plate.  50 µL of 4% para-formaldehyde-PBS was 
added to the wells and mixed, and the plate was incubated at 4 oC for 60 minutes. The 
plate was centrifuged at 300 x g for 5 minutes and the supernatant aspirated leaving 
approximately 15 µL in each well. The remaining volume was used to resuspend the 
cells and 200 µL of ice cold 70 % ethanol was added gradually to each well. The plates 
were then stored at -20 oC overnight.  The fixed cells were stained according to the 
protocol for the TUNEL assay (Guava Technologies). Cells were analysed on the 
Guava EasyCyte machine using the CytoSoft TUNEL assay software (Guava 
Technologies).  Positive and negative controls supplied with the TUNEL assay kit 
were run with each assay. 
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2.9 Cell Cycle Assays 
3 – 5x104 cells were plated in wells of 24-well plates, in media containing 5 % FCS.  
After 24 hours, cells were treated with trastuzumab (10 nM), NVP-AEW541 (1 µM), 
or both, in 2 % FCS. Dimethyl sulfoxide (DMSO) control wells were included in each 
assay, and gefitinb (Iressa, AstraZeneca) (1 µM) was used as a positive control for cell 
cycle arrest. After 48 (MCF7), or 72 hours (SKBR3 and SKBR3/Tr), media was 
collected into microcentrifuge tubes and the wells were washed with PBS, which was 
also collected.  Cells were trypsinized and added to the media collected for each 
sample. The tubes were centrifuged at 300 x g for 5 minutes and the media was 
aspirated. The cell pellets were re-suspended in PBS, and each cell suspension was 
transferred to a well of a round bottomed 96 well plate.  The plate was centrifuged at 
450 x g for 5 minutes and the supernatant aspirated leaving approximately 15 µL in 
each well. The remaining volume was used to resuspend the cells and 200 µL of ice 
cold 70 % ethanol was added gradually to each well. The plates were then stored at 4 
oC overnight.  After fixing the cells were stained according to the protocol for the 
Guava PCA-96 cell cycle assay (Guava Technologies). Cells were analysed on the 
Guava EasyCyte machine and the data was analysed using the Modfit LT software 
(Verity Software House). 
 
2.10 Lapatinib and Trastuzumab conditioning of cells 
Trastuzumab-sensitive SKBR3, and trastuzumab-resistant SKBR3/Tr and HCC1419 
cells were selected to be conditioned in lapatinib (Tykerb, GW572016, 
GlaxoSmithKline) and/or trastuzumab- containing growth media. 96-well dose 
response proliferation assays were performed in 0 – 600 nM lapatinib in order to select 
an appropriate concentration for conditioning. Each cell line was grown in duplicate 
flasks containing either control media or conditioned media, and media was replaced 
twice weekly for 6 months. SKBR3 cells were conditioned in trastuzumab (10 µg/ml 
(68 nM)) alone, lapatinib (200 nM) alone, or combined trastuzumab (5 µg/ml (34 nM)) 
and lapatinib (100 nM); SKBR3/Tr cells were conditioned in lapatinib (400 nm), and 
HCC1419 cells were conditioned in lapatinib (250 nM). After two months, the 
lapatinib concentration for SKBR3 cells was increased to 250 nM. After three and six 
months of conditioning, dose-response assays were performed to monitor alterations in 
response to lapatinib and trastuzumab.   
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2.11 Doubling time assays 
3.x103 cells were plated in wells of 48-well plates. After 24 hours, cells were treated 
with  and without 100 nM trastuzumab or 100 nM lapatinib.  The Guava EasyCyte was 
used to count cell numbers at days 0, 3, 5 and 7.  Doubling times were calculated 
between days 3 and 7 using the formula   
 
 
where Tt is the end timepoint and T0 is the beginning timepoint (days), which in this 
case were 7 and 3, respectively.  Each assay was performed in triplicate. 
 
2.12 Phosphoprotein preparation 
Cells were grown in 175 cm2 flasks, and treated for 24 hours with control growth 
media (RPMI + 10 % FCS), or media containing trastuzumab (10 µg/ml (68 nM)) or 
lapatinib (1 µM). Triplicate samples of each treatment were prepared. Total protein 
was extracted and the phosphoprotein fragements were concentrated using the 
PierceTM Phosphoprotein Enrichment Kit (Pierce Biotechnology). Using this kit, cells 
were washed twice with cold HEPES buffer (50 mM, pH 7), and lysed using the 
Lysis/Binding/Wash buffer provided, supplemented with CHAPS (0.25%), 1X Halt 
Protease Inhibitor EDTA-free and 1X Halt Phosphatase Inhibitor Cocktail (Pierce 
Biotechnology). Cells were scraped into microcentrifuge tubes, and placed on ice for 
45 minutes, vortexing periodically. The lysed cells were centrifuged at 10,000 x g for 
20 minutes at 4 oC and the supernatant collected and stored at -80 oC. After protein 
quantification, the concentration of each lysate was adjusted to 0.5 mg/ml and the 
phosphoprotein fraction of each was enriched using columns supplied with the kit, 
according to the protocol provided. The eluted phosphoprotein fractions were then 
concentrated according to the protocol, yielding 150-200 µl of concentrated 
phosphoprotein for each sample.  The samples were then stored at -80oC.  
 
2.13 Phosphoproteomic analysis 
2.13.1 Protein labelling and two-dimensional differential gel electrophoresis 
(DIGE) 
All proteomic analysis detailed in this thesis was carried out by Dr. Paul Dowling.  
DIGE was performed using three CyDye DIGE Fluor Minimal dyes Cy3, Cy5 and Cy2 
Doubling time  =  
 (Tt – T0) (Log2) 
 (LogTt – LogT0)  , 
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(GE Healthcare) [428].  In this technique, 25 µg of each phosphoprotein sample was 
added to microcentrifuge tubes and labelled with Cy3 or Cy5 dye (200 pico mole 
(pmol) in 1 µl anhydrous dimethylformamide (DMF)). Each tube was mixed by 
vortexing, and placed on ice for 30 minutes in the dark. Under these conditions 
approximately 1% of the lysine residues of the protein are covalently conjugated to the 
CyDyes. The reaction was quenched by the addition of a 50-fold molar excess of free 
lysine to the dye for 10 minutes on ice in the dark.  The labelled samples were stored at 
–80 oC. 
 
Each gel compared two samples, one labelled with Cy3 and the other with Cy5 [Table 
2.2]. Triplicate gels were run for each comparison. A Cy2-labelled pool was prepared 
containing 12.5 µg of protein from each of the 18 samples. This pool was used on all 
gels as an internal standard to allow for accurate quantification [428]. A mix of each 
sample was also prepared to run on a preparative gel to facilitate protein identification 
after electrophoresis.  An equal volume of 2x sample buffer (2.5 ml rehydration buffer 
stock solution (7 M urea, 2 M thiourea, 4 % CHAPS), pharmalyte broad range pH 4-7 
(2%) (GE Healthcare), DTT (2%)) (Sigma) was added to the labelled protein samples. 
The mixture was left on ice for 10 minutes before the next step. 
 
The protein samples were then passively rehydrated into immobiline 24-cm linear pH 
gradient strips (IPG, pH 3-11) (GE Healthcare) using rehydration buffer solution (7 M 
urea, 2 M thiourea, 4 % CHAPS, 0.5% IPG buffer, 50 mM DTT). Each strip was 
overlaid with 3 ml IPG Cover Fluid (GE Healthcare) and allowed to rehydrate 
overnight at RT. Isoelectric focussing (IEF) was then performed using the IPGphor 
apparatus (40 kv/hr @ 20 oC with resistance set at 50mA) (GE Healthcare).  
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Table 2.2. DIGE experimental design, showing gel number and the Cy dye used for 
each sample. Triplicate gels were run for each comparison. Gel no.s 3, 6 and 9 are 
examples of reverse labelling, and are introduced to avoid any slight bias caused 
because of the different molecular weights of the Cy dyes. 
 
Gel no. Cy2 Cy3 Cy5
1 Cy2 pool SKBR3 (C) SKBR3-L (C)
2 Cy2 pool SKBR3 (C) SKBR3-L (C)
3 Cy2 pool SKBR3-L (C) SKBR3 (C)
4 Cy2 pool SKBR3 (T) SKBR3-L (T)
5 Cy2 pool SKBR3 (T) SKBR3-L (T)
6 Cy2 pool SKBR3-L (T) SKBR3 (T)
7 Cy2 pool SKBR3 (L) SKBR3-L (L)
8 Cy2 pool SKBR3 (L) SKBR3-L (L)
9 Cy2 pool SKBR3-L (L) SKBR3 (L)  
_______________________________________________________________________________________________________ 
 
For second dimension separation, the strips were equilibrated by incubating in 
equilibrium solution (50 mM Tris-HCL, pH 8.8, 6 M urea, 30% glycerol, 1% SDS) 
containing 65 mM DTT for 20 minutes, followed by 20 minutes incubation in the same 
buffer containing 240 mM iodoacetamide (both at RT). 12.5 % acrylamide gel 
solutions (acrylamide/bis 40 %, 1.5 M Tris pH 8.8, 10 % SDS) were prepared, and 
prior to pouring, 10 % ammonium persulfate and 100 µl neat TEMED were added. The 
gels were overlaid with 1 ml saturated butanol, and  left to set for at least three hours at 
RT. Equilibrated IPG strips were transferred onto 24 cm 12.5% uniform 
polyacrylamide gels poured between low fluorescence glass plates. Strips were 
overlaid with 0.5% low melting point agarose in running buffer containing 
bromophenol blue. Gels were run at 2.5 W/gel for 30 min and then 100 W total at 10 
oC until the dye front had run off the bottom of the gels.   
 
2.13.2  Gel Imaging 
All of the gels were scanned using the Typhoon 9400 Variable Mode Imager (GE 
Heathcare) to generate gel images at the appropriate excitation and emission 
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wavelengths from the Cy2-, Cy3- and Cy5-labelled samples. The resultant gel images 
were cropped using the ImageQuant software tool and imported into Decyder 6.5 
software. The biological variation analysis (BVA) module of Decyder 6.5 was used to 
compare the control versus test samples to generate lists of differentially expressed 
proteins. 
 
2.13.3  Spot digestion 
Preparative gels containing 400 mg of protein were fixed and then poststained with 
colloidal CBB stain (Sigma). The subsequent gels were scanned using the Typhoon 
9400 Variable Mode Imager (GE Heathcare) to generate gel images at the appropriate 
excitation and emission wavelengths for the colloidal CBB stain. Preparative gel 
images were then matched to the Master gel image generated from the DIGE 
experiment. Spots of interest were selected and a pick list was generated and imported 
into the software of the Ettan Spot Picker robot (GE Healthcare). Gel plugs were 
placed into presiliconised microtitre plate and stored at 47C until digestion. Tryptic 
digestions were performed using the Ettan Digestor robot (GE Healthcare). Excess 
liquid was removed from each plug, and washed for three cycles of 20 min using 50 
mM NH4HCO3 in 50% methanol solution. The plugs were then washed for two cycles 
of 15 min using 70% ACN and left to air dry for 1 h. Lyophilised sequencing grade 
tryspin (Promega) was reconstituted with 50 mM acetic acid as a stock solution and 
then diluted to a working solution with 40 mM NH4HCO3 in 10% ACN solution, to a 
concentration of 12.5 ng trypsin per mL. Samples were digested at 37ºC overnight and 
were then extracted twice with 50% ACN and 0.1% TFA solution for 20 min each. All 
extracts were pooled and concentrated by SpeedVac (Thermo Scientific) for 40 min. 
 
2.13.4  MALDI ToF/ToF Mass Spectrometry and Protein Identification 
One fifth of the peptide extract solution from the digest was added to a 384 spot 
MALDI sample plate (Applied Biosystems) and supplemented with 0.5 µl of a 5 
mg/ml solution of recrystalised a-cyano-4-hydroxy-trans-cinnamic acid matrix (Laser 
Biolabs) plus 10mM NH4H2PO4 in 50% acetonitrile/water containing 0.1% TFA and 
allowed to air dry prior to analysis. MALDI mass spectra were generated using a 4800 
TOF/TOF Proteomics Analyzer instrument (Applied Biosystems). An internal sample 
mix, Pep4 (Laser Biolabs) was also spotted onto target slides and used as an internal 
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calibrant. All MS and MS/MS experiments were carried out in positive reflectron 
mode. Ten precursor ions for MS/MS were selected automatically on the basis of 
intensity from the MS spectra. The MS and MS/MS data were combined and searched 
against a number of databases using GPS Explorer software (Applied Biosystems) and 
a local MASCOT (Matrix Science) search engine for protein identification. A mass 
window of 20 ppm was set for database searching on all precursors.  
 
2.14 Tissue Micro-Array (TMA) construction 
Formalin-fixed paraffin-embedded tumour samples were obtained from 230 HER-2-
overexpressing patients; 150 were obtained from St. Vincent’s University Hospital, 
Dublin, and 68 were obtained from St. James’ Hospital, Dublin.  Ethical approval was 
obtained from the ethics committees of both hospitals. The samples were collected 
between 1994 and 2006. All patients were treated with trastuzumab. Relevant 
clinicopathologic features, treatment and follow-up were compiled for all patients by 
Dr. Zulfi Qadir and Dr Thamir Mahgoub.  Slides of each tumour sample were 
prepared, and Haematoxylin and Eosin (H&E) staining was performed by Deirdre 
McMahon in St. Vincent’s University Hospital.  The tumour-containing area of each 
sample was identified and marked by Dr. Susan Kennedy.  TMAs were then 
constructed using a Tissue Arrayer (Beecher) [Fig. 2.1]: Four cores (6mm) were taken 
from each sample and placed into empty cores of a recipient paraffin block.  An array 
map is used to log the position of each sample, and cores of paraffin-embedded liver 
sample are placed around the perimeter of each TMA in a unique pattern for easy 
distinguishing of each TMA.  Approximately 30 patient samples were included in each 
TMA.    TMAs were also obtained from Dr Susan Kennedy which contained cores 
from unselected breast tumours and in some cases corresponding normal tissues.   
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Figure 2.1 Construction of tissue microarrays using the Beecher TMA arrayer: One 
needle is used to punch a hole in the recipient block, and a second needle is used to 
remove a core of tumour from a donor paraffin block and place it in the hole made in 
the recipient block. 
_______________________________________________________________________________________________________ 
 
2.15 Immunohistochemistry 
All immunohistochemical staining was performed using the DAKO Autostainer 
(DAKO). Deparaffinization and antigen retrieval was performed using Epitope 
Retrieval 3-in-1 Solution (pH 6) (DAKO) and the PT Link system (DAKO), whereby 
slides are heated to 97 oC for 40 minutes, then cooled to 65 oC. The slides are then 
immersed in wash buffer (DAKO). HER-2 staining was performed using the 
HercepTestTM (DAKO). A control slide supplied with the HercepTestTM kit was 
included in each staining run; this slide contains three pelleted, formalin-fixed, 
paraffin-embedded human breast cancer cell lines with staining intensity scores of 0, 
1+ and 3+. A positive control 3+ patient sample slide, and a negative control score 0 
patient sample slide were also included in each run. Each slide was also run with 
Negative Control Reagent, supplied with the kit, in place of the primary antibody, to 
allow evaluation of non-specific staining and allow better interpretation of specific 
staining at the antigen site. IGF-IR staining was performed using rabbit anti-IGF-IRß 
antibody (Cell Signalling technology). All slides were counterstained with 
haematoxylin (Sigma) for 5 minutes, and rinsed with deionised water, followed by 
wash buffer. All slides were then dehydrated in graded alcohols (2 x 3 minutes each 
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in 70% IMS, 90% IMS and 100% IMS), and cleared in xylene (2 x 5 minutes), and 
mounted with coverslips using DPX mountant (Sigma).  Protein expression levels 
were assessed by Dr. Susan Kennedy.  HER-2 levels were scored using the 
HercepTestTM scoring guidelines, which assigns scores of 0, 1+ (both HER-2 
negative), 2+ (weakly positive) or 3+ (strongly positive) based on membrane staining 
intensity.  IGF-IR cytoplasmic staining was assigned the following scores based on 
staining intensity:  and scored as negative (0), weak (1+), moderate (2+), strong (3+). 
Membrane IGF-IR staining was scored as either positive or negative, with membrane 
staining only recorded as positive when it clearly exceeded the cytoplasmic level of 
staining [273]. 
 
2.16  Statistical Analysis 
Analysis of the difference of comparisons in protein levels and response to treatment 
was performed using student t-tests (two-tailed with unequal variance). Chi-square 
tests, parametric Pearson’s correlation analysis and nonparametric Mann-Whitney U 
and Kruskal-Wallis tests were performed using StatView 5.0.1 (SAS Institue Inc.). 
P<0.05 was regarded as statistically significant. 
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Chapter 3  
 
CHARACTERISATION OF BREAST CANCER 
CELL LINE PANEL 
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3.1 HER-2, IGF-IR AND SURVIVIN PROTEIN LEVELS IN BREAST CANCER 
CELL LINE PANEL 
 
HER-2, IGF-IR and survivin protein levels were measured by western blot in a panel of 
23 breast cancer cell lines, including four HER-2-transfected cell lines and their 
corresponding control-transfected cells [Fig. 3.1]. HER-2 and IGF-IR expression levels 
were semi-quantified by densitometry [Table 3.1].  Analysis by student’s t-test 
confirmed that HER-2 expression levels are significantly higher in HER-2-amplified 
cell lines compared to non-amplified cell lines (p = 0.0006), while no significant 
difference was observed in IGF-IR levels between HER-2-amplified and non-amplified 
cells. No direct correlations were observed between levels of HER-2, IGF-IR and 
survivin [Fig. 3.2]. IGF-IR expression was elevated by over 50% in two out of four, and 
reduced by 44% in one HER-2-transfected cell line compared to control-transfected 
cells. Survivin protein expression was also reduced in three out of four HER-2-
transfected cell lines [Fig. 3.3].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.  Western blot of HER-2, IGF-IRß and survivin expression levels in 23 
breast cancer cell lines. a-tubulin was used as a loading control. 
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Table 3.1.  HER-2 and IGF-IRß levels in breast cancer cell lines. HER-2 amplification 
status was obtained from UCLA. Protein levels were measured by western blotting and 
semi-quantified relative to a-tubulin using ImageQuant densitometry software 
(Amersham).  Protein levels are expressed as arbitrary units; the highest of each protein 
level is assigned a value of 1 and all others are expressed relative to this. 
 
Cell line HER-2 Amplified HER-2 IGF-IR
T47D-HER2 + 1.00 0.85
UACC-812 + 0.88 0.56
ZR751-HER2 + 0.88 0.43
SKBR3 + 0.65 0.32
BT474 + 0.59 0.20
SUM190 + 0.58 0.14
SUM225 + 0.45 0.33
MCF7-HER2 + 0.33 0.68
MDA-MB-361 + 0.16 0.29
MDA-MB-231-HER2 + 0.12 0.25
ZR751neo - 0.11 0.77
MDA-MB-175 + 0.08 0.26
MDA-MB-453 + 0.06 0.36
T47Dneo - 0.04 0.48
EFM-19 - 0.03 0.34
CAL-51 - 0.02 0.25
HCC1937 - 0.01 0.16
MCF7neo - 0.01 0.61
MDA-MB-231neo - 0.01 0.15
CAMA-1 - 0.00 0.53
MDA-MB-468 - 0.00 1.00
MDA-MB-435 - 0.00 0.56
KPL-1 - 0.00 0.18  
 
 
_______________________________________________________________________________________________________ 
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Figure 3.2  Relationships between HER-2, IGF-IRß and survivin protein levels in 
breast cancer cell lines. Levels were measured by western blotting and semi-quantified 
relative to a-tubulin using ImageQuant densitometry software (Amersham).  Protein 
levels are expressed as arbitrary units; the highest of each protein level is assigned a 
value of 1 and all others are expressed relative to this.  A. IGF-IRß levels in cell lines 
arranged from left to right with increasing HER-2 expression.  B. HER-2 levels in cell 
lines arranged from left to right with increasing survivin expression.  C. IGF-IRß levels 
in cell lines arranged from left to right with increasing survivin expression.  
__________________________________________________________________________________________________________
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Figure 3.3  IGF-IRß and survivin expression in HER-2- and control empty vector-
transfected (neo) breast cancer cell lines.  Protein levels were measured by western 
blotting and semi-quantified relative to a-tubulin using ImageQuant densitometry 
software (Amersham).  Levels of (A) IGF-IRß and (B) survivin are expressed as 
percentage of expression in control transfected cells.  
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3.2 RESPONSE TO TRASTUZUMAB IN HER-2-POSITIVE BREAST CANCER 
CELL LINES 
Response to trastuzumab was investigated in 14 HER-2-overexpressing cell lines [Fig. 
3.4].  BT474 was the most sensitive cell line (59 ± 5 % inhibition), while ZR751-HER-2 
was the most resistant cell line (0.5 ± 0.7 % inhibition). None of the three HER-2 
transfected cell lines (ZR751-H2, T47D-H2, MCF7-H2) showed significant response to 
trastuzumab treatment in the proliferation assay. 
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Figure 3.4.  Percentage proliferation of HER-2-overexpressing breast cancer cell lines 
treated with trastuzumab (100 nM). Proliferation was measured after 5 days by cell 
counting and is expressed relative to untreated control. Error bars represent standard 
deviation of triplicate experiments. 
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3.3 RELATIONSHIP BETWEEN HER-2, P-HER-2, IGF-IR, P-IGF-IR, EGFR 
AND P-EGFR AND RESPONSE TO TRASTUZUMAB 
 
HER-2, IGF-IR, EGFR, and phosphorylated HER-2, IGF-IR, and EGFR were 
quantified by ELISA in the panel of HER-2-overexpressing cell lines [Table 3.2 and 
Figs. 3.5 – 3.7]. While the ELISAs for the total proteins are quantitative and give a 
value in nanogram per milligram of total protein, the phospho-protein ELISAs give an 
arbitrary optical density value. Thus for the phospho-protein ELISAs the values for each 
cell line were expressed relative to the cell line with the highest level of that phospho-
protein. 
 
Statistical analyses were performed to analyse the relationships between total protein 
expression and phosphorylation level of each receptor.  Using Pearson’s correlation 
analysis, no correlation was observed between receptor expression and phosphorylation 
of HER-2, IGF-IR or EGFR [Table 3.3]. However, both HER-2 and phospho-HER-2 
correlate positively with phospho-IGF-IR levels (HER-2, p = 0.16, r = 0.628; p-HER-2 
p = 0.002, r = 0.742) [Fig. 3.10]. A positive trend was also observed between IGF-IR 
and phospho-EGFR levels, but did not reach statistical significance (p = 0.079, r = 
0.551) [Fig. 3.10]. 
 
Statistical analyses were also performed to assess the relationships between protein 
level, or phosphorylation level, and response to trastuzumab in vitro.  No significant 
correlations were observed between protein expression levels, or phosphorylation levels 
of any of the three receptors, and response to trastuzumab [Fig. 3.8 and Fig. 3.9].   
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Table 3.2.  Total and phosphorylated HER-2, IGF-IR and EGFR levels in 14 HER-2-overexpressing breast cancer cell lines.  Protein levels 
were measured by ELISA; phospho-HER-2, phospho-IGF-IR and phospho-EGFR levels are expressed as arbitrary units, relative to the cell 
line with the highest ELISA optical density reading, which was assigned a value of 1 (± standard error). 
HER-2 ng/mg IGF-IR ng/mg EGFR ng/mg p-HER-2 p-IGF-IR p-EGFR
HCC1419 577.6 ± 64.7 3.02 ± 0.35 0.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 0.20 ± 0.05
SUM 190 406.6 ± 82.1 4.10 ± 0.53 5.97 ± 0.18 0.22 ± 0.04 0.53 ± 0.08 0.22 ± 0.01
HCC2218 392.9 ± 94.1 1.83 ± 0.26 2.45 ± 0.31 0.55 ± 0.02 0.43 ± 0.04 0.23 ± 0.01
SUM 225 354.2 ± 97.8 1.35 ± 0.09 5.90 ± 0.17 0.44 ± 0.06 0.36 ± 0.06 0.21 ± 0.01
SKBR3 228.1 ± 37.6 0.71 ± 0.06 2.41 ± 0.22 0.34 ± 0.02 0.30 ± 0.04 0.57 ± 0.01
ZR75-30 205.7 ± 41.6 2.04 ± 0.07 0.00 ± 0.00 0.76 ± 0.10 0.42 ± 0.02 0.10 ± 0.02
T47D-H2 172.1 ± 30.8 7.10 ± 0.43 ND 0.92 ± 0.08 0.55 ± 0.02 ND
BT474 147.9 ± 13.3 3.65 ± 0.51 3.18 ± 0.13 0.44 ± 0.05 0.50 ± 0.03 0.37 ± 0.01
MDA-MB-361 141.0 ± 35.8 0.67 ± 0.12 0.00 ± 0.00 0.10 ± 0.00 0.16 ± 0.02 0.04 ± 0.01
HCC1954 132.2 ± 18.2 3.09 ± 0.35 7.60 ± 0.57 0.32 ± 0.04 0.52 ± 0.09 0.23 ± 0.02
ZR751-H2 131.1 ± 29.2 4.88 ± 0.41 ND 0.09 ± 0.01 0.38 ± 0.13 ND
UACC-812 104.0 ± 9.1 7.96 ± 0.87 3.60 ± 0.50 0.90 ± 0.05 0.56 ± 0.04 0.62 ± 0.02
MCF7-H2 27.0 ± 8.2 6.76 ± 0.29 ND 0.37 ± 0.04 0.40 ± 0.04 ND
MDA-MB-453 26.0 ± 1.6 1.57 ± 0.19 0.00 ± 0.00 0.01 ± 0.00 0.10 ± 0.02 0.03 ± 0.01
 
ND; not determined 
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Table 3.3.  Pearson’s correlation analysis of the relationship between HER-2, IGF-IR 
and EGFR expression and phosphorylation in HER-2-overexpressing cell lines.           
(r; Pearson’s correlation coefficient; p, significance (2-tailed)).   
 
  p-HER-2 IGF-IR p-IGFIR EGFR p-EGFR
r 0.392 -0.293 0.628 0.044 -0.065
p 0.166 0.309 0.016 0.899 0.850
r 0.410 0.742 -0.136 0.378
p  0.145 0.002 0.690 0.252
r 0.380 0.309 0.551
p  0.180 0.356 0.079
r 0.123 0.246
p 0.719 0.467
r 0.314
p 0.347
EGFR
p-HER-2
p-IGFIR
HER-2
IGF-IR
 
_____________________________________________________________________
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Figure 3.5.  A. HER-2 and  B. phospho-HER-2 protein levels in 14 HER-2-
overexpressing breast cancer cell lines. HER-2 is expressed as ng/mg total protein; p-
HER-2 is expressed as arbitrary units, relative to the cell line with the highest optical 
density reading, which was assigned a value of 1. Error bars represent standard error of 
triplicate experiments. 
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Figure 3.6.  A. IGF-IR and B. phospho-IGF-IR protein levels in 14 HER-2-
overexpressing breast cancer cell lines. IGF-IR is expressed as ng/mg total protein; p-
IGF-IR is expressed as arbitrary units, relative to the cell line with the highest optical 
density reading, which was assigned a value of 1. Error bars represent standard error of 
triplicate experiments. 
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Figure 3.7.  A. EGFR and B. phospho-EGFR protein levels in 11 HER-2-
overexpressing breast cancer cell lines. EGFR is expressed as ng/mg total protein; p-
EGFR is expressed as arbitrary units, relative to the cell line with the highest optical 
density reading, which was assigned a value of 1. Error bars represent standard error of 
triplicate experiments. 
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Figure 3.8. Scatterplots relating A. HER-2, B. IGF-IR and C. EGFR levels to 
percentage inhibition by trastuzumab in the HER-2-overexpressing breast cancer cell 
lines. Proliferation was measured by cell counting after 5 days, and % inhibition is 
expressed relative to untreated control. Protein levels were quantified by ELISA. 
Correlations were analysed by calculating Pearson’s correlation coefficient (r). 
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Figure 3.9. Scatterplots relating A. p-HER-2, B. p-IGF-IR and C. p-EGFR levels to 
percentage inhibition by trastuzumab in the HER-2-overexpressing breast cancer cell 
lines. Proliferation was measured by cell counting after 5 days, and % inhibition is 
expressed relative to untreated control. Protein levels were quantified by ELISA. 
Correlations were analysed by calculating Pearson’s correlation coefficient (r). 
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Figure 3.10. Scatterplots relating A. HER-2 to p-IGF-IR, B. p-HER-2 to p-IGF-IR and 
C. IGF-IR to p-EGFR expression levels in the HER-2-overexpressing breast cancer cell 
lines, as measured by ELISA. Correlations were analysed by calculating Pearson’s 
correlation coefficient (r). 
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4.1 REDUCED IGF-I STIMULATION DOES NOT CONFER SENSITIVITY TO 
TRASTUZUMAB 
 
It has previously been reported that IGF/IGF-IR signalling interferes with trastuzumab 
inhibition in HER-2-transfected MCF7/HER2-18 cells, and that reduction of IGF-IR 
stimulation of cells by reducing the serum content of the growth media restores 
sensitivity to trastuzumab in these cells [177]. We found that reduction of serum in the 
growth media of MCF7-HER2 cells did not sensitise these cells to trastuzumab, nor did 
IGF-I stimulation affect the growth in 1 %, 5 % or 10 % serum [Fig. 4.1].  These assays 
were performed at varied conditions: proliferation was measured at different time-points 
up to six days; serum concentration was varied between 0 – 10 %; IGF-I concentration 
was used at 40, 80 and 100 ng/ml. Response to trastuzumab was not enhanced at any of 
these conditions (results not shown). 
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Figure 4.1. Proliferation of MCF7-HER2 cells treated with and without trastuzumab (T) 
(100 nM) and IGF-I (40 ng/ml) in varying serum concentrations. Proliferation was 
measured by cell counting after 5 days, and is expressed relative to untreated control. 
Error bars represent standard deviation of three experiments.  
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4.2 ELEVATED HER-2 SIGNALLING INTERFERES WITH IGF-I-INDUCED 
MAPK SIGNALLING 
 
Transfection of HER-2 into MCF7 cells causes elevated HER-2 signalling, and HER-2-
transfected MCF7 cells have elevated Akt activity compared to control-transfected cells 
grown in serum-free or serum-containing growth media [Fig. 4.2].   IGF-I treatment 
causes phosphorylation of Akt in both MCF7neo and MCF7-HER2 cells. Elevated 
HER-2 signalling, however, interferes with IGF-I-induced MAPK signalling; MCF7-
HER2 cells have reduced MAPK phosphorylation in response to IGF-I compared to 
MCF7neo cells.  This suggests that HER-2 and IGF-IR may have independent pathways 
for signalling through Akt, but may share common signalling molecules in the MAPK 
pathway. 
 
_______________________________________________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2   Western blot of phosphorylated Akt and MAPK in MCF7neo and MCF7-
HER2 cells.  Cells were serum-starved for 24 hours and treated with serum-free (SF) 
media, serum-containing (S) media, or SF media with IGF-I (100 ng/ml) for 10 minutes.  
a-tubulin was used as a loading control.  
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4.3 TRASTUZUMAB TREATMENT ANTAGONISES IGF-I-STIMULATED 
AKT SIGNALLING 
 
Trastuzumab treatment of MCF7-HER2 cells results in a slight elevation of Akt 
phosphorylation, which returns to almost basal levels within two hours [Fig 4.3].  IGF-I 
stimulation caused an increase in phosphorylated Akt levels after two hours of treatment  
and this effect was reduced by trastuzumab [Fig. 4.3].  After two hours, trastuzumab 
reduced the IGF-I-stimulated phospho-Akt levels by 50 % [Fig. 4.3].  
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Figure 4.3  Phosphorylated Akt levels in MCF7-HER2 cells.  Cells were serum-starved 
for 24 hours and then treated alone or in combination with trastuzumab (T, Tmab) (100 
nM) and IGF-I (I) (10, 40 or 80 ng/ml).  Phospho-Akt was measured by western blot at 
10 and 120 minutes. Levels were normalised against total Akt levels, and are expressed 
relative to untreated control.   
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4.4 TRASTUZUMAB-CONDITIONED CELLS ARE MORE RESISTANT TO 
TRASTUZUMAB 
 
BT474 and SKBR3 cells were continuously maintained in media containing 700 nM 
(100 µg/ml) trastuzumab for 18 months.  After this time, conditioned cells (BT474/Tr 
and SKBR3/Tr) were less responsive to trastuzumab. 100 nM trastuzumab inhibited 
proliferation by 25.4 % in BT474/Tr cells, compared to 65.6 % in parental BT474 cells, 
and 24.1 % in SKBR3/Tr cells compared to 42.6 % in parental SKBR3 cells.  When 
trastuzumab was removed from the growth media of conditioned cells for up to 12 
weeks, conditioned cells maintained their relative resistance [Fig. 4.4]. 
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Figure 4.4  Proliferation of BT474 and SKBR3 parental and trastuzumab-conditioned 
treated with trastuzumab (100 nM). Trastuzumab-conditioned cells were maintained in 
media with (+T) or without trastuzumab (-T) for up to 12 weeks. Proliferation was 
measured after five days by cell counting and is expressed relative to untreated control.  
Error bars represent standard deviation of triplicate experiments. 
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4.5 HER-2, EGFR AND IGF-IR IN TRASTUZUMAB-RESISTANT CELLS 
 
HER-2, IGF-IR, EGFR and phosphorylated HER-2, IGF-IR and EGFR levels were 
quantified by ELISAs in parental and trastuzumab-resistant BT474 and SKBR3 cells 
[Table 4.1].  HER-2 and phospho-HER-2 levels were not significantly altered in 
trastuzumab-resistant SKBR3 cells, but were significantly increased in the BT474/Tr 
cells compared to parental cells (T-test: HER-2, p = 0.041; p-HER-2, p = 0.044).  While 
total EGFR results where similar in SKBR3 and SKBR3/Tr cells, SKBR3/Tr had 
significantly decreased phospho-EGFR levels compared to parental SKBR3 cells (p = 
0.002), while both total and phospho- EGFR levels were significantly elevated in 
BT474/Tr compared to BT474 cells (EGFR, p = 0.003; p-EGFR, p = 0.002).  IGF-IR 
levels were significantly higher in the SKBR3/Tr cells than in parental SKBR3 cells (p 
= 0.029), while they were unchanged in BT474/Tr cells [Table 4.1].  HER-2, phospho-
HER-2 and EGFR ELISA results were confirmed by immunoblotting [Fig. 4.5]. 
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Figure 4.5   Western blot of HER-2, phospho-HER-2 and EGFR protein expression in 
parental (par) and trastuzumab-resistant (Tr) BT474 and SKBR3 cells.  a-tubulin was 
used as a loading control.  
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Table 4.1 Expression and phosphorylation levels of HER-2, IGF-1R and EGFR and sensitivity to trastuzumab (T) (100 nM) in parental and 
trastuzumab-resistant BT474 and SKBR3 cells. Protein levels were measured by ELISA; phospho-HER-2, phospho-IGF-IR and phospho-EGFR 
levels are expressed as arbitrary units, relative to the cell line with the highest ELISA optical density reading, which was assigned a value of 1 
(± standard error). Cell proliferation was measured by cell counting after 5 days treatment, and % growth was calculated relative to untreated 
control (± standard deviation). 
 
 % GROWTH 
IN T 
HER-2    
NG/MG 
P-HER-2 
IGF-IR 
NG/MG 
P-IGF-1R 
EGFR NG/MG P-EGFR 
BT474 38.1 ± 7.6 147.9 ± 13.3 0.44 ± 0.05 3.6 ± 0.5 0.50 ± 0.03 3.18 ± 0.13 0.38 ± 0.01 
BT474/TR 73.6 ± 4.4* 411.4 ± 78.2* 0.62 ± 0.05* 3.1 ± 0.4 0.57 ± 0.09 13.16 ± 0.34** 1.00 ± 0.00** 
SKBR3 57.4 ± 0.9 228.1 ± 37.6 0.34 ± 0.02 0.7 ± 0.1 0.30 ± 0.04 2.41 ± 0.22 0.56 ± 0.01 
SKBR3/TR 75.9 ± 4.0* 184.7 ± 16.8 0.34 ± 0.06 1.8 ± 0.3* 0.31 ± 0.03 2.56 ± 0.25 0.20 ± 0.01** 
 
* indicates p<0.05; ** indicates p<0.001 for comparisons of resistant cell lines with parental cell lines, as determined by the Student’s t-test. 
__________________________________________________________________________________________________________________________________________________________ 
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4.6 DIMERISATION BETWEEN HER-2 AND IGF-IR 
 
Immunoprecipitation (IP) of IGF-IR protein and subsequent western blotting for HER-2 
were performed in order to investigate HER-2/IGF-IR heterodimerisation in parental 
and trastuzumab-conditioned BT474 and SKBR3 cells.  HER-2 co-precipitated with 
IGF-IR in parental and conditioned cells treated with trastuzumab (100 nM) for 24 
hours, but not in untreated samples [Fig. 4.6]. However, in control IP experiments, 
without antibody present, HER-2 was also detected, suggesting that trastuzumab itself 
immunoprecipitated HER-2 in these samples [Fig. 4.6].   IP of HER-2 protein followed 
by western blotting for IGF-IR protein was then attempted to investigate if IGF-IR co-
immunoprecipitates with HER-2 in any of the cell line samples. However, the results of 
this experiment were unclear, due to problems detecting low amounts of 
immunoprecipitated IGF-IR protein.  Numerous antibodies were tested, but as BT474 
and SKBR3 cells express relatively low levels of IGF-IR protein, none of the western 
blots were successful. Fig 4.7B shows a western blot of MCF7-HER2 cell protein after 
IGF-IR IP along side total IGF-IR; as IGF-IR was undetectable after IP in this cell line, 
which expresses high levels of IGF-IR, it is unlikely that IGF-IR could be detected in 
immunoprecipitated BT474 or SKBR3 cell lysates.  
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Figure 4.6  Immunoprecipitation (IP) -western blots (wb). A. HER-2 protein levels in 
parental and trastuzumab-resistant BT474 and SKBR3 cells after IGF-IR IP, and control 
IP, which was performed with no antibody present. Cells were treated with and without 
(C) trastuzumab (100 nM) (T) for 24 hours. B.  IGF-IR levels in MCF7-HER-2 without 
any IP (lane 1) and after IGF-IR IP (lane 2).  
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4.7 AKT AND MAPK SIGNALLING IN TRASTUZUMAB-RESISTANT CELLS 
 
While Akt and MAPK protein expression are unaltered in conditioned cells, BT474/Tr 
cells have significantly reduced phosphorylation of Akt and MAPK compared to BT474 
cells [Fig 4.7].  Phospho-Akt levels were also reduced in SKBR3/Tr compared to 
parental SKBR3 cells. SKBR3/Tr cells displayed no alteration in phospho-MAPK 
levels.  Changes in phospho-Akt and phospho-MAPK levels in response to 100 nM 
trastuzumab treatment were investigated in SKBR3 and SKBR3/Tr cells over 5 days 
[Fig. 4.8]. A similar response to trastuzumab was seen in both cell lines: while at 16 
hours, both phospho-Akt and phospho-MAPK levels were reduced; however, by 5 days, 
phosphoprotein levels were again upregulated. 
 
_______________________________________________________________________________________________________ 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 4.7   Western blot of Akt, phospho-Akt, MAPK and phospho-MAPK protein 
expression in parental (par) and trastuzumab-resistant (Tr) BT474 and SKBR3 cells.      
a-tubulin was used as a loading control.  
_______________________________________________________________________________________________________ 
 SKBR3 
 
 par   Tr 
 BT474 
 
 par   Tr 
 pAkt 
 a- tubulin 
 MAPK 
 pMAPK 
 Akt 
 107 
 
 
 
 
 
 
                 
        
               
 
 
 
 
 
 
 
               
 
 
 
 
 
               
  
 
 
Figure 4.8   Western blot of Akt, phospho-Akt, MAPK and phospho-MAPK protein 
expression in SKBR3 and SKBR3/Tr cells after trastuzumab treatment (100 nM) for up 
to 5 days, compared to control untreated cells (C). a-tubulin was used as a loading 
control.  
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4.8 RESPONSE TO LAPATINIB IN TRASTUZUMAB-RESISTANT CELLS 
 
In order to examine cross-resistance, response to lapatinib was measured in parental and 
trastuzumab-resistant SKBR3 and BT474 cells [Fig. 4.9].  BT474 and BT474/Tr cells 
were equally sensitive to lapatinib at concentrations lower than 100 nM, with IC50 
concentrations of 27.0 ± 2.8 nM and 27.5 ± 9.2 nM, respectively.  However, at higher 
concentrations, BT474/Tr cells were more sensitive to lapatinib, though this did not 
reach statistical significance.  SKBR3/Tr cells were significantly less responsive to 
lapatinib than parental SKBR3 cells with an IC50 of 174 ± 40.2 nM, compared to 71.3 ± 
18.0 nM in parental cells (t-test, p =  0.009)  
 109 
0
25
50
75
100
0 100 200 300
Lapatinib (nM)
%
 P
ro
lif
er
at
io
n
BT474
BT474/Tr
 
0
25
50
75
100
0 200 400 600
Lapatinib (nM)
%
 P
ro
lif
er
at
io
n
SKBR3
SKBR3/Tr
 
Figure 4.9  Proliferation of A. BT474 and B. SKBR3 parental and trastuzumab-resistant 
cells treated with increasing doses of lapatinib. Proliferation was measured after five 
days by the acid phosphatase method and is expressed relative to untreated control.  
Error bars represent standard deviation of at least duplicate experiments. 
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5.1 IGF-BINDING PROTEIN 3 (IGFBP3) AND ANTI-IGF-IR ANTIBODY 
aIR3         
 
IGF-stimulated IGF-IR signalling was targeted using two molecules; IGFBP3 to reduce 
available ligand, and aIR3 to block the ligand-binding domain of IGF-IR. Neither 
molecule inhibited proliferation nor enhanced the inhibitory effects of trastuzumab in 
parental or trastuzumab-resistant BT474 and SKBR3 cells [Fig. 5.1].  The activity of 
IGFBP3 and aIR3 against IGF-I/IGF-IR signalling was confirmed with MCF7 cells, in 
which both molecules inhibited IGF-I-stimulated growth [Fig. 5.2].  
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Figure 5.1  Proliferation of A. BT474 and B. SKBR3 parental and trastuzumab-resistant 
cells. Cells were cultured in the presence of 5 % serum and treated alone or in 
combinations with trastuzumab (T) (100 nM), aIR3 (1 µg/ml) and IGFBP3 (1 µg/ml). 
Proliferation was measured after five days by the acid phosphatase method, and is 
expressed relative to untreated control.  Error bars represent standard deviation of 
triplicate experiments.  
__________________________________________________________________________________________________________ 
B 
A 
 113 
0
50
100
150
200
Co
ntr
ol
IG
F-1
 25
IG
F-1
 10
0
IG
FB
P3
I25
 + 
IBP
I10
0 +
 IB
P
P
ro
lif
er
at
io
n
(%
 u
n
tr
ea
te
d
 c
o
n
tr
o
l)
 
Figure 5.2  Proliferation of MCF7 cells.  Cells were cultured in the presence of 1 % 
serum and treated alone or in combinations with IGF-I (25 or 100 ng/ml) (I), aIR3 (1 
µg/ml) and IGFBP3 (1 µg/ml) (IBP). Proliferation was measured after five days by the 
acid phosphatase method, and is expressed relative to untreated control.  Error bars 
represent standard deviation of replicate wells (single experiment).   
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5.2 IGF-IR SMALL INTERFERING RNA (siRNA) ENHANCES THE 
INHIBITORY EFFECTS OF TRASTUZUMAB 
 
Transfection with an anti-IGF-IR siRNA molecule reduced IGF-IR protein levels by 
33.8 ± 3.5 % in SKBR3 cells, 11.2 ± 4.1 % in SKBR3/Tr cells, 24.0 ± 2.5 % in BT474 
cells, and 20.6 ± 5.3 % in BT474/Tr cells, as quantified by IGF-IR ELISA.  The IGF-IR 
siRNA also reduced proliferation of each of the cell lines [Fig. 5.3 and Fig. 5.4].  While 
combined treatment with IGF-IR siRNA and trastuzumab did not improve response 
compared to trastuzumab alone in BT474 cells, the combination inhibited significantly 
more growth than trastuzumab alone in BT474/Tr cells [Fig. 5.3]. The combined 
treatment also significantly enhanced response, compared to siRNA treatment alone in 
SKBR3 cells, and compared to either treatment alone, in SKBR3/Tr cells [Fig. 5.4]. 
Two other siRNA molecules, targeting different exons of the IGF-IR gene, were also 
studied in SKBR3/Tr cells; both reduced expression of IGF-IR (by 49.2 ± 10.6 % and 
34.2 ± 3.2 %), inhibited proliferation, and enhanced response when combined with 
trastuzumab [Fig. 5.5].  IGF-IR protein knockdown was confirmed in SKBR3 and 
SKBR3/Tr cells by western blotting [Fig. 5.6]. 
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Figure 5.3  Proliferation of A. BT474 and B. BT474/Tr cells treated with and without  
trastuzumab (Tmab, T) (100 nM) and anti-IGF-IR siRNA (I) (30 nM).  NeoFx 
transfection reagent, and a scrambled siRNA molecule (Neg) were used as negative 
controls.  Proliferation was measured by cell counting after four days, and is expressed 
relative to untreated control. Student’s t-test was performed to determine significance. 
Error bars represent standard error of triplicate experiments.  
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Figure 5.4  Proliferation of A. SKBR3 and B. SKBR3/Tr cells treated with and without  
trastuzumab (Tmab, T) (100 nM) and anti-IGF-IR siRNA (I) (30 nM).  NeoFx 
transfection reagent, and a scrambled siRNA molecule (Neg) were used as negative 
controls.  Proliferation was measured by cell counting after four days, and is expressed 
relative to untreated control. Student’s t-test was performed to determine significance. 
Error bars represent standard error of triplicate experiments.  
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Figure 5.5  Proliferation of SKBR3/Tr cells treated with and without trastuzumab 
(Tmab, T) (100 nM) and three anti-IGF-IR siRNA molecules 1-3 (30nM).  siRNA 
molecule 1 was also used to treat SKBR3, BT474 and BT474/Tr cells (see Figs. 5.4 and 
5.5). NeoFx transfection reagent, and scrambled siRNA (Neg) were used as negative 
transfection controls.  Proliferation was measured by cell counting after four days, and 
is expressed relative to untreated control. Student’s t-test was performed to determine 
significance: * denotes p < 0.05; ** denotes p < 0.01, when comparing combined 
treatment with trastuzumab alone. Error bars represent standard error of three 
experiments.  
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Figure 5.6  Western blot of SKBR3 and SKBR3/Tr cells transfected with anti-IGF-IR 
siRNA molecules no.s 1, 2 and 3. Untreated cells (C), NeoFx transfection reagent 
treated (Neo), and scrambled siRNA treated (Neg) cells were used as controls. Cells 
were lysed after 72 hours treatment. a-tubulin was used as a loading control. 
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5.3 IGF-IR TYROSINE KINASE INHBITORS ENHANCE RESPONSE TO 
TRASTUZUMAB 
5.3.1 IGF-IR tyrosine kinase inhibitors inhibit growth of trastuzumab-sensitive 
and -resistant cells 
Two IGF-IR tyrosine kinase inhibitors (TKIs) were used to target IGF-IR tyrosine 
kinase signalling. Neither NVP-AEW541 nor BMS-536924 significantly inhibited the 
proliferation of BT474 or BT474/Tr cells [Fig. 5.7].  However, combined treatment 
with trastuzumab and each TKI inhibited more growth than treatment with either 
trastuzumab or TKI in BT474/Tr cells; the combination of trastuzumab and NVP-
AEW541 had significantly enhanced effects compared to trastuzumab alone (p = 0.042), 
while the combination of trastuzumab and BMS-536924 did not reach statistical 
significance (p = 0.066) [Fig. 5.7].  NVP-AEW541 inhibited the growth of both SKBR3 
and SKBR3/Tr cells, while BMS-536924 alone had no effects on the proliferation of 
these cells [Fig. 5.8].  Combined treatment with trastuzumab and NVP-AEW541 
inhibited significantly more growth than trastuzumab alone in both SKBR3 and 
SKBR3/Tr cells (SKBR3, p = 0.010; SKBR3/Tr, p = 0.00002).  The combination of 
trastuzumab with BMS-536924 had no inhibitory advantage over trastuzumab alone in 
these cells [Fig. 5.8].  To confirm the activity of the two TKIs, MCF7 cells (which 
express high levels of IGF-IR and low levels of HER-2) were also treated with 
combinations of trastuzumab and TKIs. Each inhibitor alone decreased growth of 
MCF7 cells by over 80 % [Fig. 5.9 A].  HER-2-transfected MCF7 cells, MCF7-HER2, 
which are resistant to trastuzumab, were also treated; each inhibitor alone decreased less 
than 25 % of cell growth, and the addition of trastuzumab to TKI treatment reduced 
these effects [Fig. 5.9 B].  
 
Protein lysates of SKBR3 and SKBR3/Tr cells were prepared from cells treated for 24 
hours with trastuzumab, NVP-AEW541 and BMS-536924. While trastuzumab 
treatment decreased phospho-Akt and phospho-MAPK levels in both cell lines, no 
change in levels of phosphoprotein were observed with either inhibitor alone [Fig. 
5.10].  Combining trastuzumab with either NVP-AEW541 or BMS-536924 had a 
similar effect on phospho-Akt and phospho-MAPK levels to trastuzumab alone. 
 
 119 
 
BT474
0
25
50
75
100
Control DMSO Tmab NVP BMS T + NVP T + BMS
%
 P
ro
lif
er
at
io
n
 
BT474/Tr
0
25
50
75
100
Control DMSO Tmab NVP BMS T + NVP T + BMS
%
 P
ro
lif
er
at
io
n
 
Figure 5.7  Proliferation of A. BT474 and B. BT474/Tr cells treated with and without 
trastuzumab (Tmab, T) (100 nM) and IGF-IR TKIs NVP-AEW541 (NVP) (1 µM) and 
BMS-536924 (BMS) (1 µM).  Cells were grown in 2 % serum, and proliferation was 
measured after five days by the acid phosphatase method. Percent proliferation is 
expressed relative to untreated control. DMSO-containing media was included as a 
control. Student’s t-test was performed to determine significance of the difference in 
response to treatment: * denotes p < 0.05 when comparing combined treatment with 
trastuzumab alone. Error bars represent standard deviation of triplicate experiments. 
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Figure 5.8  Proliferation of A. SKBR3 and B. SKBR3/Tr cells treated with and without 
trastuzumab (Tmab, T) (100 nM) and IGF-IR TKIs NVP-AEW541 (NVP) (1 µM) and 
BMS-536924 (BMS) (1 µM).  Cells were grown in 2 % serum, and proliferation was 
measured after five days by the acid phosphatase method. Percent proliferation is 
expressed relative to untreated control. DMSO-containing media was included as a 
control. Student’s t-test was performed to determine significance of the difference in 
response to treatment: ** denotes p < 0.01; *** denotes p < 0.001 when comparing 
combined treatment with trastuzumab alone. Error bars represent standard deviation of 
triplicate experiments. 
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Figure 5.9  Proliferation of A. MCF7 and B. MCF7-HER2 cells treated with and 
without trastuzumab (Tmab, T) (100 nM) and IGF-IR TKIs NVP-AEW541 (NVP) (1 
µM) and BMS-536924 (BMS) (1 µM).  Cells were grown in 2 % serum, and 
proliferation was measured after five days by the acid phosphatase method. Percent 
proliferation is expressed relative to untreated control. DMSO-containing media was 
included as a control. Error bars represent standard deviation of triplicate experiments. 
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Figure 5.10  Western blot of MAPK, phospho-MAPK, Akt and phosho-Akt expression 
in SKBR3 and SKBR3/Tr cells that were untreated (C) or treated with trastuzumab (100 
nM) (T), NVP-AEW541 (1 µM) (N), BMS-536924 (1 µM) (B), or combined 
trastuzumab plus NVP-AEW541 or BMS-536924, in 2 % serum for 24 hours. a-tubulin 
was used as a loading control. 
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5.3.2 NVP-AEW541 induces cell cycle arrest in trastuzumab-resistant cells 
 
The effects of NVP-AEW541 on cell cycle progression were investigated in SKBR3 
and SKBR3/Tr cells [Figs. 5.11 – 5.13].  While NVP-AEW541 alone had no significant 
effect on cell cycle progression in SKBR3 cells, treatment of SKBR3/Tr cells with 
NVP-AEW541 significantly increased the percentage of cells in the G1 (Gap 1) phase 
of the cell cycle (p = 0.040)  [Fig. 5.11].  Trastuzumab induces G1 arrest, and this was 
demonstrated in SKBR3 (p = 0.019), and to a lesser extent, in SKBR3/Tr (p = 0.040) 
cells.  NVP-AEW541 also increased the number of cells in G1 in both cell lines, and 
this effect was statistically significant in SKBR3/Tr cells (p = 0.040).  The combination 
of trastuzumab and NVP-AEW541significantly increased the percentage of cell in G1 in 
both cells (SKBR3, p = 0.023; SKBR3/Tr, p = 0.006, compared to DMSO control). The 
combination had a greater effect than either treatment alone in SKBR3/Tr cells; 
however, this effect did not reach statistical significance (p = 0.106).  
 
While single agent treatment had no significant effect on the number of cells in the 
synthesis (S) phase of the cell cycle, the combined treatment significantly decreased the 
proportion of cells in S phase in both SKBR3 and SKBR3/Tr cells (SKBR3, p = 0.039; 
SKBR3/Tr, p = 0.016, compared to DMSO control). 
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Figure 5.11  Percentage of diploid cells in G1, G2 and S phases of the cell cycle in A. 
SKBR3 and B. SKBR3/Tr cells. Cells were treated with trastuzumab (Tmab, T) (100 
nM) and IGF-IR TKI NVP-AEW541 (NVP, N) (1 µM), alone and in combination. Cells 
were grown in 2 % serum, and were fixed after three days. Cell cycle analysis was 
performed using the Guava EasyCyte.  Student’s t-test was performed to determine 
significance: * denotes p < 0.05; ** denotes p < 0.01, when comparing combined 
treatment with control or DMSO control. Error bars represent standard deviation of 
triplicate experiments. 
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Figure 5.12  Sample graphs of A. control and B. trastuzumab (100 nM) + NVP-
AEW541 (1 µM) treated SKBR3 cells analysed using ModFit software. This software 
calculates numbers of diploid (Dip) cells in G1, G2 and S phases of the cell cycle, as 
well as cell debris and cell aggregates.  
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Figure 5.13  Sample graphs of A. control and B. trastuzumab (100 nM) and NVP-
AEW541 (1 µM) treated SKBR3/Tr cells analysed using ModFit software.  This 
software calculates numbers of diploid (Dip) cells in G1, G2 and S phases of the cell 
cycle, as well as cell debris and cell aggregates.  
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Chapter 6 
 
DEVELOPMENT AND CHARACTERISATION       
OF LAPATINIB- AND TRASTUZUMAB-
CONDITIONED CELLS 
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6.1 DEVELOPMENT OF TRASTUZUMAB- AND LAPATINIB-
CONDITIONED CELLS 
 
SKBR3 cells, which are sensitive to trastuzumab, and SKBR3/Tr and HCC1419 cells, 
which are both relatively resistant to trastuzumab, were chosen to be conditioned in 
lapatinib-containing media. Lapatinib dose-response assays were performed in order to 
choose concentrations of lapatinib that inhibit approximately 70 – 80 % of cell growth 
[Fig. 4.9. and Fig. 6.1]. SKBR3 cells were also conditioned in media containing 
trastuzumab, and media containing trastuzumab and lapatinib. Table 6.1 shows the 
concentrations used to condition each cell line, and the names assigned for each new 
conditioned cell line.  After four weeks of treatment, SKBR3-L and SKBR3-TL cells 
had visibly altered morphology compared to parental SKBR3 cells; however, by six 
months, the conditioned cells resembled the parental cells once again [Fig. 6.2]. 
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Figure 6.1  Proliferation of HCC1419 resistant cells treated with increasing doses of 
lapatinib. Proliferation was measured after five days by the acid phosphatase method 
and is expressed relative to untreated control.  These results are from a single 
experiment. 
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Table 6.1  List of parental and conditioned cell lines and the treatment in which they 
were conditioned for six months. The concentration of lapatinib in SKBR3-L cells was 
increased from 200 nM to 250 nM after two months of exposure. 
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Parent cell line Conditioned cell line Treatment
SKBR3 SKBR3  -
SKBR3-T Trastuzumab 10 ug/ml
SKBR3-L Lapatinib 200-250 nM
SKBR3-TL T  5 ug/ml + L 100 nM
SKBR3/Tr SKBR3/Tr  -
SKBR3/Tr-L Lapatinib 400 nM
HCC1419 HCC1419  -
HCC1419-L Lapatinib 250 nM
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Figure 6.2  Images (100x) of  SKBR3, SKBR3-T, SKBR3-L and SKBR3-TL cells after 
A. one month, and B. six months of conditioning. 
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6.2 TRASTUZUMAB- AND LAPATINIB-CONDITIONED SKBR3 CELLS ARE 
MORE RESISTANT TO TRASTUZUMAB AND LAPATINIB  
6.2.1 Proliferation assays 
After six months of conditioning, SKBR3-T, SKBR3-L and SKBR3-TL were 
significantly more resistant to trastuzumab than parental SKBR3 cells [Fig. 6.3].  
SKBR3/Tr-L cells also had significantly reduced response to trastuzumab compared to 
SKBR3/Tr cells [Fig. 6.3].  
 
SKBR3-L, SKBR3-TL and SKBR3/Tr-L cells were also significantly more resistant to 
inhibition by lapatinib than the parental cells [Fig. 6.3 and Fig. 6.4].  Exposure of 
SKBR3 cells to trastuzumab alone (SKBR3-T) did not result in resistance to lapatinib.  
 
The combination of lapatinib and trastuzumab treatment in SKBR3 cells inhibits 
significantly more growth than either treatment alone (T-test comparing combination 
versus lapatinib alone, p = 0.0083).  SKBR3-TL cells showed significantly reduced 
response to the combination compared to parental SKBR3 cells (T-test, p = 0.0035), and 
the combination treatment did not improve response compared to either treatment alone 
in these cells [Fig. 6.5].  
 
After six months of conditioning, SKBR3, SKBR3-T, SKBR3-L and SKBR3-TL cells 
were frozen in liquid nitrogen and thawed one month later. After one further month of 
growth, the stability of resistance was investigated by repeating proliferation assays 
with trastuzumab and lapatinib treatments. Each cell line showed a similar response to 
previous results [Fig. 6.6]. 
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Figure 6.3  Proliferation of conditioned A. SKBR3 cells and B. SKBR3/Tr cells treated 
with trastuzumab (Tmab) (100 nM) and lapatinib (Lapat) (1 µM). Proliferation was 
measured after five days by the acid phosphatase method and is expressed relative to 
untreated control.  Student’s t-test was performed to determine significance of the 
difference in response to treatment: * denotes p < 0.05; ** denotes p < 0.01; *** 
denotes p < 0.001 when comparing response in conditioned cells with response in 
parental cells. Error bars represent standard deviation of triplicate experiments. 
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Figure 6.4  Proliferation of conditioned A. SKBR3 cells and B. SKBR3/Tr cells treated 
with increasing concentrations of lapatinib. Proliferation was measured after five days 
by the acid phosphatase method and is expressed relative to untreated control. Error bars 
represent standard deviation of triplicate experiments. 
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Figure 6.5  Proliferation of A. SKBR3 cells and B. SKBR3-TL cells treated with a 
combination of trastuzumab (Tmab) (100 nM) and increasing concentrations of 
lapatinib (Lap). Proliferation was measured after five days by the acid phosphatase 
method and is expressed relative to untreated control. Error bars represent standard 
deviation of triplicate experiments. 
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Figure 6.6 Proliferation of conditioned SKBR3 cells treated with trastuzumab (Tmab) 
(100 nM) or lapatinib (Lapat) (1 µM) before (A) and after (B) freeze-thawing of cells. 
Proliferation was measured after five days by the acid phosphatase method and is 
expressed relative to untreated control. Error bars represent standard deviation of 
triplicate experiments. 
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6.2.2 Doubling time assays 
Twenty-four-well plate assays were used to investigate cell growth rate over seven days 
with and without trastuzumab or lapatinib treatment of SKBR3, SKBR3-T, SKBR3-L 
and SKBR3-TL cells.  Cell doubling times were determined for each cell line, and the 
alteration in growth rate caused by each treatment was calculated.  Trastuzumab 
treatment significantly slowed the growth rate of SKBR3 cells only (p = 0.0006) [Fig. 
6.7 and Table 6.2].  Lapatinib treatment significantly slowed the growth rate of both 
SKBR3 and SKBR3-T cells (SKBR3, p = 0.0037; SKBR3-T, p = 0.0010), while it did 
not affect the rate of proliferation of the two lapatinib-conditioned SKBR3-L and 
SKBR3-TL cells [Fig. 6.8 and Table 6.2]. 
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Figure 6.7  Proliferation of A. SKBR3 cells and B. SKBR3-T cells treated with 
trastuzumab or lapatinib for 7 days. Cells were plated in 24-well plates and proliferation 
was measured at days 3, 5 and 7 by cell counting. Error bars represent standard 
deviation of triplicate experiments. 
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Figure 6.8  Proliferation of A. SKBR3-L cells and B. SKBR3-TL cells treated with 
trastuzumab or lapatinib for 7 days. Cells were plated in 24-well plates and proliferation 
was measured at days 3, 5 and 7 by cell counting. Error bars represent standard 
deviation of triplicate experiments. 
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Table 6.2  Doubling times (hours) of conditioned SKBR3 cells with and without 
trastuzumab (Tmab) (100 nM) or lapatinib (Lap) (100 nM) treatment.  (± standard 
deviation of triplicate experiments). Student’s t-test was performed to determine 
significance of the response to treatment: ** denotes p < 0.01; *** denotes p < 0.001 
when comparing doubling time in treated compared to untreated cells. The growth rate 
of each was calculated relative to untreated parental SKBR3 cells.  
 
Control         Tmab Lap
SKBR3 Doubling time (hrs) 35.0 ± 0.6 40.0 ± 0.4 44.7 ± 1.5
Growth rate (%) 100.0 87.5 78.3
SKBR3-T Doubling time (hrs) 36.6 ± 1.3 38.7 ± 1.9 44.6 ± 2.0
Growth rate (%) 95.8 90.5 78.6
SKBR3-L Doubling time (hrs) 43.3 ± 7.4 42.5 ± 3.9 43.5 ± 3.1
Growth rate (%) 80.9 82.4 80.6
SKBR3-TL Doubling time (hrs) 37.1 ± 3.8 39.6 ± 3.1 39.5 ± 4.6
Growth rate (%) 94.5 88.5 88.7
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6.3 LAPATINIB-CONDITIONED HCC1419 CELLS REMAIN SENSITIVE TO 
LAPATINIB 
 
After six months of conditioning HCC1419 cells in lapatinib-containing media, 
lapatinib treatment was discontinued and the cells were grown in growth media without 
lapatinib. However, HCC1419-L cells did not actively proliferate for over three months. 
After three months, their growth rate began to increase, and at six months, a sufficient 
number of cells were available to perform a proliferation assay.  HCC1419-L cells were 
equally sensitive to both trastuzumab and lapatinib as parental HCC1419 cells [Fig. 
6.9].  
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Figure 6.9  Proliferation of parental HCC1419 and lapatinib-conditioned HCC1419-L 
cells treated with trastuzumab (Tmab) (100 nM) and lapatinib (Lap) (0.25 µm and 1 
µM). Proliferation was measured after 5 days and is expressed relative to untreated 
control. Error bars represent standard deviation of replicate wells in a single experiment. 
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6.4 WESTERN BLOT ANALYSIS OF TRASTUZUMAB- AND LAPATINIB-
RESISTANT SKBR3 CELLS 
6.4.1 HER-2, pHER-2, EGFR AND Pgp expression  
HER-2, EGFR and phosphorylated HER-2, levels were determined by western blotting 
in conditioned SKBR3 and SKBR3/Tr cells.  HER-2, phospho-HER-2 and EGFR levels 
were not significantly altered in any conditioned SKBR3 cells. However, SKBR3/Tr-L 
cells appear to have higher levels of HER-2 phosphorylation compared to SKBR3/Tr 
cells [Fig. 6.10 A].   IGF-IR and P-glycoprotein (Pgp) expression levels were also 
measured in the conditioned SKBR3 cells. Pgp levels were undetectable in each of the 
cell lines. IGF-IR expression was elevated in SKBR3-T, SKBR3-L and SKBR3-TL 
cells compared to parental SKBR3 cells [Fig. 6.10 B].  
__________________________________________________________________________________________________________ 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 6.10   A. Western blot of HER-2, phospho-HER-2 and EGFR protein expression 
in parental SKBR3 (par), and SKBR3-T, SKBR3-L, SKBR3-TL cells, and parental and 
lapatinib conditioned SKBR3/Tr and SKBR3/Tr-L cells. B. Western blot of IGF-IR and 
Pgp in parental SKBR3 (par), and SKBR3-T, SKBR3-L, SKBR3-TL cells T47D (1) and 
DLKP-A (2) cell lysates were used as positive controls for IGF-IR and Pgp, 
respectively. a-tubulin was used as a loading control in each western blot. 
__________________________________________________________________________________________________________ 
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6.4.2 Akt and MAPK signalling in SKBR3-L cells   
As SKBR3-L cells were most resistant to both lapatinib and trastuzumab, this cell line 
was chosen for further analysis to study the mechanisms of resistance. Phosphorylation 
of Akt and MAPK was assessed in the SKBR3-L cells compared to the parental SKBR3 
cells. Phospho-MAPK levels were slightly elevated in SKBR3-L cells compared to 
parental SKBR3 cells while phospho-Akt levels were unchanged in the SKBR3-L cells 
[Fig. 6.11]. 
 
______________________________________________________________________ 
 
 
 
 
 
 
 
 
  
 
 
Figure 6.11   Western blot of phospho-MAPK, MAPK, phospho-Akt and Akt in 
parental SKBR3 (par) and SKBR3-L (-L) cells. a-tubulin was used as a loading control 
in each western blot. 
__________________________________________________________________________________________________________ 
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6.4.3 Response to trastuzumab and lapatinib in SKBR3-L cells 
Protein lysates from SKBR3 and SKBR3-L cells were prepared in order to characterise 
alterations in phosphoprotein signalling in response to trastuzumab and lapatinib 
treatment.  Trastuzumab treatment (5 µg/ml and 10 µg/ml) induced phosphorylation of 
HER-2 in both SKBR3 and SKBR3-L cells [Fig. 6.12]. Lapatinib treatment (1 µM) 
decreased phospho-HER-2 levels in both SKBR3 and SKBR3-L cells. While lapatinib 
slightly reduced EGFR levels in parental SKBR3 cells, EGFR levels were increased by 
lapatinib treatment in SKBR3-L cells [Fig. 6.12].  
 
______________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.12   Western blot of HER-2, phospho-HER-2 and EGFR protein expression in 
SKBR3 and SKBR3-L cells untreated (C) or treated with trastuzumab (T) (2, 5 and 10 
µg/ml) and lapatinib (L) (0.1, 0.5 and 1.0 µM).  a-tubulin was used as a loading control 
in each western blot. 
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6.5 PHOSPHOPROTEOMIC ANALYSIS OF LAPATINIB-RESISTANCE 
6.5.1  2-D DIGE analysis  
Protein lysates were prepared from parental SKBR3 cells and SKBR3-L cells untreated 
and treated with trastuzumab (10 µg/ml) and lapatinib (1 µM).  Phosphoprotein 
enrichment was performed, and the yield of phosphoprotein was approximately 10 % of 
total protein.   Proteomic analysis was performed on the phosphoprotein samples as 
described in chapter 2 (section 2.13).  2,500 spots were detected on the DIGE gels, and 
each was assigned a unique ID number [Fig. 6.13].  The results of each set of replicate 
gels were analysed using the DeCyder differential in-gel analysis (DIA) module, and the 
difference in protein expression between two samples is expressed as fold-change.  The 
DeCyder software produces 3-D images of protein abundance, and constructs graphs of 
relative protein abundance of each of the samples analysed [Fig. 6.14]. 
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Figure 6.13   Example of DIGE gel pictures from Gel no. 1 scanned at different 
wavelengths to reveal spots from A. Cy3-labelled parental SKBR3 cells, B. Cy5-
labelled SKBR3-L cells.  The spots detected by the DeCyder software are marked with 
red dots.  C. and D. are cropped pictures of A and B, respectively, focusing on the upper 
region of the gel, with the location of spot ID 350 circled. 
__________________________________________________________________________________________________________ 
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Figure 6.14   Examples of 3-D view of protein abundance in untreated SKBR3 ad 
SKBR3-L cells, and graphs of protein abundance in untreated (C), trastuzumab-treated 
(T) and lapatinib-treated (L) parental SKBR3 (par) and SKBR3-L cells, analysed by the 
DeCyder software.  The solid line in the graph is the average of three replicate 
measurements (dotted lines) of protein abundance. A. ID no. 350, Eukaryotic translation 
elongation factor 2; B. ID no. 362, Eukaryotic translation elongation factor 2; C. ID no. 
1945, aB-crystallin. 
__________________________________________________________________________________________________________ 
par(C)   -L(C)     par(T)     -L (T)      par(L)      -L (L) 
par(C)   -L(C)     par(T)     -L (T)      par(L)      -L (L) 
par(C)   -L(C)     par(T)     -L (T)      par(L)      -L (L) 
A. ID 350 
SKBR3           SKBR3-L 
SKBR3           SKBR3-L 
SKBR3           SKBR3-L 
B. ID 362 
C. ID 1945 
 147 
6.5.2 Phosphoprotein identification by MS 
Of 2,500 spots detected on the DIGE gels, 81 spots were picked for identification by 
MALDI-ToF-MS.  The DeCyder differential in-gel analysis (DIA) module analysed the 
difference in phosphoprotein levels between each set of two samples, and this difference 
is expressed as fold-change.  Replicate results were analysed by ANOVA. Proteins 
which demonstrated a fold-change of = 1.2 and had an ANOVA p value = 0.05 were 
analysed. Student t-tests were also performed for the comparison of phosphoprotein 
levels in SKBR3-L compared to SKBR3 cells; proteins with a t-test p value = 0.05 were 
included in the analysis.  A second cut-off of = 1.99-fold change was also applied to this 
comparison to select phosphoproteins with the greatest fold change.   
 
The comparisons performed between SKBR3 and SKBR3-L cells with and without 
trastuzumab or lapatinib treatment are listed in Table 6.3 and the phosphoproteins 
identified are listed in Tables 6.4 - 6.11. 
 
______________________________________________________________________ 
Table 6.3   Summary of the comparisons performed and displayed in Tables 6.4-6.11. 
 
Comparison Table 
SKBR3-L versus SKBR3 Table 6.4 – 6.6 
SKBR3 +/- trastuzumab Table 6.7 
SKBR3 +/- lapatinib Table 6.8 
SKBR3-L +/- trastuzumab Table 6.9 
SKBR3-L +/- lapatinib Table 6.10 
Trastuzumab treated SKBR3 versus SKBR3-L Table 6.11 
Lapatinib treated SKBR3 versus SKBR3-L Table 6.12 
______________________________________________________________________ 
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Of the 81 phosphoproteins identified, 20 were significantly higher and 21 were 
significantly lower in SKBR3-L compared to parental SKBR3 cells [Tables 6.4 and 
6.5].  Using a higher cut-off of = 1.99-fold difference combined with a significant T-
test, 14 phosphoproteins which are significantly altered in SKBR3-L compared to 
parental SKBR3 cells were identified [Table 6.6]. 
 
In trastuzumab-treated (10 µg/ml) SKBR3 cells, levels of eight of the identified 
phosphoproteins were higher, while a further eight were lower in trastuzumab-treated 
compared to untreated SKBR3 cells [Table 6.7].  In lapatinib-treated (1 µM) SKBR3 
cells, 11 identified phosphoproteins were upregulated, and 21 were downregulated 
compared to untreated SKBR3 cells [Table 6.8]. 
 
In SKBR3-L cells, eight identified phosphoproteins showed altered levels in 
trastuzumab-treated (10 µg/ml) compared to untreated cells: two were upregulated and 
six were downregulated [Table 6.9]. In lapatinib-treated (1 µM) SKBR3-L cells, 16 
phosphoproteins were differentially regulated: four were upregulated and 12 were 
downregulated [Table 6.10].  
 
Comparisons in response to each drug between SKBR3 and SKBR3-L were performed 
with the aid of Venn diagrams [Fig. 6.15]. Five phosphoproteins had altered levels in 
response to trastuzumab in both SKBR3 and SKBR3-L cells. However, 11 
phosphoproteins had altered levels only in SKBR3 cells; these proteins may mediate 
response to trastuzumab [Table 6.11A]. Three phosphoproteins were altered only in 
SKBR3-L; these may be contributing to the trastuzumab-resistant phenotype of 
SKBR3-L cells [Table 6.11B]. 
 
13 phosphoproteins had altered levels in response to lapatinib in both SKBR3 and 
SKBR3-L cells. 19 phosphoproteins had altered levels only in SKBR3 cells; these 
proteins may mediate response to lapatinib [Table 6.12A]. Three phosphoproteins were 
altered only in SKBR3-L and may be contributing to the lapatinib-resistant phenotype 
of SKBR3-L cells [Table 6.12B]. 
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7 phosphoproteins were altered only in parental SKBR3 cells in response to both 
trastuzumab and lapatinib, and may be mediators of response to both HER-2 antagonists 
[Table 6.13]. 
 
The proteins identified that may play a role in response or resistance to trastuzumab 
and/or lapatinib included a number of heat shock proteins (e.g. Hsp27, ab-crystallin, 
HSPA1A (Hsp70), gp96, stress-induced-phosphoprotein 1), proteins involved in protein 
translation and degradation (e.g. translation elongation factor 2,  translation initiation 
factor 4A, and ubiquitin activating enzyme E1), actin related proteins (e.g. adseverin, 
actinin) and proteins involved in metabolism (e.g. catalase, enoyl-CoA hydratase). 
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Table 6.4   List of identified phosphoproteins with = 1.2-fold increase in levels in 
SKBR3-L compared to SKBR3 cells. Fold change: protein abundance in SKBR3-L 
compared to SKBR3. ANOVA and Students’ t-tests were performed to determine the 
significance of the results. 
 
ID Protein ID
Fold 
change
t-test p
ANOVA 
p
1945 Crystallin; alpha B 11.26 0.010 0.000
1921 Crystallin; alpha B 7.74 0.002 0.000
2203 S100 calcium binding protein A8 (calgranulin A) 3.97 0.009 0.000
2166 Chain H; Crystal structure of Mrp14 complexed with chaps 3.67 0.005 0.000
2152 Chain H; Crystal structure of Mrp14 complexed with chaps 3.61 0.015 0.000
2213 S100 calcium binding protein A8 (calgranulin A) 3.46 0.009 0.000
2145 Chain H; Crystal structure of Mrp14 complexed with chaps 3.24 0.007 0.000
580 Adseverin 2.57 0.012 0.000
1797 Heat shock 27kDa protein 1 2.38 0.037 0.004
461 Tumor rejection antigen (gp96) 1 2.16 0.005 0.000
366 Tumor rejection antigen (gp96) 1 1.92 0.016 0.000
1789 High-mobility group box 1 1.67 0.014 0.004
925 FK506 binding protein 4 1.60 0.006 0.000
1467 Uracil DNA glycosylase 1.52 0.014 0.000
1462 Uracil DNA glycosylase 1.46 0.003 0.000
951 FK506 binding protein 4 1.45 0.018 0.000
1647 Lactamase; beta 2 1.44 0.014 0.000
1486 Glyceraldehyde-3-phosphate dehydrogenase 1.35 0.032 0.002
1688 Methylthioadenosine phosphorylase 1.33 0.014 0.000
369 Eukaryotic translation elongation factor 2 1.22 0.040 0.005
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Table 6.5   List of identified phosphoproteins with = 1.2-fold decrease in levels in 
SKBR3-L compared to SKBR3 cells. Fold change: protein abundance in SKBR3-L 
compared to SKBR3. ANOVA and Students’ t-tests were performed to determine the 
significance of the results. 
 
ID Protein ID
Fold 
change
t-test p
ANOVA 
p
1720 PSMA4 protein -1.21 0.015 0.009
1750 Proteasome (prosome; macropain) subunit; alpha type; 3 -1.24 0.006 0.005
1909 Proteasome subunit Y -1.26 0.000 0.038
1774 Proteasome (prosome; macropain) subunit; alpha type; 7 -1.28 0.003 0.006
844 Stress-induced-phosphoprotein 1(Hsp70/90-organizing protein) -1.31 0.040 0.000
1816 Proteasome (prosome; macropain) subunit; beta type; 4 -1.34 0.043 0.005
1135 Proteasome (prosome; macropain) 26S subunit; ATPase; 2 -1.34 0.004 0.001
783 HSPA1A protein; HSPA1A protein -1.36 0.012 0.007
1701 PSMB7 protein -1.37 0.016 0.004
982 Glucose-6-phosphate dehydrogenase -1.41 0.034 0.000
361 Eukaryotic translation elongation factor 2 -1.46 0.005 0.000
1484 Putative sialoglycoprotease -1.48 0.015 0.012
985 Glucose-6-phosphate dehydrogenase -1.64 0.020 0.000
338 Eukaryotic translation elongation factor 2 -1.68 0.001 0.004
354 Eukaryotic translation elongation factor 2 -1.68 0.000 0.000
1006 Glucose-6-phosphate dehydrogenase -1.72 0.010 0.000
948 Adenylyl cyclase-associated protein -1.98 0.003 0.000
1659 Chain D; Crystal structure of human Dt-Diaphorase -1.99 0.026 0.002
340 Eukaryotic translation elongation factor 2 -1.99 0.000 0.000
341 Eukaryotic translation elongation factor 2 -2.00 0.002 0.000
350 Eukaryotic translation elongation factor 2 -2.42 0.000 0.000
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Table 6.6   List of identified phosphoproteins with = 1.99-fold change in levels in 
SKBR3-L compared to SKBR3 cells. Fold change: protein abundance in SKBR3-L to 
SKBR3. ANOVA and Students’ t-tests were performed to determine the significance of 
the results. 
 
ID Protein ID
Fold 
change
t-test p
ANOVA 
p
1945 Crystallin; alpha B 11.26 0.010 0.000
1921 Crystallin; alpha B 7.74 0.002 0.000
2203 S100 calcium binding protein A8 (calgranulin A) 3.97 0.009 0.000
2166 Chain H; Crystal structure of Mrp14 complexed with chaps 3.67 0.005 0.000
2152 Chain H; Crystal structure of Mrp14 complexed with chaps 3.61 0.015 0.000
2213 S100 calcium binding protein A8 (calgranulin A) 3.46 0.009 0.000
2145 Chain H; Crystal structure of Mrp14 complexed with chaps 3.24 0.007 0.000
580 Adseverin 2.57 0.012 0.000
1797 Heat shock 27kDa protein 1 2.38 0.037 0.004
461 Tumor rejection antigen (gp96) 1 2.16 0.005 0.000
1659 Chain D; Crystal structure of human Dt-Diaphorase -1.99 0.026 0.002
340 Eukaryotic translation elongation factor 2 -1.99 0.000 0.000
341 Eukaryotic translation elongation factor 2 -2.00 0.002 0.000
350 Eukaryotic translation elongation factor 2 -2.42 0.000 0.000
 
 
 153 
______________________________________________________________________ 
 
Table 6.7  List of identified phosphoproteins with = 1.2-fold change in levels in 
trastuzumab-treated (10 µg/ml) compared to untreated SKBR3 cells. Fold change: 
protein abundance in trastuzumab-treated to untreated SKBR3 cells. ANOVA was 
performed to determine the significance of the results. 
 
 
ID Protein ID
Fold 
Change
ANOVA        
p
369 Eukaryotic translation elongation factor 2 1.53 0.0047
375 Eukaryotic translation elongation factor 2 1.51 0.0017
713 Enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase 1.50 0.0046
461 Tumor rejection antigen (gp96) 1 1.28 0.0001
1797 Heat shock 27kDa protein 1 1.28 0.0037
366 Tumor rejection antigen (gp96) 1 1.27 0.0005
1921 Crystallin; alpha B 1.21 0.0000
362 Eukaryotic translation elongation factor 2 1.20 0.0011
2203 S100 calcium binding protein A8 (calgranulin A) -1.21 0.0002
387 Actinin; alpha 4 -1.26 0.0120
783 HSPA1A protein -1.27 0.0065
354 Eukaryotic translation elongation factor 2 -1.31 0.0000
338 Eukaryotic translation elongation factor 2 -1.38 0.0035
341 Eukaryotic translation elongation factor 2 -1.61 0.0000
340 Eukaryotic translation elongation factor 2 -1.63 0.0001
350 Eukaryotic translation elongation factor 2 -1.82 0.0000
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Table 6.8  List of identified phosphoproteins with = 1.2-fold change in levels in 
lapatinib-treated (1 µM) compared to untreated SKBR3 cells. Fold-change: protein 
abundance in lapatinib-treated to untreated SKBR3 cells. ANOVA was performed to 
determine the significance of the results. 
 
ID Protein ID
Fold 
Change
ANOVA      
p
713 Enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase 2.00 0.0046
1721 Platelet-activating factor acetylhydrolase 1.73 0.0004
1557 Inorganic pyrophosphatase 2 1.63 0.0043
1921 Crystallin; alpha B 1.63 0.0000
580 Adseverin 1.61 0.0002
892 Catalase 1.56 0.0035
375 Eukaryotic translation elongation factor 2 1.50 0.0017
1945 Crystallin; alpha B 1.47 0.0005
369 Eukaryotic translation elongation factor 2 1.45 0.0047
362 Eukaryotic translation elongation factor 2 1.29 0.0011
1736 Tryptophan 5-monooxgenase activation protein 1.26 0.0340
925 FK506 binding protein 4 -1.23 0.0000
948 Adenylyl cyclase-associated protein -1.24 0.0000
390 Ubiquitin activating enzyme E1 -1.27 0.0034
2152 Chain H; Crystal Structure of Mrp14 Complexed With Chaps -1.29 0.0001
1124 Protein disulfide isomerase-related protein 5 -1.34 0.0009
783 HSPA1A protein -1.35 0.0065
826 Stress-induced-phosphoprotein 1(Hsp70/90-organizing protein) -1.39 0.0021
420 Eukaryotic translation elongation factor 2 -1.40 0.0160
951 FK506 binding protein 4 -1.40 0.0000
1484 Putative sialoglycoprotease -1.41 0.0120
1116 Protein disulfide isomerase-related protein 5 -1.45 0.0270
1197 Eukaryotic translation initiation factor 4A; isoform 1 -1.46 0.0010
1134 OTTHUMP00000017054 -1.48 0.0029
844 Stress-induced-phosphoprotein 1(Hsp70/90-organizing protein) -1.59 0.0001
361 Eukaryotic translation elongation factor 2 -1.62 0.0000
387 Actinin; alpha 4 -1.63 0.0120
354 Eukaryotic translation elongation factor 2 -1.67 0.0000
338 Eukaryotic translation elongation factor 2 -1.80 0.0035
340 Eukaryotic translation elongation factor 2 -2.13 0.0001
341 Eukaryotic translation elongation factor 2 -2.68 0.0000
350 Eukaryotic translation elongation factor 2 -3.07 0.0000
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Table 6.9   List of identified phosphoproteins with = 1.2-fold change in levels in 
trastuzumab-treated (10 µg/ml) compared to untreated SKBR3-L cells. Fold change: 
protein abundance in trastuzumab-treated to untreated SKBR3-L cells.  ANOVA was 
performed to determine the significance of the results. 
 
ID Protein ID
Fold 
Change
ANOVA 
p
1736 Tryptophan 5-monooxgenase activation protein 1.22 0.0340
1266 Brain creatine kinase 1.21 0.0078
354 Eukaryotic translation elongation factor 2 -1.21 0.0000
341 Eukaryotic translation elongation factor 2 -1.23 0.0000
340 Eukaryotic translation elongation factor 2 -1.28 0.0001
2203 S100 calcium binding protein A8 (calgranulin A) -1.28 0.0002
350 Eukaryotic translation elongation factor 2 -1.40 0.0000
420 Eukaryotic translation elongation factor 2 -1.42 0.0160  
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Table 6.10  List of identified phosphoproteins with = 1.2-fold change in levels in 
lapatinib-treated (1 µM) compared to untreated SKBR3-L cells. Fold change: protein 
abundance in lapatinib-treated to control treated SKBR3-L cells.  ANOVA was 
performed to determine the significance of the results. 
 
ID Protein ID
Fold 
Change
ANOVA  
p
1721 Platelet-activating factor acetylhydrolase 1.37 0.0004
713 Enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase 1.33 0.0046
580 Adseverin 1.24 0.0002
1736 Tryptophan 5-monooxgenase activation protein 1.22 0.0340
354 Eukaryotic translation elongation factor 2 -1.22 0.0000
2166 Chain H; Crystal Structure of Mrp14 complexed with chaps -1.24 0.0000
826 Stress-induced-phosphoprotein 1(Hsp70/90-organizing protein) -1.25 0.0021
844 Stress-induced-phosphoprotein 1(Hsp70/90-organizing protein) -1.26 0.0001
361 Eukaryotic translation elongation factor 2 -1.29 0.0000
340 Eukaryotic translation elongation factor 2 -1.33 0.0001
2145 Chain H; Crystal Structure of Mrp14 complexed with chaps -1.34 0.0000
341 Eukaryotic translation elongation factor 2 -1.36 0.0000
420 Eukaryotic translation elongation factor 2 -1.37 0.0160
2152 Chain H; Crystal Structure of Mrp14 complexed with chaps -1.40 0.0001
2203 S100 calcium binding protein A8 (calgranulin A) -1.55 0.0002
350 Eukaryotic translation elongation factor 2 -1.57 0.0000
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Figure 6.15 Venn diagrams showing the number of identified phosphoproteins with 
altered levels in response to A. trastuzumab (100 nM) and B. lapatinib (1 µM) treatment 
in SKBR3 compared to SKBR3-L cells.  
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Table 6.11  List of identified phosphoproteins that had altered levels only in A. SKBR3 
cells and B. SKBR3-L cells in response trastuzumab (100 nM) treatment. ANOVA was 
performed to determine the significance of the results. 
 
  
ID Protein ID
Fold 
change
ANOVA 
p
369 Eukaryotic translation elongation factor 2 1.53 0.005
375 Eukaryotic translation elongation factor 2 1.51 0.002
713 Enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase 1.50 0.005
461 Tumor rejection antigen (gp96) 1 1.28 0.000
1797 Heat shock 27kDa protein 1 1.28 0.004
366 Tumor rejection antigen (gp96) 1 1.27 0.000
1921 Crystallin; alpha B 1.21 0.000
362 Eukaryotic translation elongation factor 2 1.20 0.001
387 Actinin; alpha 4 -1.26 0.012
783 HSPA1A protein -1.27 0.007
338 Eukaryotic translation elongation factor 2 -1.38 0.004
 
 
ID Protein ID
Fold 
change
ANOVA 
p
1736 Tryptophan 5-monooxgenase activation protein 1.22 0.034
1266 Brain creatine kinase 1.21 0.008
420 Eukaryotic translation elongation factor 2 -1.42 0.016
 
B 
A 
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Table 6.12  List of identified phosphoproteins that had altered levels only in A. SKBR3 
cells and B. SKBR3-L cells in response lapatinib (1 µM) treatment. ANOVA was 
performed to determine the significance of the results. 
 
ID Protein ID
Fold 
change
ANOVA 
p
1557 Inorganic pyrophosphatase 2 1.63 0.004
1921 Crystallin; alpha B 1.63 0.000
892 Catalase 1.56 0.004
375 Eukaryotic translation elongation factor 2 1.50 0.002
1945 Crystallin; alpha B 1.47 0.000
369 Eukaryotic translation elongation factor 2 1.45 0.005
362 Eukaryotic translation elongation factor 2 1.29 0.001
925 FK506 binding protein 4 -1.23 0.000
948 Adenylyl cyclase-associated protein -1.24 0.000
390 Ubiquitin activating enzyme E1 -1.27 0.003
1124 Protein disulfide isomerase-related protein 5 -1.34 0.001
783 HSPA1A protein -1.35 0.007
951 FK506 binding protein 4 -1.40 0.000
1484 Putative sialoglycoprotease -1.41 0.012
1116 Protein disulfide isomerase-related protein 5 -1.45 0.027
1197 Eukaryotic translation initiation factor 4A; isoform 1 -1.46 0.001
1134 OTTHUMP00000017054 -1.48 0.003
387 Actinin; alpha 4 -1.63 0.012
338 Eukaryotic translation elongation factor 2 -1.80 0.004
 
 
ID Protein ID
Fold 
change
ANOVA 
p
2166 Chain H; Crystal Structure of Mrp14 Complexed With Chaps -1.24 0.000
2145 Chain H; Crystal Structure of Mrp14 Complexed With Chaps -1.34 0.000
2203 S100 calcium binding protein A8 (calgranulin A) -1.55 0.000
 
B 
A 
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Table 6.13  List of identified phosphoproteins that had altered levels only in SKBR3 
cells after both trastuzumab (100 nM) and lapatinib (1 µM) treatment.  ANOVA was 
performed to determine the significance of the results. 
ID Protein ID
Fold 
change
ANOVA 
p
369 Eukaryotic translation elongation factor 2 1.53 0.005
375 Eukaryotic translation elongation factor 2 1.51 0.002
1921 Crystallin; alpha B 1.21 0.000
362 Eukaryotic translation elongation factor 2 1.20 0.001
387 Actinin; alpha 4 -1.26 0.012
783 HSPA1A protein -1.27 0.007
338 Eukaryotic translation elongation factor 2 -1.38 0.004
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6.5.5 Identification of phosphorylated peptides 
The MALDI-ToF-MS analysis also provides information on the amount of the total 
protein sequence, or the percent coverage, that was identified for each protein, and on 
post-translational modifications of the identified proteins, such as the presence of 
phosphate groups.  Of the proteins that were identified, the average percent coverage 
was 45.4 %.   
 
A MASCOT score is calculated for each protein identified and reflects the level of 
confidence in the identification.  Fig 6.15 shows an example of an identified protein 
sequence; protein ID no. 783 (HSPA1A/ Hsp70), which had a high MASCOT score of 
953, and 60 % protein coverage.  Each individual peptide sequenced is also given an ion 
score, which indicates the level of homology between the peptide sequence and the 
protein identified [Fig 6.15]. 
______________________________________________________________________ 
  
     1 MAKAAAIGID LGTTYSCVGV FQHGKVEIIA NDQGNRTTPS YVAFTDTERL  
    51 IGDAAKNQVA LNPQNTVFDA KRLIGRKFGD PVVQSDMKHW PFQVINDGDK  
   101 PKVQVSYKGE TKAFYPEEIS SMVLTKMKEI AEAYLGYPVT NAVITVPAYF  
   151 NDSQRQATKD AGVIAGLNVL RIINEPTAAA IAYGLDRTGK GERNVLIFDL  
   201 GGGTFDVSIL TIDDGIFEVK ATAGDTHLGG EDFDNRLVNH FVEEFKRKHK  
   251 KDISQNKRAV RRLRTACERA KRTLSSSTQA SLEIDSLFEG IDFYTSITRA  
   301 RFEELCSDLF RSTLEPVEKA LRDAKLDKAQ IHDLVLVGGS TRIPKVQKLL  
   351 QDFFNGRDLN KSINPDEAVA YGAAVQAAIL MGDKSENVQD LLLLDVAPLS  
   401 LGLETAGGVM TALIKRNSTI PTKQTQIFTT YSDNQPGVLI QVYEGERAMT  
   451 KDNNLLGRFE LSGIPPAPRG VPQIEVTFDI DANGILNVTA TDKSTGKANK  
   501 ITITNDKGRL SKEEIERMVQ EAEKYKAEDE VQRERVSAKN ALESYAFNMK  
   551 SAVEDEGLKG KISEADKKKV LDKCQEVISW LDANTLAEKD EFEHKRKELE  
   601 QVCNPIISGL YQGAGGPGPG GFGAQGPKGG SGSGPTIEEV D 
 
Figure 6.15   Protein sequence of protein ID no. 783 (HSPA1A/ Hsp70), which had 60 
% protein coverage.   The matched peptide sequences are in red. The outlined peptide 
sequence corresponds to amino acids 221 – 236, and this peptide fragment had a high 
ion score of 131, indicating a high level of homology.  
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60 of the identified proteins were further analysed for post-translational modifications.  
Between 1 and 12 phosphorylation sites were identified on 44 of the 60 proteins.  Table 
6.12A shows a comparison of the phosphorylation sites found on peptide sequences in 
six identified forms of eukaryotic elongation translation factor 2 (eEF2) that were 
downregulated in SKBR3-L compared to parental SKBR3 cells. Table 6.12B shows a 
comparison of the phosphorylation sites found on peptide sequences in three identified 
forms of eukaryotic Mrp14 (S100A9/Calgranulin B) that were upregulated in SKBR3-L 
compared to parental SKBR3 cells.  
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Table 6.12  Matched peptide information for identified phosphorylated isoforms of A. 
eEF2 and B. Mrp14/S100A9 proteins, showing MASCOT scores, % coverage and 
highest ion score obtained for the matched peptides. The peptide sequences with 
identified phosphorylation groups are listed, and the no. of phosphorylation sites found 
on each sequence, as well as the total no. of phosphorylation sites identified, is shown 
for each protein ID. 
 
Protein ID 338 340 341 350 354 361
Fold change - 1.68 - 1.99 - 2.00 - 2.42 - 1.68 - 1.46
MASCOT Score 105 300 247 72 393 90
% Coverage 22 34 29 24 33 20
Highest ion score 19 42 52 18 61 26
Total no. phosphate groups identified 0 6 3 3 7 7
Peptide sequences and no. phosphate groups identified
33 - 50 K.STLTDSLVCKAGIIASAR.A 0 0 0 0 2 0
43 - 50 K.AGIIASAR.A 0 0 1 1 1 1
51 - 61 R.AGETRFTDTR.K 0 2 1 0 1 0
163 - 180 R.ALLELQLEPEELYQTFQR.I 0 0 1 1 1 0
392 - 409 K.GPLMMYISKMVPTSDKGR.F 0 3 0 0 3 3
408 - 415 K.GRFYAFGR.V 0 0 0 0 0 1
450 - 456 R.TILMMGR.Y 0 1 0 0 0 0
482 - 498 K.TGTITTFEHAHNMRVMK.F 0 0 0 0 0 2
648 - 667 R.KIWCFGPDGTGPNILTDITK.G 0 0 0 1 0 0
 
Protein ID 2145 2152 2166
Fold change 3.24 3.61 3.67
MASCOT Score 242 349 350
% Coverage 74 72 75
Total no. phosphate groups identified 1 1 0
Peptide sequences and no. phosphate goups identified
72 - 84 K.QLSFEEFIMLMAR.L 0 1 0
93 - 113 K.MHEGDEGPGHHHKPGLGEGTP. 1 0 0  
A 
B 
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HER-2 AND IGF-IR       
IMMUNOHISTOCHEMISTRY (IHC)                         
IN PATIENT SAMPLES 
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7.1 HER-2 AND IGF-IR IMMUNOHISTOCHEMISTRY (IHC) 
 
HER-2 levels were scored using the DAKO HercepTestM scoring guidelines, and were 
assigned scores of 0, 1+ (both HER-2-negative), 2+ (weakly positive) or 3+ (strongly 
positive) based on membrane staining intensity [Fig. 71].   Membrane IGF-IR (mIGF-
IR) and cytoplasmic IGF-IR (cIGF-IR) staining were scored separately; mIGF-IR was 
scored as positive or negative, while cIGF-IR levels were assigned scores of 0 
(negative), 1+ (weakly positive), 2+ (moderately positive), or 3+ (strongly positive) 
[Fig. 7.2].  
 
Two different studies were performed.  Study 1 was an analysis of HER-2 and IGF-IR 
expression in 93 unselected breast cancer patients from St. Vincent’s University 
Hospital. Study 2 was an analysis of HER-2 and IGF-IR expression in 150 HER-2-
positive breast cancer patients from St. Vincent’s University Hospital and St. James’ 
Hospital.  Results of each study will be presented separately in Sections 7.2 and 7.3.  
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Figure 7.1 Representative pictures of HER-2 staining with different scores:  
A. HER-2 negative; B. HER-2 1+; C. HER-2 2+ and D. HER-2 3+. 
__________________________________________________________________________________________________________ 
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Figure 7.2 Representative pictures of IGF-IR staining with different membrane and 
cytoplasmic scores: A. IGF-IR membrane negative, cytoplasm 0; B. IGF-IR membrane 
positive, cytoplasm 1+; C. IGF-IR membrane positive, cytoplasm 2+, and D. IGF-IR 
membrane negative, cytoplasm 3+. 
__________________________________________________________________________________________________________ 
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7.2 STUDY 1: HER-2 AND IGF-IR EXPRESSION IN UNSELECTED BREAST 
CANCER PATIENTS 
7.2.1  HER-2 and IGF-IR IHC scores  
Tissue microarrays (TMAs) containing 93 breast tumour samples were obtained and 
were stained for HER-2, membrane IGF-IR and cytoplasmic IGF-IR expression [Table 
7.1]. Consistent with previous reports, 20% of the breast tumours were HER-2 positive 
(2+ or 3+).  All of the breast tumours, except one, were positive for cytoplasmic 
staining of IGF-IR, whereas only 34.4% were positive for IGF-IR membrane staining. 
 
______________________________________________________________________ 
 
Table 7.1  HER-2 and IGF-IR scores in 93 patient samples, as measured by IHC. 
 
n %
HER-2
0 70 77.8
1+ 2 2.2
2+ 4 4.4
3+ 14 15.6
Unknown 3
IGF-IR cytoplasm
0 1 1.1
1+ 14 15.6
2+ 64 71.1
3+ 11 12.2
Unknown 3
IGF-IR membrane
Negative 59 65.6
Positive 31 34.4
Unknown 3
 
______________________________________________________________________ 
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7.2.2  HER-2 and IGF-IR correlation with prognostic indicators 
Table 7.2 outlines the histopathological characteristics of the 93 patients studied.  
 
No significant correlation was observed between HER-2 expression and patient age at 
diagnosis, tumour size, nodal status, histological type, or ER or PR status [Table 7.3].  
However, HER-2 expression was significantly associated with tumour grade (Chi-
squared test, p = 0.031); while the majority of HER-2-negative tumours were grade 2 
(41/69, 59 %), the majority of HER-2 3+ tumours were grade 3 (11/14, 79 %) [Fig. 7.3]. 
 
Cytoplasmic expression of IGF-IR was not associated with patient age at diagnosis, 
tumour size, nodal status, histological type, or ER or PR status [Table 7.4].  However, a 
significant correlation was observed between cytoplasmic expression of IGF-IR and 
tumour grade (Chi-squared test, p = 0.046) [Fig. 7.3]; grade 3 tumours had a higher 
proportion of 2+ or 3+ cytoplasmic IGF-IR staining than lower grade tumours. 
 
No correlation was observed between membrane IGF-IR expression and patient age at 
diagnosis, tumour size, tumour grade, or ER or PR status [Table 7.5]. A significant 
correlation was observed between membrane IGF-IR staining and histological type 
(Mann-Whitney test, p = 0.005) [Fig. 7.5].  No IGF-IR membrane staining was detected 
in lobular tumours, while 39 % of ductal tumours were membrane IGF-IR-positive and 
61 % were membrane IGF-IR-negative. An inverse association was also observed 
between membrane IGF-IR expression and the number of positive nodes detected, 
although this association did not reach significance (Mann-Whitney test, p = 0.079) 
[Fig. 7.6]. 
 
No correlation was observed between HER-2 expression and membrane or cytoplasmic 
IGF-IR expression in this group of patients. 
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Table 7.2 Characteristics of the breast cancer patients analysed in Study 1 (n = 93).  
 
n %
Age at diagnosis
< 50 years 26 28.0
= 50 years 64 68.8
Unknown 3 3.2
Tumour size
= 2 cm 25 26.9
> 2 cm 68 73.1
Unknown 0 0.0
Nodal status
Neg 37 39.8
Pos 53 57.0
Unknown 3 3.2
Grade
1 6 6.5
2 46 49.5
3 39 41.9
Unknown 2 2.2
Histology
Ductal 79 84.9
Lobular 13 14.0
Unknown 1 1.1
ER status
Negative 27 29.0
Positive 60 64.5
Unknown 6 6.5
PR status
Negative 42 45.2
Positive 46 49.5
Unknown 5 5.4
 
______________________________________________________________________ 
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Table 7.3 Relationship between HER-2 levels and patient prognostic indicators. 
 
0 1+ 2+ 3+ p
 Age (years)
< 50 (n=26) 18 (69.2%) 0 (0%) 1 (3.8%) 7 (26.9%)
= 50 (n=62) 51 (82.3%) 1 (1.6%) 3 (4.8%) 7 (11.3%)
 Size (cm)
= 2 (n=24) 20 (83.3%) 0 (0%) 1 (4.2%) 3 (12.5%)
> 2 (n=66) 51 (77.3%) 1 (1.5%) 3 (4.5%) 11 (16.7%)
 Nodal status
Neg (n=35) 28 (80.0%) 1 (2.9%) 2 (5.7%) 4 (11.4%)
Pos (n=52) 41 (78.8%) 0 (0%) 2 (3.8%) 9 (17.3%)
 Grade
1 (n=5) 4 (80%) 0 (0%) 1 (20.0%) 0 (0%)
2 (n=45) 41 (91.1%) 0 (0%) 1 (2.2%) 3 (6.7%) 0.0314
3 (n=38) 24 (63.2%) 1 (2.6%) 2 (5.3%) 11 (28.9%)
 Histology
D (n=77) 58 (75.3%) 1 (1.3%) 4 (5.2%) 14 (18.2%)
L (n=12) 12 (100%) 0 (0%) 0 (0%) 0 (0%)
 ER status
Neg (n=26) 18 (69.2%) 0 (0%) 1 (3.8%) 7 (26.9%)
Pos (n=59) 48 (81.4%) 1 (1.7%) 3 (5.1%) 7 (11.9%)
 PR status
Neg (n=41) 28 (68.3%) 0 (0%) 3 (7.3%) 10 (24.4%)
Pos (n=45) 39 (86.7%) 1 (2.2%) 1 (2.2%) 4 (8.9%)
HER-2 staining
0.2994
0.8854
0.5455
0.2880
0.3441
0.1021
 
 
______________________________________________________________________ 
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Figure 7.3  Number of patients divided by HER-2 status in grade 1, 2 and 3 tumours. 
The relationships were analysed by the Chi-squared test. 
__________________________________________________________________________________________________________ 
 
p =0.031 
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Table 7.4 Relationship between cytoplasmic IGF-IR levels and patient prognostic 
indicators. 
 
0 1+ 2+ 3+ p
 Age (years)
< 50 (n=26) 1 (3.8%) 3 (11.5%) 17 (65.4%) 5 (19.2%)
= 50 (n=61) 0 (0%) 8 (13.1%) 37 (60.7%) 16 (26.2%)
 Size (cm)
= 2 (n=24) 0 (0%) 1 (4.2%) 16 (66.7%) 7 (29.2%)
> 2 (n=66) 1 (1.5%) 10 (15.2%) 41 (62.1%) 14 (21.2%)
 Nodal status
Neg (n=36) 1 (2.8%) 4 (11.1%) 23 (63.9%) 8 (22.2%)
Pos (n=51) 0 (0%) 7 (13.7%) 31 (60.8%) 13 (25.5%)
 Grade
1 (n=5) 0 (0%) 1 (20.0%) 4 (80.0%) 0 (0%)
2 (n=44) 0 (0%) 10 (22.7%) 23 (52.3%) 11 (25.0%) 0.0459
3 (n=39) 1 (2.6%) 1 (2.6%) 28 (71.8%) 10 (25.6%)
 Histology
D (n=76) 1 (1.3%) 8 (10.5%) 47 (61.8%) 20 (26.3%)
L (n=13) 0 (0%) 3 (23.1%) 9 (69.2%) 1 (7.7%)
 ER status
Neg (n=26) 1 (3.8%) 4 (15.4%) 17 (65.4%) 4 (15.4%)
Pos (n=59) 0 (0%) 5 (8.5%) 38 (64.4%) 16 (27.1%)
 PR status
Neg (n=41) 0 (0%) 6 (14.6%) 29 (70.7%) 6 (14.6%)
Pos (n=44) 1 (2.3%) 4 (9.1%) 25 (56.8%) 14 (31.8%)
0.3457
0.2466
0.1873
IGF-IR cytoplasmic staining
0.4206
0.4512
0.6466
 
 
 
______________________________________________________________________
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Figure 7.4  Number of patients divided by cytoplasmic IGF-IR status in grade 1, 2 and 
3 tumours. The relationships were analysed by the Chi-squared test. 
__________________________________________________________________________________________________________ 
p =0.046 
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Table 7.5 Relationship between membrane IGF-IR staining and patient prognostic 
indicators. 
 
n No. positive % p
 Age (years)
< 50 26 10 38.5
= 50 61 20 32.8
 Size (cm)
= 2 24 9 37.5
> 2 66 22 33.3
 Nodal status
Neg 36 16 44.4
Pos 51 15 29.4
 Grade
1 5 2 40.0
2 44 17 38.6 0.5817
3 39 11 28.2
 Histology
D 76 30 39.5
L 13 0 0.0
 ER status
Neg 26 7 26.9
Pos 59 21 35.6
 PR status
Neg 41 14 34.1
Pos 44 15 34.1
0.0054
0.4332
0.9957
IGF-IR membrane staining
0.6102
0.7103
0.1493
 
 
______________________________________________________________________ 
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Figure 7.5  Number of patients with membrane IGF-IR staining in ductal and lobular 
tumours. The relationships were analysed by the Chi-squared test. 
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Figure 7.6 Number of positive nodes detected in patients with tumours positive and 
negative for membrane-IGF-IR. The relationship was analysed by the Mann-Whitney 
test. 
_______________________________________________________________________________________________
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7.3 STUDY 2: HER-2 AND IGF-IR EXPRESSION IN HER-2-POSITIVE 
BREAST CANCER PATIENTS 
7.3.1  HER-2 and IGF-IR IHC scores  
We constructed TMAs from 223 tumours, which had previously tested positive for 
HER-2 in hospital laboratories, by immunohistochemistry or FISH analysis. For 
patients where treatment details were available, approximately 83% (158/190) received 
trastuzumab, with the majority receiving trastuzumab in the adjuvant setting. The TMAs 
were stained for HER-2, membrane IGF-IR and cytoplasmic IGF-IR expression [Table 
7.6]. Although all these tumours were believed to be HER-2 positive only 105 of 182 
samples stained were either HER-2 2+ or HER-2 3+. All of the tumour samples showed 
some degree of IGF-IR cytoplasmic staining, with the majority being 2+ (143/187), 
whereas only approximately 20% were positive for IGF-IR membrane staining 
(38/187). 
 
______________________________________________________________________ 
 
Table 7.6  HER-2 and IGF-IR scores in 223 patient samples measured by IHC. 
 
Protein n %
HER-2
0 62 34.1
1+ 15 8.2
2+ 21 11.5
3+ 84 46.2
Unknown 41
IGF-IR cytoplasm
0 0 0.0
1+ 18 9.6
2+ 143 76.5
3+ 26 13.9
Unknown 36
IGF-IR membrane
Negative 149 79.7
Positive 38 20.3
Unknown 36
 
______________________________________________________________________ 
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7.3.2  HER-2 and IGF-IR correlation with patient characteristics 
Table 7.7 shows the histopathological characteristics of the 223 patients studied.  
 
No correlation was observed between HER-2 expression and membrane or cytoplasmic 
IGF-IR expression in these tumour samples. 
 
No significant correlation was observed between HER-2 expression and patient age at 
diagnosis, tumour size, nodal status, or PR status [Table 7.8].  However, a significant 
positive association was observed between HER-2 expression and tumour grade (Chi-
squared test, p = 0.004) [Fig. 7.7]. HER-2 expression was also significantly higher in 
ductal compared to lobular tumours (Chi-squared test, p = 0.033) [Fig. 7.8]. A 
significant inverse relationship was also observed between HER-2 expression and ER 
status (Chi-squared test, p = 0.033) [Fig. 7.9]. 
 
A significant correlation was also observed between HER-2 IHC levels quantified on 
the TMAs with HER-2 IHC staining as scored by the hospital histopathology 
laboratories (Chi-squared test, p = 0.016). However, 41 of the tumour samples were 
scored as HER-2 0 and 15 as HER-2 1+. This discordance in results may be due to 
tumour heterogeneity and the small size of the tumour samples represented in the TMA 
cores (0.6 mm). 
 
Cytoplasmic IGF-IR levels did not correlate with any of the histopathological 
characteristics studied [Table 7.9]. Membrane IGF-IR staining was not associated with 
patient age at diagnosis, nodal status, tumour grade, or histopathological type [Table 
7.10]. However, membrane IGF-IR was detected significantly more frequently in ER-
positive tumours than ER negative tumours (Chi-squared test, p = 0.0002) [Fig. 7.10]. 
Membrane IGF-IR expression was also found more frequently in PR-positive tumours, 
with this association was approaching statistical significance (Chi-squared test, p = 
0.055).  A trend towards a correlation between positive membrane IGF-IR staining and 
tumour size was also observed, however, this association did not reach statistical 
significance (Chi-squared test, p = 0.094) [Table 7.10]. 
 
 178 
No correlation was observed between HER-2 expression and membrane or cytoplasmic 
IGF-IR expression in these tumour samples.  
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Table 7.7 Characteristics of the breast cancer patients analysed in Study 2 (n = 223).  
 n % 
Menopausal status   
   Pre 71 31.8 
   Peri 4 1.8 
   Post 88 39.5 
   Unknown 60 26.9 
Tumour size   
  £ 2 cm 57 25.6 
   > 2 cm 147 65.9 
   Unknown 19 8.5 
Nodal status   
   Neg 83 37.2 
   Pos 132 59.2 
   Unknown 8 3.6 
Grade   
   1 7 3.1 
   2 44 19.7 
   3 163 73.1 
   Unknown 9 4.0 
Histology   
   D 206 92.4 
   L 8 3.6 
   D+L 2 0.9 
   Other 3 1.3 
   Unknown 4 1.8 
ER   
   Neg 87 39.0 
   Pos 129 57.8 
   Unknown 7 3.1 
PR   
   Neg 70 31.4 
   Pos 34 15.2 
   Unknown 119 53.4 
HER-2 FISH   
   Neg 1 0.4 
   Pos 79 35.4 
   Unknown 143 64.1 
HER-2 Status (3+ IHC or FISH)  
   Neg 1 0.4 
   Pos 202 90.6 
   Unknown 20 9.0 
   ______________________________________________________________________ 
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Table 7.8 Relationship between HER-2 levels and patient prognostic indicators. 
 
                               HER-2 Staining 
 0 1+ 2+ 3+ p 
Menopausal status     
   Pre (n=55) 19 (34.5%) 5 (9.1%) 7 (12.7%) 24 (43.6%) 0.5259 
   Peri (n=3) 0 (0%) 1 (33.3%) 0 (0%) 2 (66.7%)  
   Post (n=74) 21 (28.4%) 5 (6.8%) 8 (10.8%) 40 (54.1%)  
Tumour size (cm)     
   £ 2 (n=47) 22 (46.8%) 3 (6.4%) 5 (10.6%) 17 (36.2%) 
   > 2 (n=125) 38 (30.4%) 12 (9.6%) 16 (12.8%) 59 (47.2%) 
0.2495 
Nodal status      
   Neg (n=66) 26 (39.4%) 4 (6.1%) 10 (15.2%) 26 (39.4%) 
   Pos 35 (31.5%) 11 (9.9%) 11 (9.9%) 54 (48.6%) 
0.3605 
Grade      
   1 (n=4) 1 (25.0%) 0 (0%) 3 (75.0%) 0 (0%)  
   2 (n=39) 13 (33.3%) 6 (15.4%) 4 (10.3%) 16 (41.0%) 0.0044 
   3 (n=133) 47 (36.3%) 9 (6.8%) 14 (10.5%) 63 (47.4%)  
Histology      
   D (n=169) 56 (33.1%) 13 (7.7%) 21 (12.4%) 79 (46.7%)  
   L (n=7) 4 (57.1%) 1 (14.3%) 0 (0%) 2 (28.6%) 0.0331 
   D+L (n=1) 0 (0%) 1 (100%) 0 (0%) 0 (0%)  
ER      
   Neg (n=71) 19 (26.8%) 3 (4.2%) 5 (7.0%) 44 (62.0%) 
   Pos 42 (39.3%) 12 (11.2%) 16 (14.9%) 37 (34.6%) 
0.0033 
PR      
   Neg (n=58) 14 (24.1%) 4 (6.9%) 7 (12.1%) 33 (56.9%) 
   Pos (n=28) 11 (39.3%) 2 (7.1%) 1 (3.6%) 14 (50.0%) 
0.3731 
HER-2 IHC      
   2+ (n=18) 10 (55.6%) 4 (22.2%) 0 (0%) 4 (22.2%) 
   3+ (n=110) 31 (28.2%) 11 (10.0%) 15 (13.6%) 53 (48.2%) 
0.0156 
       
 
 
______________________________________________________________________ 
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Fig 7.7   Number of patients divided by HER-2 status in grade 1, 2 and 3 tumours. The 
relationships were analysed by the Chi-squared test. 
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Fig 7.8   Number of patients divided by HER-2 status in ductal and lobular tumour 
histological groups. The relationships were analysed by the Chi-squared test. 
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Fig 7.9   Number of patients divided by HER-2 status in ER-positive and -negative 
tumours. The relationships were analysed by the Chi-squared test. 
__________________________________________________________________________________________________________ 
p =0.003 
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Table 7.9  Relationship between cytoplasmic IGF-IR levels and patient prognostic 
indicators. 
 
           TMA IGF-IR Cytoplasmic staining 
 1+ 2+ 3+ p 
Menopausal status     
   Pre (n=56) 5 (8.9%) 43 (76.8%) 8 (14.3%) 0.6174 
   Peri (n=3) 0 (0%) 2 (66.7%) 1 (33.3%)  
   Post (n=77) 11 (14.3%) 58 (75.3%) 8 (10.4%)  
Tumour size (cm)     
   £ 2  (n=48) 3 (6.2%) 38 (79.2%) 7 (14.6%) 
   > 2  (n=129) 15 (11.6%) 99 (76.7%) 15 (11.6%) 
0.5951 
Nodal status     
   Neg (n=67) 6 (9.0%) 53 (79.1%) 8 (11.9%) 
   Pos (n=115) 12 (10.4%) 87 (75.7%) 16 (13.9%) 
0.9032 
Grade     
   1 (n=4) 0 (0%) 4 (100%) 0 (0%)  
   2 (n=40) 5 (12.5%) 28 (70.0%) 7 (17.5%) 0.7209 
   3 (n=137) 13 (9.5%) 107 (78.1%) 17 (12.4%)  
Histology     
   D (n=174) 17 (9.8%) 133 (76.4%) 24 (13.8%)  
   L (n=7) 1 (14.3%) 5 (71.4%) 1 (14.3%) 0.9723 
   D+L (n=1) 0 (0%) 1 (100%) 0 (0%)  
ER     
   Neg (n=74) 10 (13.5%) 57 (77.0%) 7 (9.5%) 
   Pos (n=108) 8 (7.4%) 84 (77.8%) 16 (14.8%) 
0.1906 
PR     
   Neg (n=61) 11 (18.0%) 42 (68.9%) 8 (13.1%) 
   Pos (n=29) 5 (17.2%) 23 (79.3%) 1 (3.4%) 
0.3084 
HER-2 IHC     
   2+ (n=20) 3 (15.0%) 15 (75.0%) 2 (10.0%) 
   3+ (n=112) 10 (8.9%) 89 (79.5%) 13 (11.6%) 
0.9693 
      
 
______________________________________________________________________
 184 
______________________________________________________________________ 
 
Table 7.10 Relationship between membrane IGF-IR staining and patient prognostic 
indicators. 
 
  TMA IGF-IR Membrane staining 
 n No. positive % p 
Menopausal status     
   Pre 56 15 26.8 0.2323 
   Peri 2 1 50.0  
   Post 66 12 18.2  
Tumour size     
   £ 2 cm 48 6 12.5 
   > 2 cm 129 31 24.0 
0.0935 
Nodal status     
   Neg 67 16 23.9 
   Pos 115 22 19.1 
0.4470 
Grade     
   1 4 0 0.0  
   2 40 8 20.0 0.5615 
   3 137 30 21.9  
Histology     
   D 174 37 21.3  
   L 7 0 0.0 0.3438 
   D+L 1 0 0.0  
ER     
   Neg 74 5 6.8 
   Pos 108 32 29.6 
0.0002 
PR     
   Neg 61 7 11.5 
   Pos 29 8 27.6 
0.0553 
HER-2 IHC     
   2+ 20 4 20.0 
   3+ 112 23 20.5 
0.9564 
 
 
______________________________________________________________________
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Fig 7.10  Number of patients and with membrane IGF-IR-positive and –negative 
staining in  ER-positive and –negative tumour groups. The relationships were analysed 
by the Chi-squared test. 
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p =0.0002 
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7.4 POOLED ANALYSIS OF HER-2 AND IGF-IR IN STUDY 1 AND STUDY 2 
 
Although no correlation between HER-2 and IGF-IR expression was observed in either 
study, pooled analysis of IGF-IR and HER-2 staining from study 1 and study 2 shows 
that there is a significant inverse correlation between membrane IGF-IR and HER-2 
expression, with HER-2 score 0 tumours showing the highest frequency of IGF-IR 
membrane staining (32.3%,  42/130) and HER-2 3+ tumours having the lowest 
frequency of IGF-IR membrane staining (15.3%, 15/98) (Chi-squared test, p = 0.025) 
[Fig. 7.11]. 
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Figure 7.11  Number of patients with membrane IGF-IR staining in  HER-2 0, 1+, 2+ 
and 3+ tumours in both study 1 and study 2. The relationships were analysed by the 
Chi-squared test. 
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p=0.0255 
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Chapter 8  
 
DISCUSSION 
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HER-2, EGFR and IGF-IR signalling in breast cancer cells and response to 
trastuzumab 
Long-term response rates to trastuzumab monotherapy in HER-2-overexpressing breast 
cancer patients are low, ranging from 12-34%, and with median response durations of 
only 9–12 months [133, 134].  Data has been emerging to suggest the role of  alternative 
receptor tyrosine kinase (RTK) signalling, such as IGF-IR or EGFR signalling, in 
trastuzumab-resistance [163, 164, 177, 180]. In this study, response to trastuzumab was 
investigated in a panel of 14 HER-2-overexpressing breast cancer cell lines. HER-2 
expression or activity levels did not correlate with response to trastuzumab. IGF-IR 
expression or phosphorylation also did not correlate with response. EGFR protein levels 
and phosphorylation levels were also analysed, and no correlation with response was 
observed. These data suggest that alternative signalling via IGF-IR or EGFR does not 
play a key role in innate trastuzumab resistance in HER-2 positive breast cancer. 
 
When the relationships between total protein expression and phosphorylation of each of 
the three receptors were analysed, no correlation was observed between receptor 
expression and phosphorylation of HER-2, IGF-IR or EGFR. However, both HER-2 
and phospho-HER-2 levels correlated positively with phospho-IGF-IR, and a trend was 
also observed between IGF-IR and phospho-EGFR levels.  These results are consistent 
with previous reports of cross-talk between IGF-IR and EGFR/HER-2 signalling 
pathways. Stimulated EGFR can transactivate IGF-IR, and IGF-IR in turn can cause 
transactivation of EGFR [306, 346, 347].   Targeting EGFR with the tyrosine kinase 
inhibitor (TKI) gefitinib reduced IGF-I-stimulated Erk activity in normal mammary 
epithelial cells [349], and elevated IGF-IR signalling has been implicated in resistance 
to gefitinib and erlotinib, another EGFR TKI  [307, 351].  Previous studies also reported 
interactions between HER-2 and IGF-IR signalling; Balana et al [353] reported that 
knockdown of IGF-IR protein inhibited HER-2-stimulated proliferation in mammary 
tumour primary cells, and decreased phosphorylation of HER-2 [182]. They also found 
that suppression of HER-2 expression had no effect on IGF-IR phosphorylation, 
suggesting a hierarchical interaction, whereby IGF-IR directs HER-2 phosphorylation.  
Here, we confirmed previous reports [354] that overexpression of HER-2 inhibits IGF-
I-stimulated MAPK signalling in MCF7 cells, suggesting that HER-2 sends proliferative 
signals through the MAPK pathway in an IGF-IR-independent manner. Previous reports 
have shown that HER-2-overexpression does not affect IGF-IR-mediated Akt signalling 
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[354], and in HER-2 overexpressing cells in culture, Akt is predominantly activated by 
serum elements [356], suggesting that Akt signalling in HER-2-overexpressing cells 
may be directed by IGF-IR. We also found that HER-2 overexpression did not 
significantly alter Akt phosphorylation in response to IGF treatment in MCF-7-HER-2 
cells. However, trastuzumab treatment of MCF7-HER2-cells reduced IGF-I-stimulated 
phosphorylation of Akt. Therefore, though an increase in HER-2 expression does not 
alter IGF-IR-Akt signalling, inhibition of HER-2 signalling does; this suggests that 
HER-2 may also regulate IGF-IR-Akt activity.  Overall, these data suggest that HER-2 
proliferation signals may be independent of IGF-IR, while its survival signalling may 
interact with that of IGF-IR in a complex manner.  
 
Lu et al [177] reported that reduction of IGF-IR signalling in MCF7/HER-2-18 cells by 
reducing the serum content of the growth media restores sensitivity to trastuzumab. In 
this study, also in an MCF7 HER2-transfected cell line, reduction of serum in the 
growth media did not sensitise cells to trastuzumab; these cells were in fact less 
responsive in these conditions. This may be explained by the fact that the cells grew at a 
slower rate in reduced serum. Trastuzumab inhibits proliferation in growing cells; if 
proliferation has diminished, the inhibitory effects of trastuzumab are also likely to be 
reduced.  Perhaps the MCF7/HER-2-18 cells studied by Lu et al [177] have a higher 
level of transfected HER-2, which could result in phenotypically different cells, 
possibly with a different growth rate. Those cells could, therefore, be less dependent on 
serum elements for growth, and this may explain the different results obtained. 
Differences in the growth factor content of the serum used in the two studies could also 
contribute to the inconsistency in results.  
 
 
HER-2, EGFR and IGF-IR in acquired trastuzumab resistance 
SKBR3 and BT474 parental and trastuzumab-conditioned cell lines were obtained from 
Dr. Slamon’s laboratory, UCLA.  We confirmed that the conditioned cells had acquired 
resistance to trastuzumab relative to parental cells, and that this resistance was stable 
after trastuzumab was removed from the growth media for up to three months.  
Molecular differences between parental and resistant cells were then investigated.   
HER-2, phospho-HER2, EGFR and phospho-EGFR levels were significantly elevated 
in BT474/Tr compared to parental BT474 cells, while no alteration in IGF-IR 
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expression or phosphorylation was observed. These results are consistent with recent 
reports of trastuzumab-resistant BT474 models. Ritter et al [429] developed a 
trastuzumab-resistant cell model from BT474 xenografts treated with trastuzumab.  
These cells retained HER-2 amplification and trastuzumab-binding, and had increased 
levels of EGFR, phospho-EGFR, and EGFR ligands [163].  Higher levels of 
EGFR/HER-2 heterodimers were detected in the resistant cells, suggesting that this 
could be a possible mechanism of resistance, as trastuzumab does not have the ability to 
block heterodimerisation [163].  Therefore, our BT474/Tr cells, which have elevated 
HER-2 and EGFR levels and signalling, may be less responsive to trastuzumab due to 
increased heterodimerisation between HER-2 and EGFR. 
  
SKBR3/Tr cells showed no change in HER-2 expression or phosphorylation compared 
to parental cells; however, phospho-EGFR levels were significantly reduced.  
SKBR3/Tr cells also have significantly elevated IGF-IR levels compared to parental 
cells.  Previous studies have reported that transfection of IGF-IR into SKBR3 cells 
confers resistance to trastuzumab, and that increased IGF-IR signalling mediates 
trastuzumab resistance [177, 180].  However, phospho-IGF-IR levels were not altered in 
SKBR3/Tr compared to parental SKBR3 cells. Perhaps investigation of IGF-IR 
response to stimulation would reveal differences in IGF-IR activity in these cells. In this 
model, cells were treated with fresh growth media 24 hours before protein lysis.  A 
previous report has shown that IGF-I stimulation of IGF-IR causes maximal 
phosphorylation of IRS-1 within 1-2 minutes [178].  It is possible that differences in 
IGF-IR activity between parental and resistant cells would be apparent at earlier 
timepoints following stimulation, but that by 24 hours, IGF-IR activity has returned to 
basal levels in both cell lines.  
 
Given that there appears to be increased HER-2 and EGFR signalling in BT474/Tr cells, 
one would expect to find elevated levels of Akt and MAPK signalling. However, the 
BT474/Tr cells have reduced phospho-Akt and phospho-MAPK levels compared to 
parental cells. This reduced signalling could be due to an increase in EGFR-containing 
receptor dimers, caused by the increase in EGFR expression. HER-2 has the strongest 
kinase activity of the HER family [16], and increased formation of EGFR/HER-2 
heterodimers, accompanied by a reduction in HER-2 homodimerisation, could cause an 
overall reduction in HER intracellular signalling. It is also possible that HER signalling 
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through alternative pathways has increased to compensate for reduced Akt and MAPK 
activity; investigation of other signalling pathways, such as the PKC signalling 
pathway, would be required to determine if this is the case.  
 
SKBR3/Tr cells have reduced EGFR activity, but unaltered phospho-MAPK levels, 
compared to parental SKBR3 cells. In a study mentioned above [349], IGF-I-stimulated 
Erk activity was regulated by EGFR signalling in normal mammary cells; however, 
targeting EGFR had no effect on IGF-IR signalling in MCF7 and CAL-51 breast cancer 
cells [349], which have high IGF-IR levels. Perhaps cells with increased IGF-IR 
expression, such as SKBR3/Tr, are no longer dependent on EGFR for MAPK 
signalling.  
 
SKBR3/Tr cells have reduced phospho-Akt levels compared to SKBR3 cells. However, 
trastuzumab treatment had similar effects on phospho-Akt and phospho-MAPK levels 
in SKBR3 and SKBR3/Tr cells, as measured by immunoblotting.  This suggests that 
alterations in Akt and MAPK signalling may not be playing a central role in resistance 
to trastuzumab in this model. In fact, Smith et al [185] analysed both phospho-Akt and 
phospho-MAPK levels in trastuzumab-treated breast cancer patient samples, and found 
no correlation between response and levels of either phospho-protein. However, 
response to trastuzumab in SKBR3/Tr cells is not completely diminished compared to 
parental cells; therefore, a similar, but reduced, effect on intracellular signalling in 
response to trastuzumab might be expected.   The reduction in phospho-Akt and 
phospho-MAPK levels appear similar by western blotting but more subtle alterations 
may not be observed by this technique, and might be detected by a more sensitive 
method of detection, such as ELISA.  
 
Overall, these data suggest differences in the mechanisms of resistance to trastuzumab 
in BT474/Tr and SKBR3/Tr cells, characterised by different receptor activity and 
different signalling pathways. Consistently, a previous study reported that HER-2 
signalling via Akt had different effects in SKBR3 and BT474 cells; inhibition of HER-
2/Akt signalling using trastuzumab and an Akt inhibitor increased the susceptibility of 
SKBR3 cells to TRAIL-induced apoptosis, but decreased the susceptibility of BT474 
cells [430]. 
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Nahta et al [181] reported that HER-2 and IGF-IR heterodimerise in trastuzumab-
resistant SKBR3/HerR cells, and not in parental SKBR3 cells, and suggested that 
heterodimerisation contributes to trastuzumab resistance.  IGF-I also stimulated 
phosphorylation of HER-2 only in the resistant cells, while a specific IGF-IR tyrosine 
kinase inhibitor decreased phosphorylation, again only in the resistant cells. Earlier 
studies, however, have shown that HER-2 and IGF-IR heterodimerise in response to 
IGF-I or heregulin in MCF7 cells [182], and that knocking out IGF-IR expression in 
breast cancer cells and xenografts also reduced HER-2 phosphorylation [182, 183].  
Furthermore, in our study, HER-2 and phospho-HER-2 levels correlated with phospho-
IGF-IR levels in the panel of cell lines, which contained both trastuzumab-sensitive and 
–resistant cells. Heterodimerisation and activation of HER-2 by IGF-IR, therefore, does 
not appear to be exclusively a characteristic of trastuzumab resistant cells.  We 
immunoprecipitated (IP) IGF-IR protein from SKBR3 and BT474 parental and resistant 
cell lysates, and immunoblotted for HER-2 protein, to investigate if HER-2 co-
precipitated with IGF-IR.  Trastuzumab was removed from the growth media of 
resistant cells for at least seven days before protein lysate preparation. HER-2 was 
detected in parental and resistant immunoprecipitated samples, only when the cells had 
been treated with trastuzumab for 24 hours, suggesting that trastuzumab treatment may 
induce dimerisation. However, in control IPs without antibody, HER-2 was also 
precipitated, suggesting that trastuzumab itself immunoprecipitated HER-2 in these 
samples. Attempts were also made to immunoprecipitate HER-2 and investigate the co-
precipitation of IGF-IR.  However, the IP for IGF-IR was not successful.   In a control 
experiment, IGF-IR was immunoprecipitated from MCF7-HER-2 cells, (which express 
high IGF-IR levels) and IGF-IR immunoblotting was subsequently performed; however, 
IGF-IR could not be detected. A number of IGF-IR antibodies were tested, without 
success. Therefore we were unable to confirm the presence of HER-2/IGF-IR 
heterodimers. Perhaps the development of more sensitive and specific anti-IGF-IR 
antibodies will aid such investigations in the future.  
 
 
Inhibition of IGF-IR in HER-2-positive breast cancer cells 
Previous studies have reported that inhibition of IGF-I/IGF-IR signalling sensitises 
trastuzumab-resistant cells to trastuzumab [180, 181].  However, we found that blocking 
IGF-IR stimulation with IGFBP3 or aIR3 antibody did not sensitise SKBR3/Tr or 
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BT474/Tr cells to trastuzumab.  Although SKBR3/Tr cells have elevated IGF-IR levels, 
targeting ligand-activation of the receptor has no effect on proliferation. Perhaps 
resistant cells have developed ligand-independent mechanisms of IGF-IR signalling; an 
intracellular mechanism of IGF-IR activation has been reported [431]. 
 
In contrast, knockdown of IGF-IR expression with siRNA inhibited proliferation in both 
parental and trastuzumab-resistant BT474 and SKBR3 cells.  The combination of anti-
IGF-IR siRNA and trastuzumab had significantly greater inhibitory effects than either 
treatment alone in the two resistant cell lines. This enhanced effect was also seen in 
parental SKBR3 cells.  IGF-IR signalling was also targeted in these cells with IGF-IR 
TKIs BMS-536924 and NVP-AEW541.  Each inhibitor alone had little effect on the 
proliferation of BT474 or BT474/Tr cells. BT474 cells are estrogen-receptor (ER)-
positive, while SKBR3 cells are ER-negative. Cross-talk between IGF-IR and ER 
signalling pathways has been reported, and ER signalling enhances IGF-IR signalling in 
breast cancer cells [334]; ER upregulation of IGF-IR signalling could therefore 
compensating for IGF-IR tyrosine kinase inhibition in BT474 cells. A recent study 
reported synergistic effects when combining NVP-AEW541 with an ER inhibitor in 
MCF7 and T474D breast cancer cells [432].  However, in BT474/Tr cells, combined 
treatment of each TKI with trastuzumab inhibited significantly more growth than single 
treatments. BT474/Tr cells have elevated EGFR signalling. EGFR has also been shown 
to heterodimerise with IGF-IR in breast cancer cells [349]; perhaps BT474Tr cells have 
increased levels of EGFR heterodimerisation with both HER-2 and IGF-IR; so while 
targeting HER-2 or IGF-IR alone has little effect, co-targeting HER-2 and IGF-IR 
inhibits signalling from HER-2/HER-2, IGF-IR/IGF-IR and IGF-IR/EGFR  dimers, 
resulting in enhanced inhibitory effects.  
 
SKBR3 and SKBR3/Tr cells were unresponsive to BMS-536924, either alone or in 
combination with trastuzumab.  NVP-AEW541, however, inhibited proliferation by 
approximately 30 % in both SKBR3 and SKBR/Tr cells.  Combined treatment of NVP-
AEW541 and trastuzumab had significantly enhanced inhibitory effects compared to 
either treatment alone in both cell lines. In cell cycle assays, NVP-AEW541 increased 
the number of cells in the G1 phase in both SKBR3 and SKBR3/Tr cells, and combined 
treatment with NVP-AEW541 and trastuzumab significantly increased the number of 
cells in G1, and significantly decreased the number of cells in the synthesis phase 
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compared to untreated cells, suggesting that both NVP-AEW541 and trastuzumab may 
induce G1 arrest.  These data support the potential for co-targeting HER-2 and IGF-IR 
in the clinical setting, both in trastuzumab-sensitive patients, and those who have 
developed resistance.   
 
The differences in protein expression and phosphorylation, and response to IGF-IR 
inhibition, in BT474/Tr and SKBR3/Tr cells suggest that these two cell models differ in 
their RTK dependency for growth and survival, and that the role of IGF-IR or other 
RTKs in the development of trastuzumab resistance may vary by cell line, or by patient.  
 
 
Response to lapatinib in trastuzumab-resistant cells 
In order to study cross-resistance between trastuzumab and other HER-2 antagonists, 
response to lapatinib, a dual HER-2/EGFR TKI, was examined in parental and 
trastuzumab-resistant BT474 and SKBR3 cells. Lapatinib inhibited similar levels of 
proliferation in BT474 and BT474/Tr cells, with IC50 values of 23 nM and 26 nM, 
respectively.  SKBR3/Tr cells were less responsive to lapatinib than parental SKBR3 
cells, with an IC50 of 132 nM, compared to 62 nM in parental cells, suggesting some 
level of cross-resistance to lapatinib in the trastuzumab-resistant cells. Comparing these 
results to published data, each of the four cell lines is considered sensitive to lapatinib 
[113].  Again, these results suggest that SKBR3/Tr and BT474/Tr cells may have 
different mechanisms of resistance to trastuzumab; SKBR3/Tr cells display some cross-
resistance to lapatinib, while BT474/Tr cells do not. BT474/Tr cells have elevated 
HER-2 and EGFR signalling, and may therefore be expected to be more sensitive to 
HER-2/EGFR tyrosine kinase inhibition. The increase in EGFR activity, however, may 
not significantly affect response to lapatinib; in a phase II study of lapatinib in breast 
cancer patients grouped into HER-2-postive and EGFR-positive/HER-2-negative 
patients, the response rates were 62 % in the HER-2-positive group, and only 8 % in the 
EGFR-positive/HER-2-negative group  [187], suggesting that response to lapatinib is 
determined more by HER-2 than by EGFR expression.  Though the IC50 concentrations 
were similar for BT474 and BT474/Tr the maximum growth inhibition achieved in 
BT474/Tr cells (95.7 %) was higher than in BT474 cells (86.7 %), although not 
significantly; this effect could be related to higher levels of HER-2 expression in 
BT474/Tr.  Overall, the results with lapatinib suggest that HER-2-overexpressing 
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patients that have developed resistance to trastuzumab would benefit from lapatinib 
treatment.  Work in this and other laboratories has shown synergistic inhibitory effects 
with combinations of lapatinib and trastuzumab in vitro [113], and lapatinib has also 
shown clinical efficacy alone or in combination with trastuzumab against breast cancer 
in phase II and III clinical trials [187]. 
 
 
Lapatinib and trastuzumab resistance in breast cancer cells 
One study of in vitro acquired lapatinib resistance has been reported [196]. In a BT474 
model of lapatinib resistance, a switch from dependence on HER-2 signalling to co-
dependence on HER-2 and ER signalling was observed. We conditioned trastuzumab-
sensitive and -resistant HER-2-overexpressing, ER negative cells in lapatinib-containing 
growth media, to investigate the development of lapatinib resistance in ER negative 
breast cancer. SKBR3 (trastuzumab-sensitive), and HCC1419 (trastuzumab-resistant) 
cells were conditioned in lapatinib for six months. SKBR3 cells were also conditioned 
with trastuzumab alone, and trastuzumab combined with lapatinib, to investigate 
development of resistance to the co-treatment, SKBR3-TL, compared to the single 
agents, SKBR3-T and SKBR3-L. The trastuzumab-resistant SKBR3/Tr cells from 
UCLA were also conditioned in lapatinib-containing media in order to develop a model 
for lapatinib treatment in patients who have progressed on trastuzumab treatment.  
 
SKBR3-L, SKBR3-TL and SKBR3/Tr-L cells developed resistance to both trastuzumab 
and lapatinib, as demonstrated by standard proliferation assays and doubling time 
assays. SKBR3-T cells are resistant to trastuzumab yet retain their sensitivity to 
lapatinib.  This is consistent with clinical findings; HER-2-positive patients who have 
progressed on trastuzumab benefit from lapatinib treatment  [187].  However, lapatinib-
resistant SKBR3-L cells demonstrate cross-resistance to trastuzumab, and are in fact 
more resistant to inhibition by trastuzumab than trastuzumab-resistant SKBR3-T cells. 
SKBR3-TL cells are also resistant to inhibition by the combined treatment of 
trastuzumab and lapatinib.  These data may have important clinical implications.  While 
lapatinib has shown clinical efficacy in combination with trastuzumab [187], these 
results suggest that patients on the combination therapy may develop resistance to both 
agents.  Scheduling of treatment could be important to maximise clinical benefit. If 
patients progress on trastuzumab treatment, they may still benefit from lapatinib 
 196 
treatment; however, if patients were treated with lapatinib first and progress, they may 
also be resistant to trastuzumab treatment.   
 
Lapatinib-conditioned HCC1419-L cells did not develop resistance to lapatinib. This 
model may also have clinical relevance. The concentration of lapatinib used to 
condition the cells initially inhibited approximately 80 % of cell growth. The remaining 
cells maintained their viability, but did not actively proliferate during lapatinib 
treatment. When lapatinib treatment was discontinued after six months, the cells 
remained quiescent for a further three months. After this time, the cells began to 
proliferate again, and a proliferation assay showed that they had retained their 
sensitivity to lapatinib. This may suggest that some patients who relapse after 
completion of lapatinib treatment may benefit from further lapatinib treatment. 
 
HER-2, phospho-HER-2 and EGFR levels were not altered in the conditioned SKBR3 
cells, suggesting that alterations in other cellular pathways may be responsible for 
resistance.  A number of TKIs are substrates for drug efflux pumps, such as p-
glycoprotein (P-gp), and elevated levels of drug efflux pumps have been implicated in 
resistance to a number of number of anti-cancer agents [433]. Lapatinib is a P-gp 
substrate  [434] and P-gp levels were therefore measured in the lapatinib-resistant 
SKBR3-L and SKBR3-TL cells; however, no detectable increase in P-gp levels was 
observed in these cells. 
 
IGF-IR levels were also measured in the conditioned SKBR3 cells, and each of SKBR3-
T, SKBR3-L and SKBR3-TL cells had elevated IGF-IR expression. IGF-IR has been 
implicated in resistance to EGFR TKIs erlotinib and gefitinib in breast cancer cells 
[307, 351].  However, using our ELISA data, our collaborators in UCLA found a 
positive correlation between phospho-IGF-IR levels and response to lapatinib in a panel 
of breast cancer cell lines [O’Brien et al, manuscript in preparation]. Furthermore, a 
recent phase II clinical trial also reported a positive correlation between IGF-IR 
expression and response to lapatinib monotherapy in 30 HER-2-positive breast cancer 
patients [108]. It is possible that IGF-IR signalling could play different roles in acquired 
and intrinsic lapatinib resistance. 
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As SKBR3-L cells displayed the highest level of resistance to both trastuzumab and 
lapatinib, downstream phosphoprotein signalling was investigated in these cells. No 
alteration in phospho-Akt or phospho-MAPK, as measured by immunoblotting, was 
observed in SKBR3-L compared to parental SKBR3 cells.  
 
Phosphoproteomic analysis was performed in order to further investigate differences in 
protein phosphorylation, and thus signalling, between parental SKBR3 and lapatinib-
resistant SKBR3-L cells.  Phosphoproteins which were differentially regulated in 
SKBR3-L compared to SKBR3 cells, and in response to either trastuzumab or lapatinib 
were identified.  
 
Many phosphorylated forms of heat shock proteins (Hsp) were found to be differentially 
regulated in SKBR3 and SKBR3-L cells.  Hsp proteins are activated by 
phosphorylation, and are regulated by both Akt and MAPK signalling pathways [435].  
Two phosphorylated forms of aB-crystallin were 11.26- and 7.74-fold more abundant in 
SKBR3-L cells. aB-crystallin is a small Hsp family member that is constitutively 
expressed in many tissues [436]. aB-crystallin is a negative regulator of apoptosis, and 
has been reported as a specific marker for basal-like breast cancer, and a predictor of 
poor clinical outcome [437, 438]. Expression of aB-crystallin was also found at a low 
frequency (16 %) in HER-2-positive breast cancers [439]. Overexpression of aB-
crystallin was recently correlated with resistance to neoadjuvant trastuzumab and 
vinorelbine in a study of 48 HER-2-positive breast cancer patients [440]. Perhaps cells 
with higher aB-crystallin activity have become less dependent on HER signalling, and 
are therefore less sensitive to HER-2 inhibition.  Inhibition of apoptosis by aB-crystallin 
could contribute to lapatinib resistance in SKBR3-L cells. In fact, phospho-aB-
crystallin levels were increased 1.63-fold in lapatinib-treated parental cells, suggesting 
that increasing this regulator of apoptosis could be one cellular mechanism of opposing 
the cytotoxic effects of lapatinib. 
 
A phosphorylated form of closely related family member Hsp27 was also found to be 
upregulated 2.38-fold in SKBR3-L cells. Hsp27 expression is associated with increased 
invasiveness and resistance to chemotherapeutic drugs, and with poor prognosis in 
breast cancer [441].  Hsp27 protects from apoptosis by a number of mechanisms, 
including direct interaction with cytochrome C, and with both Akt and MAPK [442]. 
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Higher Hsp27 expression was found in gefitinib-resistant compared to gefitinib-
responsive colorectal cancer cell lines studied by proteomics [443], suggesting that 
increased interaction between Hsp27 and Akt and MAPK could be protecting these 
pathways from downregulation by HER-2/EGFR family inhibitors.  
 
Expression of a phosphorylated form of another Hsp, glycoprotein 96 (gp96/tumor 
rejection antigen) was also significantly increased (2.16-fold) in SKBR3-L cells. Gp96 
has been related to resistance to chemotherapeutic drugs [444], and has been found to be 
expressed on the surface of breast cancer cells [445]. Gp96 is known to have immune-
stimulatory properties and its potential for use in cancer therapeutics has been 
acknowledged [445].   
 
Expression of a phosphorylated form of Hsp70 (HSPA1A) was downregulated (1.36-
fold) in SKBR3-L cells compared to parental SKBR3 cells. The Hsp70 family are 
chaperone proteins that form a complex with Hsp90 proteins, regulating the maturation, 
stability and activity of numerous cellular proteins, including hormone receptors, and 
RTKs such as HER-2 [446]. Hsp70 also has important anti-apoptotic functions, 
interacting with the intrinsic and extrinsic apoptotic pathways at multiple steps, and can 
protect cells from apoptosis-induction by chemotherapy [436]. Elevated levels of Hsp70 
have been reported in breast and other cancers, where they are associated with worse 
prognosis [446-448].  Both trastuzumab and lapatinib treatment of parental SKBR3 
caused decreases in phospho-Hsp70 levels (1.27- and 1.35-fold, respectively). This 
suggests that downregulation of Hsp70 activity may play a role in response to these 
inhibitors.  Lapatinib-resistant cells have decreased phospho-Hsp70 levels, and may 
therefore be less reliant on Hsp70 activity for survival. 
 
 
A number of phosphorylated forms of the protein eukaryotic translation elongation 
factor 2 (eEF2) were significantly differentially regulated in SKBR3-L compared to 
parental SKBR3 cells. eEF2 is an enzyme that plays an important role in protein 
synthesis, where it mediates ribosomal translocation during peptide chain elongation. 
The activity of eEF2 is inhibited by its phosphorylation (at Thr56 and Thr58) by eEF2 
kinase (eEF2K), which in turn is regulated by mTOR and p70 ribosomal S6 kinase 
(p70S6K) [449].  One form of phosphorylated eEF2 was upregulated in SKBR3-L, 
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while six were downregulated. This suggests that there are higher levels of eEF2 
activity in SKBR3-L cells, and therefore a greater level of protein synthesis, and this 
may be a mechanism of resistance to inhibitors of HER-2 signalling.  
 
Between five and seven forms of phospho-eEF2 are downregulated in response to 
trastuzumab or lapatinib in both parental SKBR3 and SKBR3-L cell lines.  However, 
three phospho-eEF2 isoforms are significantly upregulated in parental cells treated with 
either drug, and are not affected by either treatment in SKBR3-L cells.  Downregulation 
of the phosphorylation of these three isoforms may therefore play a role in response to 
HER-2-antagonism in these cells. Recent studies reported that eEF2 phosphorylation 
accompanied inhibition of protein synthesis by a farnesyltransferase inhibitor (FTI) 
induced in head and neck cancer cell lines, and by a new mTOR inhibitor in multiple 
human cancer cell lines [450, 451].  
 
Multiple phosphorylation sites were identified on five forms of eEF2 which are 
downregulated in SKBR3-L cells. Three had one or two phospho-sites identified on the 
peptide sequence ranging from amino acids 51 – 61.  This peptide region contains Thr56 
and Thr58; therefore, downregulation of phosphorylation of eEF2 at these sites in 
resistant cells, which would enhance eEF2 activity and promote protein synthesis, may 
be contributing to the resistant phenotype of these cells.  Components upstream of eEF2 
have recently been implicated in lapatinib resistance. Lapatinib-resistant MCF7-HER-2 
cells had significantly elevated phosphorylation and activity of p70S6K1, and treatment 
with rapamycin, which targets mTOR, decreased phosphorylation, and re-sensitised 
these cells to lapatinib [452].  Together, these data suggest that alterations in the 
mTOR/p70S6K/eEF2 pathway could play a role in resistance to lapatinib. It would also 
be interesting, therefore, to examine expression or activity of other components of this 
pathway in the resistant cell lines. Inhibitors of this pathway could also be used to 
further investigate its role in these cells. 
 
A phosphorylated form of another protein of the translation machinery, eukaryotic 
initiation factor 4A (eIF4A) was also found to be significantly downregulated by 
lapatinib treatment in parental cells and not in SKBR3-L cells. eIF4A is a RNA helicase 
that forms part of a complex that binds the cap structure of mRNA, facilitating mRNA 
ribosome binding. eIF4A overexpression has been reported in human melanoma cells 
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and in primary hepatocellular carcinomas [453, 454].  eIF4A is regulated by the 
transformation repressor programmed cell death 4 gene (PDCD4) which inhibits eIF4A 
activity. Afonja et al [455] observed that trastuzumab induced PDCD4 expression in 
T47D breast cancer cells, suggesting that PDCD4 inhibition of protein translation may 
play a role in trastuzumab-mediated growth inhibition.  Inhibition of eIF4A activity may 
also play a role in response to lapatinib in SKBR3 cells. 
 
Two members of the S100 family of calcium-binding proteins were also found to be 
differentially regulated in SKBR3-L cells compared to parental cells. This large group 
of proteins is expressed in various tissues and is implicated in the immune response, 
differentiation, cytoskeleton dynamics, enzyme activity, Ca2+ homeostasis and growth 
[456].  A phosphorylated form of S100A8 (calgranulin A), and three forms of 
phosphorylated S100A9 (Mrp14/calgranulin B) are significantly upregulated in 
SKBR3-L cells. S100A8 and S100A9 form a complex called calprotectin, which is 
found at high levels at sites of inflammation [457]. Phosphorylation of S100A9 
promotes calcium-binding, and upregulates its translocation from the cytoplasm to the 
plasma membrane and the cytoskeleton [458]. Phosphorylation sites were detected on 
two of the three S100A9 isoforms identified; increased phosphorylation at these sites 
may therefore be increasing calprotectin activity in SKBR3-L cells, and may contribute 
to lapatinib resistance in this model.  S100A8 and S100A9 have been implicated in a 
number of cancers; they are both overexpressed in breast cancer [457], where a recent 
study reported highest expression in triple negative tumours [459].  Increased 
expression of both proteins was also found in three antiestrogen-resistant breast cancer 
cell lines [460].  Perhaps the antiestrogen-resistant cells, and our anti-HER-2-resistant 
SKBR3-L cells, are developing a phenotype resembling that of triple-negative or basal-
like breast cancers, with reduced requirements for ER and HER-2 signalling. As 
mentioned above, SKBR3-L cells also have a significant increase in phosphorylated aB-
crystallin, which is a recognised marker for basal-like breast cancer. Indeed, Harris et al 
[440] showed that HER-2 positive breast cancers with a basal-like phenotype were more 
likely to be resistant to the neoadjuvant combination of trastuzumab and vinorelbine. 
These results suggest that it may be interesting to examine expression of other markers 
of the basal-like phenotype, such as basal cytokeratins (CK 14/15, CK 5 and CK 17) in 
our resistant cell lines. 
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Phosphoproteomic analysis also identified a number of proteins that are involved in 
cytoskeleton modelling.  Phosphorylated adseverin (scinderin), an actin-bundling 
protein, is upregulated in SKBR3-L cells, while phosphorylated forms of 
adenylylcyclase-associated protein (CAP1), and actinin-4, also actin-binding proteins, 
were downregulated in response to trastuzumab or lapatinib treatment in SKBR3 cells. 
Actinin-4 has been associated with cancer cell motility and invasion [461], and is 
overexpressed in a number of human cancers [462, 463].  
 
A phosphorylated form of ubiquitin activating enzyme (E1) was also differentially 
regulated in response to lapatinib treatment in SKBR3 cells. This enzyme plays a role in 
the ubiquitin-proteosome pathway (UPP), where it catalyses the ubiquitination of 
protein substrates, which is the initial step in targeting proteins to the proteosome for 
degradation. A number of cancer-associated proteins are regulated by the UPP; these 
include p53, p27 and cell surface receptors including HER-2 and EGFR [464]. 
Response to lapatinib in SKBR3 cells may involve promoting the degradation of HER-
2, or other cellular proteins such as p27, and this response could be mediated by E1. 
Dysregulation in the ubiquitin-proteosome pathway could contribute to irregular protein 
expression and activity in cells, and inhibitors of different components of this pathway, 
including E1 [465], are being investigated for use in human cancers.   
 
 
A phosphorylated isoform of tryptophan 5-monooxygenase activation protein, otherwise 
known as 14-3-3, was upregulated 1.22-fold in SKBR3-L cells in response to 
trastuzumab, but was not altered in parental SKBR3 cells.  14-3-3 proteins are a family 
of cytosolic proteins that play key roles in a range of cellular processes including 
mitogenic and cell survival signalling, cell cycle control, apoptosis, vesicular 
trafficking, and cellular migration (reviewed in [466]).  Both growth promoting and 
tumour suppressing actions have been demonstrated for 14-3-3; these are mediated via 
direct interactions with a number of cellular proteins, such as Raf, Bcr-Abl, IGF-IR, 
IRS-1, PI3K, p53, p27kip1, p21waf1, integrins and ADAM22 [466]. Studies have reported 
that phosphorylation at specific serine residues, including Ser58 can interfere with its 
ability to dimerize with target proteins [467]. Aberrant 14-3-3 activity has been 
implicated in breast cancer [468], where a role in the transcriptional regulation of HER-
2 has been demonstrated [469], as well as an association with chemoresistance [470].  
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In our phosphoproteomic analysis, 14-3-3 levels were not altered in SKBR3-L cells 
compared to parental SKBR3 cells; however, levels of one phosphorylated form of this 
protein were altered in response to trastuzumab in SKBR3-L cells, and not in SKBR3 
cells. This may suggest that altered 14-3-3 activity could be contributing to the 
trastuzumab-resistant phenotype of these cells.  
 
Many phosphoproteins with potential roles in response or resistance to HER-2 
antagonists have been identified. Examination of phosphoprotein levels by 
immunoblotting would confirm the observed alterations. Further work may then 
determine their specific roles in response or resistance.  Stimulating or inhibiting 
phosphorylation of proteins of interest and investigating cellular responses such as 
proliferation, apoptosis induction, protein synthesis or degradation, or response to 
therapy would help to elucidate their roles. 
 
 
HER-2 and IGF-IR expression in breast cancer patient samples 
Analysis of HER-2 and IGF-IR expression in two groups of patient samples were 
performed. Study 1 was an analysis of 93 unselected breast cancer patients, and Study 2 
was an analysis of HER-2 and IGF-IR expression in 223 HER-2-positive breast cancer 
patients. In study 1, HER-2-overexpression (scores of 2+ or 3+) was detected in 18 out 
of 90 patients (20.0%).  This is consistent with published reports of HER-2 gene 
amplification or overexpression in 15-30% of invasive human breast cancers, where its 
expression is correlated with poor prognostic paramaters [53, 92]. In both TMA studies, 
HER-2 expression correlated positively with tumour grade. In Study 2, HER-2 
expression was also significantly higher in ductal compared to lobular tumours, which is 
also consistent with previous reports [471]. A significant inverse association was 
observed between HER-2 expression and ER status, which has also been reported [92]. 
These data confirm the value of HER-2 overexpression as a predictor of poor prognosis 
in breast cancer.   
 
Cytoplasmic IGF-IR expression was detected in over 99 % of the tumour samples 
studied.  In Study 1, membrane IGF-IR expression was detected in 34 % of samples. 
Previous studies of IGF-IR have reported that IGF-IR is expressed in 39-93% of breast 
cancers [283, 288].  The variation in expression levels detected may be related to 
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measurement of either membrane or cytoplasmic IGF-IR. In study 1, cytoplasmic IGF-
IR expression was significantly correlated with higher tumour grade.  Reports of the 
prognostic significance of IGF-IR expression in breast cancer have been inconsistent 
and correlation with tumour grade has not been reported [278]. Correlation of IGF-IR 
with higher grade might suggest IGF-IR as an indicator of poor prognosis. However, an 
association was also observed between membrane IGF-IR expression and a lower 
number of positive nodes detected, suggesting IGF-IR expression as a predictor of 
positive outcome. Previous studies have also found an association between IGF-IR 
expression and negative nodal status [285]. IGF-IR is a membrane RTK, and its cellular 
localisation in breast cancer cells may, therefore, be an important determinant of its 
activity. Cytoplasmic and membrane IGF-IR expression, therefore, could have different 
prognostic significance in breast cancer. Further analysis into patient outcome in this 
cohort may determine the prognostic value of IGF-IR expression and localisation.  
Membrane expression of IGF-IR was not observed in any of the lobular tumours, 
suggesting that IGF-IR signalling may not play as central a role in cell signalling in 
these tumours, although the number of lobular tumours was small (n=13). Previous 
studies have also reported a lower frequency of IGF-IR expression in lobular than ductal 
tumours [273].  
 
No association was observed between HER-2 and cytoplasmic or membrane IGF-IR 
expression in either TMA study. In Study 2, cytoplasmic IGF-IR expression was not 
associated with any of the prognostic parameters studied.  Membrane IGF-IR 
expression was detected in 20 % of tumours in this group. Compared to membrane IGF-
IR staining in 34 % of unselected breast cancer patients, this suggests that IGF-IR 
expression may be down-regulated in HER-2-positive tumours. Indeed, in the pooled 
analysis of study 1 and study 2, IGF-IR staining was detected significantly less 
frequently in HER-2-positive tumours. This relationship between IGF-IR and HER-2 
expression in breast cancer has not previously been reported. However, membrane IGF-
IR expression was recently correlated with lower response rates to neoadjuvant 
trastuzumab and vinorelbine in HER-2-positive patients [440]. The cellular localisation 
of IGF-IR may therefore be a determining factor in its involvement in trastuzumab 
response.  Functional analysis of the cellular localisation of IGF-IR has not been 
reported, though the cytoplasmic form of IGF-IR is suggested to represent a bound 
form, internalised following ligand-stimulated activation [440]. 
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Membrane IGF-IR expression was also detected significantly more frequently in ER-
positive tumours than ER-negative tumours. Cross-talk between IGF-IR and ER 
signalling has been described in breast cancer cells, and previous studies have reported 
correlations between IGF-IR and both ER and PR expression in breast cancer patients 
[273]. Positive ER status is independently associated with better outcome in breast 
cancer, and in a study of patients with HER-2-positive breast cancer, those with tumours 
that also express ER had longer overall survival than those without ER [98].  Membrane 
IGF-IR expression, therefore, may also be associated with better outcome in HER-2-
positive patients. However, a trend was also observed between positive membrane IGF-
IR staining and tumour size in this group, suggesting a correlation between IGF-IR and 
disease progression in HER-2-positive breast cancer.  Many of these patients have 
received trastuzumab treatment; further analysis of patient response and survival will be 
performed to determine correlations between IGF-IR cytoplasmic and membrane 
expression and patient outcome.  
 
 
Summary and conclusion 
In summary, these data show that HER family signalling pathways cross-talk with IGF-
IR signalling in breast cancer cells. Signalling through alternative RTKs such as EGFR 
and IGF-IR does not seem to play a role in innate resistance to trastuzumab, but 
elevated IGF-IR or EGFR expression may play a role in acquired trastuzumab 
resistance. Targeting IGF-IR protein expression or tyrosine kinase activity improves 
response to trastuzumab in both trastuzumab-sensitive and -resistant cells.  
 
Cytoplasmic IGF-IR was detected in 100 % of the HER-2-positive tumours analysed in 
this study.   Membrane IGF-IR expression was detected significantly less frequently in 
HER-2-positive tumours.  Further analysis of patient response to trastuzumab and 
overall patient survival may determine the role of IGF-IR expression and localisation in 
HER-2-overexpressing breast cancers, and in response to trastuzumab. 
 
Thus, despite the fact that IGF-IR does not predict response to trastuzumab in the panel 
of cell lines, inhibiting both HER-2 and IGF-IR in HER-2-positive cells results in an 
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enhanced response; therefore, the combination of anti-IGF-IR therapy with trastuzumab 
may be clinically beneficial in patients with HER-2-overexpressing breast cancer.    
 
Trastuzumab-resistant BT474, SKBR3 and HCC1419 cells are sensitive to the dual 
EGFR and HER-2 tyrosine kinase inhibitor lapatinib. Resistance to lapatinib, however, 
can also occur; in this study we present an ER-negative model of cells with stable 
resistance to both lapatinib and trastuzumab. It is likely that resistance to trastuzumab 
and/or lapatinib does not have a single cause, but rather, aberrations in multiple 
signalling pathways, caused by irregular activity of a number of cellular proteins, may 
be contributing to the resistant phenotype.  The identification of such proteins is an 
important step in elucidating mechanisms of resistance.  In this study, 
phosphoproteomic analysis revealed that SKBR3-L cells are characterised by many 
alterations in their phosphoproteome. This is the first reported study of phospho-
proteomic profiling of lapatinib or trastuzumab resistant cells and we have identified a 
number of phosphoproteins with potential involvement in trastuzumab and/or lapatinib 
resistance.  These include phosphoproteins involved in protein translation, maturation, 
and degradation, and in a wide range of cellular processes such as cell proliferation, 
apoptosis and migration. A number of these phosphoproteins represent rational targets 
for resistance to HER-2 antagonists and warrant further investigation. We anticipate that 
validation and functional analysis of these targets will lead to novel therapeutic targets 
and/or biomarkers for HER-2 resistant breast cancer.  
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